Patent Application
20200190192
Provided herein are antibodies with dual binding specificity for T cell immunoglobulin domain- and mucin domain-containing molecule 3 (Tim-3) and for programmed cell death protein (PD-1 or PD1), also referred to as PD-1/Tim-3 bi-specific antibodies. Also provided herein are antibodies with binding specificity for PD-1 or Tim-3. In addition, provided herein are compositions comprising the antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. Also provided are methods of making the bi-specific antibodies, and methods of using the bi-specific antibodies, for example, for therapeutic purposes, diagnostic purposes, and research purposes.
T cell immunoglobulin domain- and mucin domain-containing molecule 3 (Tim-3) is a cell surface protein molecule that belongs to the immunoglobulin superfamily. It is expressed as a transmembrane protein on differentiated type 1 T helper lymphocytes (Thl cells). See Monney et al., Nature 2002, 415:536-541. The Tim-3 protein contains an immunoglobulin variable-like domain and a mucin-like domain. See id. In a mouse model of autoimmune disease, experimental autoimmune encephalomyelitis, antibodies to Tim-3 were shown to increase the number and activation of macrophages, and to enhance clinical and pathologic severity. See id. From this, it has been proposed that Tim-3 is a regulator of immune function. See id. Later studies have shown that Tim-3 is constitutively expressed on cells of the innate immune system and can regulate Thl immunity. Anderson et al., 2007, Science 318:1141-3. Tim-3 has been shown to negatively regulate Thl cells in several studies. See Sabatos et al., Nature Immunol. 4:1102-110; Sanchez-Fueyo et al., 2003, Nature Immunol. 4:1093-1101; Sakuishi et al., 2010, J. Exp. Med. 207:2187-2194. Galectin-9 and CEACAM1 have been proposed as ligands for Tim-3. Zhu et al., 2005, Nature Immunol. 6:1245-1252; Huang et al., 2015, Nature 517:386-390.
In addition to its roles in immune regulation, autoimmune conditions, and inflammation, Tim-3 has been proposed as a target for cancer therapeutics. See, e.g., Anderson, 2014, Cancer Immunol. Res. 2:393-397. It has been shown that cancer cells can use immune checkpoint regulators such as Tim-3 to suppress the immune response against themselves. See id. Therapeutics that block other checkpoint regulators such as CTLA-4 have proved successful in treating certain cancers. See id. Indeed, target Tim-3 has shown promise for therapies in models of sarcoma, fibrosarcoma, prostate cancer, colon carcinoma, melanoma, and leukemia.
Programmed cell death protein 1 (PD-1, also referred to as “CD279” and “PD1”) is a cell surface protein molecule that belongs to the immunoglobulin superfamily. It is expressed on T and B lymphocytes and macrophages, and plays a role in cell fate and differentiation. See Ishida et al., EMBO 1, 1992, 11:3887-3895, incorporated by reference in its entirety. Activation of PD-1 is thought to negatively regulate the immune response. See Blank et al., Cancer Immunol. Immunother., 2007, 56:739-745; and Freeman et al., J. Exp. Med., 2000, 192:1027-1034, each of which is incorporated by reference in its entirety.
PD-1 has two known ligands, PD-L1 and PD-L2, which are both members of the B7 family. See Freeman et al., supra; and Latchman et al., Nat. Immunol., 2001, 2:261-268, each of which is incorporated by reference in its entirety. The interaction between PD-1 and these ligands is thought to play a role in a variety of diseases, including cancer (see Ribas and Tumeh, Clin. Cancer Res., 2014, June 26, PMID: 24970841 [Epub ahead of print]), autoimmune disease (see Dai et al., Cell Immunol., 2014, 290:72-79), and infection (see Day et al., Nature, 2006, 443:350-354). Each of the references cited in the preceding sentence is incorporated by reference in its entirety. In particular, the engagement of PD-1 by one of its ligands is thought to inhibit T-cell effector functions in an antigen-specific manner.
In view of the role of PD-1 and Tim-3 in multiple disease processes, there is a need for methods of modulating the immune regulation and downstream signaling processes activated by both Tim-3 and PD-1. There is also a need for therapeutics that can specifically target cells and tissues that express Tim-3 and/or PD-1.
Provided herein are antibodies that selectively bind Tim-3. In some embodiments, the antibodies bind human Tim-3. In some embodiments, the antibodies also bind homologs of human Tim-3. In some aspects, the homologs include a cynomolgus monkey homolog.
Also provided herein are antibodies that selectively bind PD-1. In some embodiments, the antibodies bind human PD-1. In some embodiments, the antibodies also bind homologs of human PD-1. In some aspects, the homologs include a cynomolgus monkey homolog.
Also provided herein are bi-specific antibodies or bi-specific antibody constructs that comprise a first binding domain that selectively binds Tim-3, including human Tim-3 or a homolog thereof, and a second binding domain that selectively binds PD-1, including human PD-1 or a homolog thereof.
In some embodiments, the antibodies comprise at least one CDR sequence defined by a consensus sequence provided in this disclosure. In some embodiments, the antibodies comprise an illustrative CDR, VH, or VL sequence provided in this disclosure, or a variant thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions.
Also provided are compositions and kits comprising the antibodies. In some embodiments, the compositions are pharmaceutical compositions. Any suitable pharmaceutical composition may be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration.
This disclosure also provides methods of using the anti-Tim-3 antibodies provided herein. In some embodiments, the method is a method of treatment. In some embodiments, the method is a diagnostic method. In some embodiments, the method is an analytical method. In some embodiments, the method is a method of purifying and/or quantifying Tim-3.
In some embodiments, the antibodies are used to treat a disease or condition. In some aspects, the disease or condition is selected from a cancer, autoimmune disease, and infection.
Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.
As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise.
The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ±10%, ±5%, or ±1%. In certain embodiments, the term “about” indicates the designated value ±one standard deviation of that value.
The terms “first” and “second” are intended to indicate two separate entities, but does not mean that one is before the other in time or space, unless otherwise noted.
The term “combinations thereof” includes every possible combination of elements to which the term refers to. For example, a sentence stating that “if α2 is A, then α3 is not D; α5 is not S; or α6 is not S; or combinations thereof” includes the following combinations when α2 is A: (1) α3 is not D; (2) α5 is not S; (3) α6 is not S; (4) α3 is not D; α5 is not S; and α6 is not S; (5) α3 is not D and α5 is not S; (6) α3 is not D and α6 is not S; and (7) α5 is not S and α6 is not S.
The terms “Tim-3” and “Tim-3 antigen” are used interchangeably herein. Tim-3 is also known by synonyms, including HAVCR2, T cell immunoglobulin domain- and mucin domain-containing molecule 3, and T cell immunoglobulin and mucin domains-containing molecule 3, among others. Unless specified otherwise, the terms include any variants, isoforms and species homologs of human Tim-3 that are naturally expressed by cells, or that are expressed by cells transfected with a Tim-3 gene. Tim-3 proteins include, for example, human Tim-3 (GI: 20330552; SEQ ID NO: 1). In some embodiments, Tim-3 proteins include cynomolgus monkey Tim-3 (GI: 355750365; SEQ ID NO: 2). In some embodiments, Tim-3 proteins include murine Tim-3 (GI: 17148681; SEQ ID NO: 3).
The terms “PD-1” and “PD-1 antigen” are used interchangeably herein. Unless specified otherwise, the terms include any variants, isoforms and species homologs of human PD-1 that are naturally expressed by cells, or that are expressed by cells transfected with a PD-1 gene. PD-1 proteins include full-length PD-1 (e.g., human PD-1; GI: 167857792; SEQ ID NO: 292; extracellular domain: Pro21-Gln167), as well as alternative splice variants of PD-1, such as PD-1Δex2, PD-1Δex3, PD-1Δex2,3, and PD-1Δex2,3,4. See Nielsen et al., Cellular Immunology, 2005, 235:109-116, incorporated by reference in its entirety. In some embodiments, PD-1 proteins include murine PD-1 (e.g., SEQ ID NO: 293; extracellular domain: Leu25-Gln167). In some embodiments, PD-1 proteins include cynomolgus PD-1 (e.g., SEQ ID NO: 294; extracellular domain: Pro21-Gln167).
The term “immunoglobulin” refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an “intact immunoglobulin,” all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, Pa. Briefly, each heavy chain typically comprises a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region typically comprises three domains, abbreviated CH1, CH2, and CH3. Each light chain typically comprises a light chain variable region (VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.
The term “antibody” describes a type of immunoglobulin molecule and is used herein in its broadest sense. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), and antibody fragments. Antibodies comprise at least one antigen-binding domain. One example of an antigen-binding domain is an antigen binding domain formed by a VH-VL dimer.
A “Tim-3 antibody,” “anti-Tim-3 antibody,” “Tim-3 Ab,” “Tim-3-specific antibody” or “anti-Tim-3 Ab” is an antibody, as described herein, which binds specifically to the antigen Tim-3. In some embodiments, the antibody binds the extracellular domain of Tim-3.
A “PD-1 antibody,” “anti-PD-1 antibody,” “PD-1 Ab,” “PD-1-specific antibody” or “anti-PD-1 Ab” is an antibody, as described herein, which binds specifically to the antigen PD-1. In some embodiments, the antibody binds the extracellular domain of PD-1.
The VH and VL regions may be further subdivided into regions of hypervariability (“hypervariable regions (HVRs);” also called “complementarity determining regions” (CDRs)) interspersed with regions that are more conserved. The more conserved regions are called framework regions (FRs). Each VH and VL generally comprises three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The CDRs are involved in antigen binding, and influence antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, Md., incorporated by reference in its entirety.
The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and μ, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (“Chothia” numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (“IMGT” numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme), each of which is incorporated by reference in its entirety.
Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.
Unless otherwise specified, the numbering scheme used for identification of a particular CDR herein is the Kabat/Chothia numbering scheme. Where the residues encompassed by these two numbering schemes diverge (e.g., CDR-H1 and/or CDR-H2), the numbering scheme is specified as either Kabat or Chothia. For convenience, CDR-H3 is sometimes referred to herein as either Kabat or Chothia. However, this is not intended to imply differences in sequence where they do not exist, and one of skill in the art can readily confirm whether the sequences are the same or different by examining the sequences.
CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at http://www.bioinf.org.uk/abs/abnum/, and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.
The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.
An “antibody fragment” comprises a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab′)2 fragments, Fab′ fragments, scFv (sFv) fragments, and scFv-Fc fragments.
“Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.
“Fab” fragments comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments may be generated, for example, by recombinant methods or by papain digestion of a full-length antibody.
“F(ab′)2” fragments contain two Fab′ fragments joined, near the hinge region, by disulfide bonds. F(ab′)2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab′) fragments can be dissociated, for example, by treatment with β-mercaptoethanol.
“Single-chain Fv” or “sFv” or “scFv” antibody fragments comprise a VH domain and a VL domain in a single polypeptide chain. The VH and VL are generally linked by a peptide linker. See Plückthun A. (1994). In some embodiments, the linker is SEQ ID NO: 168. Antibodies from Escherichia coli. In Rosenberg M. & Moore G. P. (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, incorporated by reference in its entirety.
“scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminus of the scFv. The Fc domain may follow the VH or VL, depending on the orientation of the variable domains in the scFv (i.e., VH-VL or VL-VH). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgG1 Fc domain. In some embodiments, the IgG1 Fc domain comprises SEQ ID NO: 270, or a portion thereof, or SEQ ID NO: 276. SEQ ID NO: 270 provides the sequence of CH1, CH2, and CH3 of the human IgG1 constant region. SEQ ID NO: 276 provides the sequence of the constant region used in the illustrative scFv-Fc antibodies provided herein.
The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and/or to reduce its immunogenicity in a subject.
The term “chimeric antibody” refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
“Humanized” forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.
A “human antibody” is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.
An “isolated antibody” is one that has been separated and/or recovered from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials. In some embodiments, an isolated antibody is purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator. In some embodiments, an isolated antibody is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody's natural environment is not present. In some aspects, an isolated antibody is prepared by at least one purification step.
In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by volume. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by weight. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by volume.
“Affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore® instrument. In some embodiments, the affinity is determined at 25° C.
With regard to the binding of an antibody to a target molecule, the terms “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. Specific binding can also be determined by competition with a control molecule that mimics the antibody binding site on the target. In that case, specific binding is indicated if the binding of the antibody to the target is competitively inhibited by the control molecule.
The term “kd” (sec−1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koff value.
The term “ka” (M−1×sec−1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the kon value.
The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. KD=kd/ka.
The term “KA” (M−1), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction. KA=ka/kd.
An “affinity matured” antibody is one with one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen, compared to a parent antibody which does not possess the alteration(s). In one embodiment, an affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies may be produced using a variety of methods known in the art. For example, Marks et al. (Bio/Technology, 1992, 10:779-783, incorporated by reference in its entirety) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by, for example, Barbas et al. (Proc. Nat. Acad. Sci. U.S.A., 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al, J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.
When used herein in the context of two or more antibodies, the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen. In one exemplary assay, an antigen is coated on a plate and allowed to bind a first antibody, after which a second, labeled antibody is added. If the presence of the first antibody reduces binding of the second antibody, then the antibodies compete. In another exemplary assay, a first antibody is coated on a plate and allowed to bind an antigen, and then the second antibody is added. The term “competes with” also includes combinations of antibodies where one antibody reduces binding of another antibody, but where no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding of each other, regardless of the order in which they are added. In some embodiments, one antibody reduces binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.
The term “epitope” means a portion of an antigen capable of specific binding to an antibody. Epitopes frequently consist of surface-accessible amino acid residues and/or sugar side chains and may have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to Tim-3 and/or PD-1 variants with different point-mutations, or to chimeric Tim-3 and/or PD-1 variants as described further in the Examples provided herein.
Percent “identity” between a polypeptide sequence and a reference sequence, is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
A “conservative substitution” or a “conservative amino acid substitution,” refers to the substitution an amino acid with a chemically or functionally similar amino acid. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences having such substitutions are known as “conservatively modified variants.” By way of example, the groups of amino acids provided in Tables 2-4 are, in some embodiments, considered conservative substitutions for one another.
Additional conservative substitutions may be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman & Co., New York, N.Y. An antibody generated by making one or more conservative substitutions of amino acid residues in a parent antibody is referred to as a “conservatively modified variant.”
The term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).
“Treating” or “treatment” of any disease or disorder refers, in certain embodiments, to ameliorating a disease or disorder that exists in a subject. In another embodiment, “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In yet another embodiment, “treating” or “treatment” includes modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both. In yet another embodiment, “treating” or “treatment” includes delaying or preventing the onset of the disease or disorder.
As used herein, the term “therapeutically effective amount” or “effective amount” refers to an amount of an antibody or composition that when administered to a subject is effective to treat a disease or disorder.
As used herein, the term “subject” means a mammalian subject. Exemplary subjects include, but are not limited to humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, avians, goats, and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has a cancer that can be treated or diagnosed with an antibody provided herein. In some embodiments, the cancer is a cancer of epithelial origin.
Provided herein are Tim-3 antibodies that selectively bind human Tim-3. In some aspects, the Tim-3 antibody selectively binds to the extracellular domain of human Tim-3.
In some embodiments, the Tim-3 antibody binds to a homolog of human Tim-3. In some aspects, the Tim-3 antibody binds to a homolog of human Tim-3 from a species selected from monkeys, mice, dogs, cats, rats, cows, horses, goats and sheep. In some aspects, the homolog is a cynomolgus monkey homolog.
In some embodiments, the Tim-3 antibody has one or more CDRs having particular lengths, in terms of the number of amino acid residues. In some embodiments, the Chothia CDR-H1 of the antibody is 6, 7, or 8 residues in length. In some embodiments, the Kabat CDR-H1 of the antibody is 4, 5, or 6 residues in length. In some embodiments, the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues in length. In some embodiments, the Kabat CDR-H2 of the antibody is 16, 17, or 18 residues in length. In some embodiments, the Kabat/Chothia CDR-H3 of the antibody is 9, 10, 11, 12, or 13 residues in length.
In some aspects, the Kabat/Chothia CDR-L1 of the antibody is 11, 12, 13, 14, 15, 16, 17, or 18 residues in length. In some aspects, the Kabat/Chothia CDR-L2 of the antibody is 6, 7, or 8 residues in length. In some aspects, the Kabat/Chothia CDR-L3 of the antibody is 8, 9, or 10 residues in length.
In some embodiments, the Tim-3 antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.
In some embodiments, the Tim-3 antibody comprises a heavy chain. In some aspects, the heavy chain is an IgA. In some aspects, the heavy chain is an IgD. In some aspects, the heavy chain is an IgE. In some aspects, the heavy chain is an IgG. In some aspects, the heavy chain is an IgM. In some aspects, the heavy chain is an IgG1. In some aspects, the heavy chain is an IgG2. In some aspects, the heavy chain is an IgG3. In some aspects, the heavy chain is an IgG4. In some aspects, the heavy chain is an IgA1. In some aspects, the heavy chain is an IgA2.
In some embodiments, the Tim-3 antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab′)2 fragment. In some aspects, the antibody fragment is a Fab′ fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.
In some embodiments, the scFv-Fc fragment comprises a constant region wherein the constant region comprises SEQ ID NO: 276. The constant region in SEQ ID NO: 276 differs from the human IgG1 constant region of SEQ ID NO: 270 in several respects. First, the sequence in SEQ ID NO: 276 comprises the linker AAGSDQEPKSS (SEQ ID NO: 282). SEQ ID NO: 276 also does not comprise the CH1 domain of the IgG1 constant region. SEQ ID NO: 276 further comprises a C220S (EU numbering system) mutation, which removes an unpaired cysteine reside that is not needed when the light chain constant region is not present (e.g., in an scFv-Fc format). SEQ ID NO: 276 further comprises two, optional, P to S mutations (P230S and P238S by the EU numbering system). Either or both of these serine residues can be reverted to the naturally occurring proline residues. Finally, SEQ ID NO: 276 comprises an aspartic acid (D) residue at EU position 356 and a leucine (L) residue at EU position 358. In contrast, SEQ ID NO: 270 comprises glutamic acid (E) in EU position 356 and methionine (M) in EU position 358. In some embodiments, the antibodies provided herein comprise constant regions comprising D356/L358, E356/M358, D356/M358, or E356/L358 (EU numbering). However, a skilled person will recognize that the antibodies provide herein may comprise any suitable constant region and that the constant region sequences provided herein are for illustrative purposes.
In some embodiments, the Tim-3 antibody is a monoclonal antibody. In some embodiments, the Tim-3 antibody is a polyclonal antibody.
In some embodiments, the Tim-3 antibody is a chimeric antibody. In some embodiments, the Tim-3 antibody is a humanized antibody. In some embodiments, the Tim-3 antibody is a human antibody.
In some embodiments, the Tim-3 antibody is an affinity matured antibody. In some aspects, the Tim-3 antibody is an affinity matured antibody derived from an illustrative sequence provided in this disclosure.
In some embodiments, the Tim-3 antibody inhibits the binding of Tim-3 to one or more of its ligands. In some aspects, the Tim-3 antibody inhibits the binding of Tim-3 to a ligand selected from a second Tim-3 molecule, claudin-7, CD44v4-v7, E-cadherin, and CD9.
In some embodiments, the Tim-3 antibody is provided as a single arm binder. For example, the Tim-3 antibody can be provided as part of a bi-specific antibody or bi-specific antibody construct as disclosed here.
The Tim-3 antibodies provided herein may be useful for the treatment of a variety of diseases and conditions including cancers. In particular, the Tim-3 antibodies provided herein may be useful for the treatment of cancers of epithelial origin.
2.1. Tim-3 CDR-H3 Sequences
In some embodiments, the Tim-3 antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the CDR-H3 sequence is a CDR-H3 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the CDR-H3 sequence is a CDR-H3 sequence of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 111. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 112. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118.
In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.2. Tim-3 VH Sequences Comprising Illustrative CDRs
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-H sequences provided in this disclosure, and variants thereof. In some embodiments, the CDR-H sequences comprise, consist of, or consist essentially of one or more CDR-H sequences provided in a VH sequence selected from SEQ ID NOs: 144-180.
2.2.1. VH Sequences Comprising Illustrative Kabat CDRs
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising one or more Kabat CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-H sequences provided in this disclosure, and variants thereof.
2.2.1.1. Kabat CDR-H3
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a CDR-H3 sequence, wherein the CDR-H3 sequence comprises, consists of, or consists essentially of a Kabat CDR-H3 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Kabat CDR-H3 sequence is a Kabat CDR-H3 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the Kabat CDR-H3 sequence is a Kabat CDR-H3 sequence of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 111. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 112. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118.
2.2.1.2. Kabat CDR-H2
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a CDR-H2 sequence, wherein the CDR-H2 sequence comprises, consists of, or consists essentially of a Kabat CDR-H2 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Kabat CDR-H2 sequence is a Kabat CDR-H2 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the Kabat CDR-H2 sequence is a Kabat CDR-H2 sequence of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 82-109. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 82. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 83. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 84. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 85. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 86. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 87. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 88. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 89. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 90. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 91. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 92. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 93. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 94. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 95. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 96. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 97. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 98. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 99. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 100. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 101. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 102. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 103. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 104. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 105. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 106. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 107. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 108. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 109.
2.2.1.3. Kabat CDR-H1
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a CDR-H1 sequence, wherein the CDR-H1 sequence comprises, consists of, or consists essentially of a Kabat CDR-H1 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Kabat CDR-H1 sequence is a Kabat CDR-H1 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the Kabat CDR-H1 sequence is a Kabat CDR-H1 sequence of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 39-56. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 39. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 40. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 41. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 42. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 43. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 44. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 45. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 46. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 47. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 48. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 49. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 50. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 51. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 52. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 53. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 54. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 55. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 56.
2.2.1.4. Kabat CDR-H3+Kabat CDR-H2
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 82-109. In some aspects, the Kabat CDR-H3 sequence and the Kabat CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H3 and Kabat CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.1.5. Kabat CDR-H3+Kabat CDR-H1
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118, and a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 39-56. In some aspects, the Kabat CDR-H3 sequence and the Kabat CDR-H1 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H3 and Kabat CDR-H1 are both from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.1.6. Kabat CDR-H1+Kabat CDR-H2
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 39-56 and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 82-109. In some aspects, the Kabat CDR-H1 sequence and the Kabat CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1 and Kabat CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.1.7. Kabat CDR-H1+Kabat CDR-H2+Kabat CDR-H3
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 39-56, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 82-109, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118. In some aspects, the Kabat CDR-H1 sequence, Kabat CDR-H2 sequence, and Kabat CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.1.8. Variants of VH Sequences Comprising Illustrative Kabat CDRs
In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure.
In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H3 sequences provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.2.2. VH Sequences Comprising Illustrative Chothia CDRs
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising one or more Chothia CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-H sequences provided in this disclosure, and variants thereof.
2.2.2.1. Chothia CDR-H3
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a CDR-H3 sequence, wherein the CDR-H3 sequence comprises, consists of, or consists essentially of a Chothia CDR-H3 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Chothia CDR-H3 sequence is a Chothia CDR-H3 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the Chothia CDR-H3 sequence is a Chothia CDR-H3 sequence of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 111. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 112. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 113. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 114. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 115. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 116. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 117. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 118.
2.2.2.2. Chothia CDR-H2
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a CDR-H2 sequence, wherein the CDR-H2 sequence comprises, consists of, or consists essentially of a Chothia CDR-H2 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Chothia CDR-H2 sequence is a Chothia CDR-H2 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the Chothia CDR-H2 sequence is a Chothia CDR-H2 sequence of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-80. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 63. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 64. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 65. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 66. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 67. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 68. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 69. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 70. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 71. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 72. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 73. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 74. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 75. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 76. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 77. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 78. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 79. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 80.
2.2.2.3. Chothia CDR-H1
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a CDR-H1 sequence, wherein the CDR-H1 sequence comprises, consists of, or consists essentially of a Chothia CDR-H1 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Chothia CDR-H1 sequence is a Chothia CDR-H1 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the Chothia CDR-H1 sequence is a Chothia CDR-H1 sequence of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-23. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 4. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 5. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 6. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 7. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 8. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 9. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 10. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 11. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 12. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 13. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 14. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 15. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 16. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 17. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 18. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 19. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 20. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 21. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 22. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 23.
2.2.2.4. Chothia CDR-H3+Chothia CDR-H2
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-80. In some aspects, the Chothia CDR-H3 sequence and the Chothia CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H3 and Chothia CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.2.5. Chothia CDR-H3+Chothia CDR-H1
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118, and a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-23. In some aspects, the Chothia CDR-H3 sequence and the Chothia CDR-H1 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H3 and Chothia CDR-H1 are both from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.2.6. Chothia CDR-H1+Chothia CDR-H2
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-23 and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-80. In some aspects, the Chothia CDR-H1 sequence and the Chothia CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1 and Chothia CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.2.7. Chothia CDR-H1+Chothia CDR-H2+Chothia CDR-H3
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-23, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-80, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118. In some aspects, the Chothia CDR-H1 sequence, Chothia CDR-H2 sequence, and Chothia CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 144-180.
2.2.2.8. Variants of VH Sequences Comprising Illustrative Chothia CDRs
In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure.
In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H3 sequences provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H2 sequences provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H1 sequences provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.3. Tim-3 VH Sequences
In some embodiments, the Tim-3 antibody comprises, consists of, or consists essentially of a VH sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some embodiments, the antibody comprises, consists of, or consists essentially of a VH sequence provided in SEQ ID NOs.: 144-180.
In some embodiments, the Tim-3 antibody comprises a VH sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 144-180. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 144. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 145. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 146. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 147. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 148. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 149. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 150. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 151. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 152. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 153. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 154. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 155. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 156. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 157. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 158. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 159. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 160. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 161. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 162. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 163. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 164. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 165. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 166. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 167. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 168. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 169. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 170. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 171. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 172. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 173. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 174. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 175. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 176. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 177. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 178. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 179. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 180.
2.3.1. Variants of VH Sequences
In some embodiments, the VH sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VH sequence provided in this disclosure.
In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.4. Tim-3 CDR-L3 Sequences
In some embodiments, the Tim-3 antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L3 sequence is a CDR-L3 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the CDR-L3 sequence is a CDR-L3 sequence of a VL sequence provided in SEQ ID NOs.: 221-235.
In some embodiments, the Tim-3 antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 140. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 141. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 356.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.5. Tim-3 VL Sequences Comprising Illustrative CDRs
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising one or more CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-L sequences provided in this disclosure, and variants thereof.
2.5.1. CDR-L3
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L3 sequence, wherein the CDR-L3 sequence comprises, consists of, or consists essentially of a CDR-L3 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L3 sequence is a CDR-L3 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the CDR-L3 sequence is a CDR-L3 sequence of a VL sequence provided in SEQ ID NOs.: 221-235.
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 140. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 141. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 142. In some aspects, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 356.
2.5.2. CDR-L2
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L2 sequence, wherein the CDR-L2 sequence comprises, consists of, or consists essentially of a CDR-L2 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L2 sequence is a CDR-L2 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the CDR-L2 sequence is a CDR-L2 sequence of a VL sequence provided in SEQ ID NOs.: 221-235.
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 125. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 126. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 127. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 128. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 129. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 130. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 131. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 132. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 133. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 355.
2.5.3. CDR-L1
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L1 sequence, wherein the CDR-L1 sequence comprises, consists of, or consists essentially of a CDR-L1 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L1 sequence is a CDR-L1 sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some aspects, the CDR-L1 sequence is a CDR-L1 sequence of a VL sequence provided in SEQ ID NOs.: 221-235.
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 120-123 and 354. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 120. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 121. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 122. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 123. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 354.
2.5.4. CDR-L3+CDR-L2
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355. In some aspects, the CDR-L3 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L3 and CDR-L2 are both from a single illustrative VL sequence selected from SEQ ID NOs: 221-235.
2.5.5. CDR-L3+CDR-L1
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356 and a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 120-123 and 354. In some aspects, the CDR-L3 sequence and the CDR-L1 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L3 and CDR-L1 are both from a single illustrative VL sequence selected from SEQ ID NOs: 221-235.
2.5.6. CDR-L1+CDR-L2
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 120-123 and 354 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355. In some aspects, the CDR-L1 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L1 and CDR-L2 are both from a single illustrative VL sequence selected from SEQ ID NOs: 221-235.
2.5.7. CDR-L1+CDR-L2+CDR-L3
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from any one of SEQ ID NOs: 120-123 and 354, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356. In some aspects, the CDR-L1 sequence, CDR-L2 sequence, and CDR-L3 sequence are all from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L1, CDR-L2, and CDR-L3 are all from a single illustrative VL sequence selected from SEQ ID NOs: 221-235.
2.5.8. Variants of VL Sequences Comprising Illustrative CDR-Ls
In some embodiments, the VL sequences provided herein comprise a variant of an illustrative CDR-L3, CDR-L2, and/or CDR-L1 sequence provided in this disclosure.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.6. Tim-3 VL Sequences
In some embodiments, the Tim-3 antibody comprises, consists of, or consists essentially of a VL sequence of an scFv-Fc sequence provided in SEQ ID NO: 287. In some embodiments, the antibody comprises, consists of, or consists essentially of a VL sequence provided in SEQ ID NOs.: 221-235.
In some embodiments, the Tim-3 antibody comprises a VL sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 221-235. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 221. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 222. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 223. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 224. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 225. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 226. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 227. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 228. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 229. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 230. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 231. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 232. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 233. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 234. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 235.
2.6.1. Variants of VL Sequences
In some embodiments, the VL sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VL sequence provided in this disclosure.
In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.7. Tim-3 Pairs
2.7.1. CDR-H3-CDR-L3 Pairs
In some embodiments, the Tim-3 antibody comprises a CDR-H3 sequence and a CDR-L3 sequence. In some aspects, the CDR-H3 sequence is part of a VH and the CDR-L3 sequence is part of a VL.
In some aspects, the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118, and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356.
2.7.1.1. Variants of CDR-H3-CDR-L3 Pairs
In some embodiments, the CDR-H3-CDR-L3 pairs provided herein comprise a variant of an illustrative CDR-H3 and/or CDR-L1 sequence provided in this disclosure.
In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.7.2. CDR-H1-CDR-L1 Pairs
In some embodiments, the Tim-3 antibody comprises a CDR-H1 sequence and a CDR-L1 sequence. In some aspects, the CDR-H1 sequence is part of a VH and the CDR-L1 sequence is part of a VL.
In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-23, and the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 120-123 and 354.
In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 39-56, and the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 120-123 and 354.
2.7.2.1. Variants of CDR-H1-CDR-L1 Pairs
In some embodiments, the CDR-H1-CDR-L1 pairs provided herein comprise a variant of an illustrative CDR-H1 and/or CDR-L1 sequence provided in this disclosure.
In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.7.3. CDR-H2-CDR-L2 Pairs
In some embodiments, the Tim-3 antibody comprises a CDR-H2 sequence and a CDR-L2 sequence. In some aspects, the CDR-H2 sequence is part of a VH and the CDR-L2 sequence is part of a VL.
In some aspects, the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-80, and the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355.
In some aspects, the CDR-H1 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 82-109, and the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355.
2.7.3.1. Variants of CDR-H2-CDR-L2 Pairs
In some embodiments, the CDR-H2-CDR-L2 pairs provided herein comprise a variant of an illustrative CDR-H2 and/or CDR-L2 sequence provided in this disclosure.
In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H2 sequence provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H2 sequences provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.7.4. VH-VL Pairs
In some embodiments, the Tim-3 antibody comprises a VH sequence and a VL sequence.
In some aspects, the VH sequence is a VH sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 144-180, and the VL sequence is a VL sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 221-235.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 221 and SEQ ID NO: 144; SEQ ID NO: 221 and SEQ ID NO: 145; SEQ ID NO: 221 and SEQ ID NO: 146; SEQ ID NO: 221 and SEQ ID NO: 147; SEQ ID NO: 221 and SEQ ID NO: 148; SEQ ID NO: 221 and SEQ ID NO: 149; SEQ ID NO: 221 and SEQ ID NO: 150; SEQ ID NO: 221 and SEQ ID NO: 151; SEQ ID NO: 221 and SEQ ID NO: 152; SEQ ID NO: 221 and SEQ ID NO: 153; SEQ ID NO: 221 and SEQ ID NO: 154; SEQ ID NO: 221 and SEQ ID NO: 155; SEQ ID NO: 221 and SEQ ID NO: 156; SEQ ID NO: 221 and SEQ ID NO: 157; SEQ ID NO: 221 and SEQ ID NO: 158; SEQ ID NO: 221 and SEQ ID NO: 159; SEQ ID NO: 221 and SEQ ID NO: 160; SEQ ID NO: 221 and SEQ ID NO: 161; SEQ ID NO: 221 and SEQ ID NO: 162; SEQ ID NO: 221 and SEQ ID NO: 163; SEQ ID NO: 221 and SEQ ID NO: 164; SEQ ID NO: 221 and SEQ ID NO: 165; SEQ ID NO: 221 and SEQ ID NO: 166; SEQ ID NO: 221 and SEQ ID NO: 167; SEQ ID NO: 221 and SEQ ID NO: 168; SEQ ID NO: 221 and SEQ ID NO: 169; SEQ ID NO: 221 and SEQ ID NO: 170; SEQ ID NO: 221 and SEQ ID NO: 171; SEQ ID NO: 221 and SEQ ID NO: 172; SEQ ID NO: 221 and SEQ ID NO: 173; SEQ ID NO: 221 and SEQ ID NO: 174; SEQ ID NO: 221 and SEQ ID NO: 175; SEQ ID NO: 221 and SEQ ID NO: 176; SEQ ID NO: 221 and SEQ ID NO: 177; SEQ ID NO: 221 and SEQ ID NO: 178; SEQ ID NO: 221 and SEQ ID NO: 179; and SEQ ID NO: 221 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 222 and SEQ ID NO: 144; SEQ ID NO: 222 and SEQ ID NO: 145; SEQ ID NO: 222 and SEQ ID NO: 146; SEQ ID NO: 222 and SEQ ID NO: 147; SEQ ID NO: 222 and SEQ ID NO: 148; SEQ ID NO: 222 and SEQ ID NO: 149; SEQ ID NO: 222 and SEQ ID NO: 150; SEQ ID NO: 222 and SEQ ID NO: 151; SEQ ID NO: 222 and SEQ ID NO: 152; SEQ ID NO: 222 and SEQ ID NO: 153; SEQ ID NO: 222 and SEQ ID NO: 154; SEQ ID NO: 222 and SEQ ID NO: 155; SEQ ID NO: 222 and SEQ ID NO: 156; SEQ ID NO: 222 and SEQ ID NO: 157; SEQ ID NO: 222 and SEQ ID NO: 158; SEQ ID NO: 222 and SEQ ID NO: 159; SEQ ID NO: 222 and SEQ ID NO: 160; SEQ ID NO: 222 and SEQ ID NO: 161; SEQ ID NO: 222 and SEQ ID NO: 162; SEQ ID NO: 222 and SEQ ID NO: 163; SEQ ID NO: 222 and SEQ ID NO: 164; SEQ ID NO: 222 and SEQ ID NO: 165; SEQ ID NO: 222 and SEQ ID NO: 166; SEQ ID NO: 222 and SEQ ID NO: 167; SEQ ID NO: 222 and SEQ ID NO: 168; SEQ ID NO: 222 and SEQ ID NO: 169; SEQ ID NO: 222 and SEQ ID NO: 170; SEQ ID NO: 222 and SEQ ID NO: 171; SEQ ID NO: 222 and SEQ ID NO: 172; SEQ ID NO: 222 and SEQ ID NO: 173; SEQ ID NO: 222 and SEQ ID NO: 174; SEQ ID NO: 222 and SEQ ID NO: 175; SEQ ID NO: 222 and SEQ ID NO: 176; SEQ ID NO: 222 and SEQ ID NO: 177; SEQ ID NO: 222 and SEQ ID NO: 178; SEQ ID NO: 222 and SEQ ID NO: 179; and SEQ ID NO: 222 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 223 and SEQ ID NO: 144; SEQ ID NO: 223 and SEQ ID NO: 145; SEQ ID NO: 223 and SEQ ID NO: 146; SEQ ID NO: 223 and SEQ ID NO: 147; SEQ ID NO: 223 and SEQ ID NO: 148; SEQ ID NO: 223 and SEQ ID NO: 149; SEQ ID NO: 223 and SEQ ID NO: 150; SEQ ID NO: 223 and SEQ ID NO: 151; SEQ ID NO: 223 and SEQ ID NO: 152; SEQ ID NO: 223 and SEQ ID NO: 153; SEQ ID NO: 223 and SEQ ID NO: 154; SEQ ID NO: 223 and SEQ ID NO: 155; SEQ ID NO: 223 and SEQ ID NO: 156; SEQ ID NO: 223 and SEQ ID NO: 157; SEQ ID NO: 223 and SEQ ID NO: 158; SEQ ID NO: 223 and SEQ ID NO: 159; SEQ ID NO: 223 and SEQ ID NO: 160; SEQ ID NO: 223 and SEQ ID NO: 161; SEQ ID NO: 223 and SEQ ID NO: 162; SEQ ID NO: 223 and SEQ ID NO: 163; SEQ ID NO: 223 and SEQ ID NO: 164; SEQ ID NO: 223 and SEQ ID NO: 165; SEQ ID NO: 223 and SEQ ID NO: 166; SEQ ID NO: 223 and SEQ ID NO: 167; SEQ ID NO: 223 and SEQ ID NO: 168; SEQ ID NO: 223 and SEQ ID NO: 169; SEQ ID NO: 223 and SEQ ID NO: 170; SEQ ID NO: 223 and SEQ ID NO: 171; SEQ ID NO: 223 and SEQ ID NO: 172; SEQ ID NO: 223 and SEQ ID NO: 173; SEQ ID NO: 223 and SEQ ID NO: 174; SEQ ID NO: 223 and SEQ ID NO: 175; SEQ ID NO: 223 and SEQ ID NO: 176; SEQ ID NO: 223 and SEQ ID NO: 177; SEQ ID NO: 223 and SEQ ID NO: 178; SEQ ID NO: 223 and SEQ ID NO: 179; and SEQ ID NO: 223 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 224 and SEQ ID NO: 144; SEQ ID NO: 224 and SEQ ID NO: 145; SEQ ID NO: 224 and SEQ ID NO: 146; SEQ ID NO: 224 and SEQ ID NO: 147; SEQ ID NO: 224 and SEQ ID NO: 148; SEQ ID NO: 224 and SEQ ID NO: 149; SEQ ID NO: 224 and SEQ ID NO: 150; SEQ ID NO: 224 and SEQ ID NO: 151; SEQ ID NO: 224 and SEQ ID NO: 152; SEQ ID NO: 224 and SEQ ID NO: 153; SEQ ID NO: 224 and SEQ ID NO: 154; SEQ ID NO: 224 and SEQ ID NO: 155; SEQ ID NO: 224 and SEQ ID NO: 156; SEQ ID NO: 224 and SEQ ID NO: 157; SEQ ID NO: 224 and SEQ ID NO: 158; SEQ ID NO: 224 and SEQ ID NO: 159; SEQ ID NO: 224 and SEQ ID NO: 160; SEQ ID NO: 224 and SEQ ID NO: 161; SEQ ID NO: 224 and SEQ ID NO: 162; SEQ ID NO: 224 and SEQ ID NO: 163; SEQ ID NO: 224 and SEQ ID NO: 164; SEQ ID NO: 224 and SEQ ID NO: 165; SEQ ID NO: 224 and SEQ ID NO: 166; SEQ ID NO: 224 and SEQ ID NO: 167; SEQ ID NO: 224 and SEQ ID NO: 168; SEQ ID NO: 224 and SEQ ID NO: 169; SEQ ID NO: 224 and SEQ ID NO: 170; SEQ ID NO: 224 and SEQ ID NO: 171; SEQ ID NO: 224 and SEQ ID NO: 172; SEQ ID NO: 224 and SEQ ID NO: 173; SEQ ID NO: 224 and SEQ ID NO: 174; SEQ ID NO: 224 and SEQ ID NO: 175; SEQ ID NO: 224 and SEQ ID NO: 176; SEQ ID NO: 224 and SEQ ID NO: 177; SEQ ID NO: 224 and SEQ ID NO: 178; SEQ ID NO: 224 and SEQ ID NO: 179; and SEQ ID NO: 224 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 225 and SEQ ID NO: 144; SEQ ID NO: 225 and SEQ ID NO: 145; SEQ ID NO: 225 and SEQ ID NO: 146; SEQ ID NO: 225 and SEQ ID NO: 147; SEQ ID NO: 225 and SEQ ID NO: 148; SEQ ID NO: 225 and SEQ ID NO: 149; SEQ ID NO: 225 and SEQ ID NO: 150; SEQ ID NO: 225 and SEQ ID NO: 151; SEQ ID NO: 225 and SEQ ID NO: 152; SEQ ID NO: 225 and SEQ ID NO: 153; SEQ ID NO: 225 and SEQ ID NO: 154; SEQ ID NO: 225 and SEQ ID NO: 155; SEQ ID NO: 225 and SEQ ID NO: 156; SEQ ID NO: 225 and SEQ ID NO: 157; SEQ ID NO: 225 and SEQ ID NO: 158; SEQ ID NO: 225 and SEQ ID NO: 159; SEQ ID NO: 225 and SEQ ID NO: 160; SEQ ID NO: 225 and SEQ ID NO: 161; SEQ ID NO: 225 and SEQ ID NO: 162; SEQ ID NO: 225 and SEQ ID NO: 163; SEQ ID NO: 225 and SEQ ID NO: 164; SEQ ID NO: 225 and SEQ ID NO: 165; SEQ ID NO: 225 and SEQ ID NO: 166; SEQ ID NO: 225 and SEQ ID NO: 167; SEQ ID NO: 225 and SEQ ID NO: 168; SEQ ID NO: 225 and SEQ ID NO: 169; SEQ ID NO: 225 and SEQ ID NO: 170; SEQ ID NO: 225 and SEQ ID NO: 171; SEQ ID NO: 225 and SEQ ID NO: 172; SEQ ID NO: 225 and SEQ ID NO: 173; SEQ ID NO: 225 and SEQ ID NO: 174; SEQ ID NO: 225 and SEQ ID NO: 175; SEQ ID NO: 225 and SEQ ID NO: 176; SEQ ID NO: 225 and SEQ ID NO: 177; SEQ ID NO: 225 and SEQ ID NO: 178; SEQ ID NO: 225 and SEQ ID NO: 179; and SEQ ID NO: 225 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 226 and SEQ ID NO: 144; SEQ ID NO: 226 and SEQ ID NO: 145; SEQ ID NO: 226 and SEQ ID NO: 146; SEQ ID NO: 226 and SEQ ID NO: 147; SEQ ID NO: 226 and SEQ ID NO: 148; SEQ ID NO: 226 and SEQ ID NO: 149; SEQ ID NO: 226 and SEQ ID NO: 150; SEQ ID NO: 226 and SEQ ID NO: 151; SEQ ID NO: 226 and SEQ ID NO: 152; SEQ ID NO: 226 and SEQ ID NO: 153; SEQ ID NO: 226 and SEQ ID NO: 154; SEQ ID NO: 226 and SEQ ID NO: 155; SEQ ID NO: 226 and SEQ ID NO: 156; SEQ ID NO: 226 and SEQ ID NO: 157; SEQ ID NO: 226 and SEQ ID NO: 158; SEQ ID NO: 226 and SEQ ID NO: 159; SEQ ID NO: 226 and SEQ ID NO: 160; SEQ ID NO: 226 and SEQ ID NO: 161; SEQ ID NO: 226 and SEQ ID NO: 162; SEQ ID NO: 226 and SEQ ID NO: 163; SEQ ID NO: 226 and SEQ ID NO: 164; SEQ ID NO: 226 and SEQ ID NO: 165; SEQ ID NO: 226 and SEQ ID NO: 166; SEQ ID NO: 226 and SEQ ID NO: 167; SEQ ID NO: 226 and SEQ ID NO: 168; SEQ ID NO: 226 and SEQ ID NO: 169; SEQ ID NO: 226 and SEQ ID NO: 170; SEQ ID NO: 226 and SEQ ID NO: 171; SEQ ID NO: 226 and SEQ ID NO: 172; SEQ ID NO: 226 and SEQ ID NO: 173; SEQ ID NO: 226 and SEQ ID NO: 174; SEQ ID NO: 226 and SEQ ID NO: 175; SEQ ID NO: 226 and SEQ ID NO: 176; SEQ ID NO: 226 and SEQ ID NO: 177; SEQ ID NO: 226 and SEQ ID NO: 178; SEQ ID NO: 226 and SEQ ID NO: 179; and SEQ ID NO: 226 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 227 and SEQ ID NO: 144; SEQ ID NO: 227 and SEQ ID NO: 145; SEQ ID NO: 227 and SEQ ID NO: 146; SEQ ID NO: 227 and SEQ ID NO: 147; SEQ ID NO: 227 and SEQ ID NO: 148; SEQ ID NO: 227 and SEQ ID NO: 149; SEQ ID NO: 227 and SEQ ID NO: 150; SEQ ID NO: 227 and SEQ ID NO: 151; SEQ ID NO: 227 and SEQ ID NO: 152; SEQ ID NO: 227 and SEQ ID NO: 153; SEQ ID NO: 227 and SEQ ID NO: 154; SEQ ID NO: 227 and SEQ ID NO: 155; SEQ ID NO: 227 and SEQ ID NO: 156; SEQ ID NO: 227 and SEQ ID NO: 157; SEQ ID NO: 227 and SEQ ID NO: 158; SEQ ID NO: 227 and SEQ ID NO: 159; SEQ ID NO: 227 and SEQ ID NO: 160; SEQ ID NO: 227 and SEQ ID NO: 161; SEQ ID NO: 227 and SEQ ID NO: 162; SEQ ID NO: 227 and SEQ ID NO: 163; SEQ ID NO: 227 and SEQ ID NO: 164; SEQ ID NO: 227 and SEQ ID NO: 165; SEQ ID NO: 227 and SEQ ID NO: 166; SEQ ID NO: 227 and SEQ ID NO: 167; SEQ ID NO: 227 and SEQ ID NO: 168; SEQ ID NO: 227 and SEQ ID NO: 169; SEQ ID NO: 227 and SEQ ID NO: 170; SEQ ID NO: 227 and SEQ ID NO: 171; SEQ ID NO: 227 and SEQ ID NO: 172; SEQ ID NO: 227 and SEQ ID NO: 173; SEQ ID NO: 227 and SEQ ID NO: 174; SEQ ID NO: 227 and SEQ ID NO: 175; SEQ ID NO: 227 and SEQ ID NO: 176; SEQ ID NO: 227 and SEQ ID NO: 177; SEQ ID NO: 227 and SEQ ID NO: 178; SEQ ID NO: 227 and SEQ ID NO: 179; and SEQ ID NO: 227 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 228 and SEQ ID NO: 144; SEQ ID NO: 228 and SEQ ID NO: 145; SEQ ID NO: 228 and SEQ ID NO: 146; SEQ ID NO: 228 and SEQ ID NO: 147; SEQ ID NO: 228 and SEQ ID NO: 148; SEQ ID NO: 228 and SEQ ID NO: 149; SEQ ID NO: 228 and SEQ ID NO: 150; SEQ ID NO: 228 and SEQ ID NO: 151; SEQ ID NO: 228 and SEQ ID NO: 152; SEQ ID NO: 228 and SEQ ID NO: 153; SEQ ID NO: 228 and SEQ ID NO: 154; SEQ ID NO: 228 and SEQ ID NO: 155; SEQ ID NO: 228 and SEQ ID NO: 156; SEQ ID NO: 228 and SEQ ID NO: 157; SEQ ID NO: 228 and SEQ ID NO: 158; SEQ ID NO: 228 and SEQ ID NO: 159; SEQ ID NO: 228 and SEQ ID NO: 160; SEQ ID NO: 228 and SEQ ID NO: 161; SEQ ID NO: 228 and SEQ ID NO: 162; SEQ ID NO: 228 and SEQ ID NO: 163; SEQ ID NO: 228 and SEQ ID NO: 164; SEQ ID NO: 228 and SEQ ID NO: 165; SEQ ID NO: 228 and SEQ ID NO: 166; SEQ ID NO: 228 and SEQ ID NO: 167; SEQ ID NO: 228 and SEQ ID NO: 168; SEQ ID NO: 228 and SEQ ID NO: 169; SEQ ID NO: 228 and SEQ ID NO: 170; SEQ ID NO: 228 and SEQ ID NO: 171; SEQ ID NO: 228 and SEQ ID NO: 172; SEQ ID NO: 228 and SEQ ID NO: 173; SEQ ID NO: 228 and SEQ ID NO: 174; SEQ ID NO: 228 and SEQ ID NO: 175; SEQ ID NO: 228 and SEQ ID NO: 176; SEQ ID NO: 228 and SEQ ID NO: 177; SEQ ID NO: 228 and SEQ ID NO: 178; SEQ ID NO: 228 and SEQ ID NO: 179; and SEQ ID NO: 228 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 229 and SEQ ID NO: 144; SEQ ID NO: 229 and SEQ ID NO: 145; SEQ ID NO: 229 and SEQ ID NO: 146; SEQ ID NO: 229 and SEQ ID NO: 147; SEQ ID NO: 229 and SEQ ID NO: 148; SEQ ID NO: 229 and SEQ ID NO: 149; SEQ ID NO: 229 and SEQ ID NO: 150; SEQ ID NO: 229 and SEQ ID NO: 151; SEQ ID NO: 229 and SEQ ID NO: 152; SEQ ID NO: 229 and SEQ ID NO: 153; SEQ ID NO: 229 and SEQ ID NO: 154; SEQ ID NO: 229 and SEQ ID NO: 155; SEQ ID NO: 229 and SEQ ID NO: 156; SEQ ID NO: 229 and SEQ ID NO: 157; SEQ ID NO: 229 and SEQ ID NO: 158; SEQ ID NO: 229 and SEQ ID NO: 159; SEQ ID NO: 229 and SEQ ID NO: 160; SEQ ID NO: 229 and SEQ ID NO: 161; SEQ ID NO: 229 and SEQ ID NO: 162; SEQ ID NO: 229 and SEQ ID NO: 163; SEQ ID NO: 229 and SEQ ID NO: 164; SEQ ID NO: 229 and SEQ ID NO: 165; SEQ ID NO: 229 and SEQ ID NO: 166; SEQ ID NO: 229 and SEQ ID NO: 167; SEQ ID NO: 229 and SEQ ID NO: 168; SEQ ID NO: 229 and SEQ ID NO: 169; SEQ ID NO: 229 and SEQ ID NO: 170; SEQ ID NO: 229 and SEQ ID NO: 171; SEQ ID NO: 229 and SEQ ID NO: 172; SEQ ID NO: 229 and SEQ ID NO: 173; SEQ ID NO: 229 and SEQ ID NO: 174; SEQ ID NO: 229 and SEQ ID NO: 175; SEQ ID NO: 229 and SEQ ID NO: 176; SEQ ID NO: 229 and SEQ ID NO: 177; SEQ ID NO: 229 and SEQ ID NO: 178; SEQ ID NO: 229 and SEQ ID NO: 179; and SEQ ID NO: 229 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 230 and SEQ ID NO: 144; SEQ ID NO: 230 and SEQ ID NO: 145; SEQ ID NO: 230 and SEQ ID NO: 146; SEQ ID NO: 230 and SEQ ID NO: 147; SEQ ID NO: 230 and SEQ ID NO: 148; SEQ ID NO: 230 and SEQ ID NO: 149; SEQ ID NO: 230 and SEQ ID NO: 150; SEQ ID NO: 230 and SEQ ID NO: 151; SEQ ID NO: 230 and SEQ ID NO: 152; SEQ ID NO: 230 and SEQ ID NO: 153; SEQ ID NO: 230 and SEQ ID NO: 154; SEQ ID NO: 230 and SEQ ID NO: 155; SEQ ID NO: 230 and SEQ ID NO: 156; SEQ ID NO: 230 and SEQ ID NO: 157; SEQ ID NO: 230 and SEQ ID NO: 158; SEQ ID NO: 230 and SEQ ID NO: 159; SEQ ID NO: 230 and SEQ ID NO: 160; SEQ ID NO: 230 and SEQ ID NO: 161; SEQ ID NO: 230 and SEQ ID NO: 162; SEQ ID NO: 230 and SEQ ID NO: 163; SEQ ID NO: 230 and SEQ ID NO: 164; SEQ ID NO: 230 and SEQ ID NO: 165; SEQ ID NO: 230 and SEQ ID NO: 166; SEQ ID NO: 230 and SEQ ID NO: 167; SEQ ID NO: 230 and SEQ ID NO: 168; SEQ ID NO: 230 and SEQ ID NO: 169; SEQ ID NO: 230 and SEQ ID NO: 170; SEQ ID NO: 230 and SEQ ID NO: 171; SEQ ID NO: 230 and SEQ ID NO: 172; SEQ ID NO: 230 and SEQ ID NO: 173; SEQ ID NO: 230 and SEQ ID NO: 174; SEQ ID NO: 230 and SEQ ID NO: 175; SEQ ID NO: 230 and SEQ ID NO: 176; SEQ ID NO: 230 and SEQ ID NO: 177; SEQ ID NO: 230 and SEQ ID NO: 178; SEQ ID NO: 230 and SEQ ID NO: 179; and SEQ ID NO: 230 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 231 and SEQ ID NO: 144; SEQ ID NO: 231 and SEQ ID NO: 145; SEQ ID NO: 231 and SEQ ID NO: 146; SEQ ID NO: 231 and SEQ ID NO: 147; SEQ ID NO: 231 and SEQ ID NO: 148; SEQ ID NO: 231 and SEQ ID NO: 149; SEQ ID NO: 231 and SEQ ID NO: 150; SEQ ID NO: 231 and SEQ ID NO: 151; SEQ ID NO: 231 and SEQ ID NO: 152; SEQ ID NO: 231 and SEQ ID NO: 153; SEQ ID NO: 231 and SEQ ID NO: 154; SEQ ID NO: 231 and SEQ ID NO: 155; SEQ ID NO: 231 and SEQ ID NO: 156; SEQ ID NO: 231 and SEQ ID NO: 157; SEQ ID NO: 231 and SEQ ID NO: 158; SEQ ID NO: 231 and SEQ ID NO: 159; SEQ ID NO: 231 and SEQ ID NO: 160; SEQ ID NO: 231 and SEQ ID NO: 161; SEQ ID NO: 231 and SEQ ID NO: 162; SEQ ID NO: 231 and SEQ ID NO: 163; SEQ ID NO: 231 and SEQ ID NO: 164; SEQ ID NO: 231 and SEQ ID NO: 165; SEQ ID NO: 231 and SEQ ID NO: 166; SEQ ID NO: 231 and SEQ ID NO: 167; SEQ ID NO: 231 and SEQ ID NO: 168; SEQ ID NO: 231 and SEQ ID NO: 169; SEQ ID NO: 231 and SEQ ID NO: 170; SEQ ID NO: 231 and SEQ ID NO: 171; SEQ ID NO: 231 and SEQ ID NO: 172; SEQ ID NO: 231 and SEQ ID NO: 173; SEQ ID NO: 231 and SEQ ID NO: 174; SEQ ID NO: 231 and SEQ ID NO: 175; SEQ ID NO: 231 and SEQ ID NO: 176; SEQ ID NO: 231 and SEQ ID NO: 177; SEQ ID NO: 231 and SEQ ID NO: 178; SEQ ID NO: 231 and SEQ ID NO: 179; and SEQ ID NO: 231 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 232 and SEQ ID NO: 144; SEQ ID NO: 232 and SEQ ID NO: 145; SEQ ID NO: 232 and SEQ ID NO: 146; SEQ ID NO: 232 and SEQ ID NO: 147; SEQ ID NO: 232 and SEQ ID NO: 148; SEQ ID NO: 232 and SEQ ID NO: 149; SEQ ID NO: 232 and SEQ ID NO: 150; SEQ ID NO: 232 and SEQ ID NO: 151; SEQ ID NO: 232 and SEQ ID NO: 152; SEQ ID NO: 232 and SEQ ID NO: 153; SEQ ID NO: 232 and SEQ ID NO: 154; SEQ ID NO: 232 and SEQ ID NO: 155; SEQ ID NO: 232 and SEQ ID NO: 156; SEQ ID NO: 232 and SEQ ID NO: 157; SEQ ID NO: 232 and SEQ ID NO: 158; SEQ ID NO: 232 and SEQ ID NO: 159; SEQ ID NO: 232 and SEQ ID NO: 160; SEQ ID NO: 232 and SEQ ID NO: 161; SEQ ID NO: 232 and SEQ ID NO: 162; SEQ ID NO: 232 and SEQ ID NO: 163; SEQ ID NO: 232 and SEQ ID NO: 164; SEQ ID NO: 232 and SEQ ID NO: 165; SEQ ID NO: 232 and SEQ ID NO: 166; SEQ ID NO: 232 and SEQ ID NO: 167; SEQ ID NO: 232 and SEQ ID NO: 168; SEQ ID NO: 232 and SEQ ID NO: 169; SEQ ID NO: 232 and SEQ ID NO: 170; SEQ ID NO: 232 and SEQ ID NO: 171; SEQ ID NO: 232 and SEQ ID NO: 172; SEQ ID NO: 232 and SEQ ID NO: 173; SEQ ID NO: 232 and SEQ ID NO: 174; SEQ ID NO: 232 and SEQ ID NO: 175; SEQ ID NO: 232 and SEQ ID NO: 176; SEQ ID NO: 232 and SEQ ID NO: 177; SEQ ID NO: 232 and SEQ ID NO: 178; SEQ ID NO: 232 and SEQ ID NO: 179; and SEQ ID NO: 232 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 233 and SEQ ID NO: 144; SEQ ID NO: 233 and SEQ ID NO: 145; SEQ ID NO: 233 and SEQ ID NO: 146; SEQ ID NO: 233 and SEQ ID NO: 147; SEQ ID NO: 233 and SEQ ID NO: 148; SEQ ID NO: 233 and SEQ ID NO: 149; SEQ ID NO: 233 and SEQ ID NO: 150; SEQ ID NO: 233 and SEQ ID NO: 151; SEQ ID NO: 233 and SEQ ID NO: 152; SEQ ID NO: 233 and SEQ ID NO: 153; SEQ ID NO: 233 and SEQ ID NO: 154; SEQ ID NO: 233 and SEQ ID NO: 155; SEQ ID NO: 233 and SEQ ID NO: 156; SEQ ID NO: 233 and SEQ ID NO: 157; SEQ ID NO: 233 and SEQ ID NO: 158; SEQ ID NO: 233 and SEQ ID NO: 159; SEQ ID NO: 233 and SEQ ID NO: 160; SEQ ID NO: 233 and SEQ ID NO: 161; SEQ ID NO: 233 and SEQ ID NO: 162; SEQ ID NO: 233 and SEQ ID NO: 163; SEQ ID NO: 233 and SEQ ID NO: 164; SEQ ID NO: 233 and SEQ ID NO: 165; SEQ ID NO: 233 and SEQ ID NO: 166; SEQ ID NO: 233 and SEQ ID NO: 167; SEQ ID NO: 233 and SEQ ID NO: 168; SEQ ID NO: 233 and SEQ ID NO: 169; SEQ ID NO: 233 and SEQ ID NO: 170; SEQ ID NO: 233 and SEQ ID NO: 171; SEQ ID NO: 233 and SEQ ID NO: 172; SEQ ID NO: 233 and SEQ ID NO: 173; SEQ ID NO: 233 and SEQ ID NO: 174; SEQ ID NO: 233 and SEQ ID NO: 175; SEQ ID NO: 233 and SEQ ID NO: 176; SEQ ID NO: 233 and SEQ ID NO: 177; SEQ ID NO: 233 and SEQ ID NO: 178; SEQ ID NO: 233 and SEQ ID NO: 179; and SEQ ID NO: 233 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 234 and SEQ ID NO: 144; SEQ ID NO: 234 and SEQ ID NO: 145; SEQ ID NO: 234 and SEQ ID NO: 146; SEQ ID NO: 234 and SEQ ID NO: 147; SEQ ID NO: 234 and SEQ ID NO: 148; SEQ ID NO: 234 and SEQ ID NO: 149; SEQ ID NO: 234 and SEQ ID NO: 150; SEQ ID NO: 234 and SEQ ID NO: 151; SEQ ID NO: 234 and SEQ ID NO: 152; SEQ ID NO: 234 and SEQ ID NO: 153; SEQ ID NO: 234 and SEQ ID NO: 154; SEQ ID NO: 234 and SEQ ID NO: 155; SEQ ID NO: 234 and SEQ ID NO: 156; SEQ ID NO: 234 and SEQ ID NO: 157; SEQ ID NO: 234 and SEQ ID NO: 158; SEQ ID NO: 234 and SEQ ID NO: 159; SEQ ID NO: 234 and SEQ ID NO: 160; SEQ ID NO: 234 and SEQ ID NO: 161; SEQ ID NO: 234 and SEQ ID NO: 162; SEQ ID NO: 234 and SEQ ID NO: 163; SEQ ID NO: 234 and SEQ ID NO: 164; SEQ ID NO: 234 and SEQ ID NO: 165; SEQ ID NO: 234 and SEQ ID NO: 166; SEQ ID NO: 234 and SEQ ID NO: 167; SEQ ID NO: 234 and SEQ ID NO: 168; SEQ ID NO: 234 and SEQ ID NO: 169; SEQ ID NO: 234 and SEQ ID NO: 170; SEQ ID NO: 234 and SEQ ID NO: 171; SEQ ID NO: 234 and SEQ ID NO: 172; SEQ ID NO: 234 and SEQ ID NO: 173; SEQ ID NO: 234 and SEQ ID NO: 174; SEQ ID NO: 234 and SEQ ID NO: 175; SEQ ID NO: 234 and SEQ ID NO: 176; SEQ ID NO: 234 and SEQ ID NO: 177; SEQ ID NO: 234 and SEQ ID NO: 178; SEQ ID NO: 234 and SEQ ID NO: 179; and SEQ ID NO: 234 and SEQ ID NO: 180.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 235 and SEQ ID NO: 144; SEQ ID NO: 235 and SEQ ID NO: 145; SEQ ID NO: 235 and SEQ ID NO: 146; SEQ ID NO: 235 and SEQ ID NO: 147; SEQ ID NO: 235 and SEQ ID NO: 148; SEQ ID NO: 235 and SEQ ID NO: 149; SEQ ID NO: 235 and SEQ ID NO: 150; SEQ ID NO: 235 and SEQ ID NO: 151; SEQ ID NO: 235 and SEQ ID NO: 152; SEQ ID NO: 235 and SEQ ID NO: 153; SEQ ID NO: 235 and SEQ ID NO: 154; SEQ ID NO: 235 and SEQ ID NO: 155; SEQ ID NO: 235 and SEQ ID NO: 156; SEQ ID NO: 235 and SEQ ID NO: 157; SEQ ID NO: 235 and SEQ ID NO: 158; SEQ ID NO: 235 and SEQ ID NO: 159; SEQ ID NO: 235 and SEQ ID NO: 160; SEQ ID NO: 235 and SEQ ID NO: 161; SEQ ID NO: 235 and SEQ ID NO: 162; SEQ ID NO: 235 and SEQ ID NO: 163; SEQ ID NO: 235 and SEQ ID NO: 164; SEQ ID NO: 235 and SEQ ID NO: 165; SEQ ID NO: 235 and SEQ ID NO: 166; SEQ ID NO: 235 and SEQ ID NO: 167; SEQ ID NO: 235 and SEQ ID NO: 168; SEQ ID NO: 235 and SEQ ID NO: 169; SEQ ID NO: 235 and SEQ ID NO: 170; SEQ ID NO: 235 and SEQ ID NO: 171; SEQ ID NO: 235 and SEQ ID NO: 172; SEQ ID NO: 235 and SEQ ID NO: 173; SEQ ID NO: 235 and SEQ ID NO: 174; SEQ ID NO: 235 and SEQ ID NO: 175; SEQ ID NO: 235 and SEQ ID NO: 176; SEQ ID NO: 235 and SEQ ID NO: 177; SEQ ID NO: 235 and SEQ ID NO: 178; SEQ ID NO: 235 and SEQ ID NO: 179; and SEQ ID NO: 235 and SEQ ID NO: 180.
2.7.4.1. Variants of VH-VL Pairs
In some embodiments, the VH-VL pairs provided herein comprise a variant of an illustrative VH and/or VL sequence provided in this disclosure.
In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.8. Tim-3 Antibodies Comprising all Six CDRs
In some embodiments, the Tim-3 antibody comprises a CDR-H1 sequence, a CDR-H2 sequence, a CDR-H3 sequence, a CDR-L1 sequence, a CDR-L2 sequence, and a CDR-L3 sequence. In some aspects, the CDR sequences are part of a VH (for CDR-H) or VL (for CDR-L).
In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 4-23; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 63-80; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 120-123 and 354; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356.
In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 39-56; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 82-109; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 111-118; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 120-123 and 354; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 125-133 and 355; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 140-142 and 356.
2.8.1. Variants of Antibodies Comprising all Six CDRs
In some embodiments, the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 provided herein comprise a variant of an illustrative CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and/or CDR-L3 sequence provided in this disclosure.
In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
2.9. Tim-3 Consensus Sequences
In some embodiments, provided herein are anti-Tim-3 antibodies comprising one or more sequences defined by consensus sequences. Each consensus sequence is based, at least in part, on one or more alignments of two or more useful anti-Tim-3 CDR sequences provided in this disclosure. Based on such alignments, a person of skill in the art would recognize that different amino acid residues may useful in certain positions of the CDRs. Accordingly, each consensus sequence encompasses two or more useful anti-Tim-3 CDR sequences.
In some embodiments, the Tim-3 antibodies comprise one to six of the consensus CDR sequences provided herein. In some embodiments, the antibodies comprise two to six of the consensus CDR sequences provided herein. In some embodiments, the antibodies comprise three to six of the consensus CDR sequences provided herein. In some embodiments, the antibodies comprise four to six of the consensus CDR sequences provided herein. In some embodiments, the antibodies comprise five to six of the consensus CDR sequences provided herein. In some embodiments, the antibodies comprise six of the consensus CDR sequences provided herein. In some embodiments, the antibodies comprise a VL comprising the CDR-L consensus sequence(s). In some embodiments, the antibodies comprise a VH comprising the CDR-H consensus sequence(s). In some embodiments, the antibodies comprise a VH comprising the CDR-H consensus sequence(s) and a VL comprising the CDR-L consensus sequence(s).
2.9.1. CDR-H3 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a CDR-H3 sequence defined by the consensus sequence α1-α2-α3-Y-R-α6-α7-α8-α9-α10-α11-α12-α13, where α1 is Q, S or G; α2 is G, F, Y, or H; α3 is G, F, V, or I; α6 is absent or S; α7 is Y, S, M, or L; α8 is D, N, or W; α9 is D; α10 is A, W, or S; α11 is M, Y, F, or L; α12 is D or V; and α13 is Y or H.
In some embodiments, the Tim-3 antibody comprises a CDR-H3 sequence defined by the consensus sequence G-β2-β3-Y-R-β7-W-D-S-β11-D-β13, where β2 is Y or H; β3 is V or I; β7 is M, or L; β11 is Y, F, or L; and β13 is Y or H.
2.9.2. Chothia CDR-H1 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a Chothia sequence defined by the consensus sequence G-γ2-γ3-γ4-γ5-γ6-γ7, where γ2 is F or Y; γ3 is S, P or N; γ4 is L, F, or I; y5 is T, I, S, G, D, K, or R; γ6 is S, G, D, R, N, or K; and γ7 is N, Y or H.
In some embodiments, the Tim-3 antibody comprises a Chothia sequence defined by the consensus sequence G-F-N-I-δ5-δ6-δ7, where δ5 is T, I, S, G, or R; δ6 is S, R, N, K, or G; and δ7 is N, Y or H.
2.9.3. Chothia CDR-H2 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a Chothia CDR-H2 sequence defined by the consensus sequence ε1-ε2-ε3-ε4-G-ε6, where ε1 is W, N, T, V, I, S, A, or M; ε2 is S or P; ε3 is absent, Y, V, G, D, N, T, or A; ε4 is D, G, N, R, Q, A, or V; and ε6 is Y, I, D, S, or F.
In some embodiments, the Tim-3 antibody comprises a Chothia CDR-H2 sequence defined by the consensus sequence ε1-P-ε3-ε4-G-ε6, where ε1 is T, V, I, S, A, or M; ε3 is V, G, D, N, T, or A; and ε4 is G, R, Q, A, or V; and ε6 is Y, I, D, S, or F.
2.9.4. Kabat CDR-H1 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a Kabat CDR-H1 sequence defined by the consensus sequence ξ1-ξ2-ξ3-ξ4-ξ5, where ξ1 is D, S, G, R, N, or K; ξ2 is Y, H, or N; ξ3 is G, T, Y, A, or V; ξ4 is V, M, or I; and ξ5 is N or H.
In some embodiments, the Tim-3 antibody comprises a Kabat CDR-H1 sequence defined by the consensus sequence η1-η2-η3-η4-η5, where η1 is G, R, N, K, or S; η2 is Y, H, or N; and η3 is Y, A, or V.
2.9.5. Kabat CDR-H2 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence θ1-I-θ3-θ4-θ5-θ6-θ7-θ8-T-θ10-θ11-θ12-θ13-θ14-θ15-θ16-θ17, where θ1 is V, L, G, D, or A; θ3 is W, N, T, V, I, S, A, or M; θ4 is S or P; θ5 is absent, Y, V, G, D, N, T, or A; θ6 is D, N, R, Q, G, A, or V; θ7 is G; θ8 is I, Y, D, S, or F; θ10 is T, E, D, or G; θ11 is Y; θ12 is N, or A; θ13 is P, Q, S, or D; θ14 is A, K, or S; θ15 is L, F, or V; θ16 is Q or K; and θ17 is S, G or D.
In some embodiments, the Tim-3 antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence V-I-W-S-D-G-S-T-T-Y-N-θ13-θ14-θ15-θ16, where θ13 is P, Q, S, or D; θ14 is S, K, or A; θ15 is F, L, or V; θ16 is Q or K; θ17 is G or S.
In some embodiments, the Tim-3 antibody comprises a Kabat CDR-H2 sequence defined by the consensus sequence θ1-I-θ3-P-θ5-θ6-G-θ8-T-θ10-Y-A-D-S-V-K-θ17, where θ1 is D, A, or G; θ3 is T, V, I, S, A, or M; θ5 is V, G, D, N, T, or A; θ6 is R, Q, G, A, or V; θ8 is Y, I, D, S, or F; θ10 is E, D, or G; and θ17 is G or D.
2.9.6. CDR-L3 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a CDR-L3 sequence defined by the consensus sequence ι1-Q-ι3-ι4-ι5-ι6-P-ι8-T, where ι1 is Q or F; ι3 S or G; ι4 is N or S ι5 is E or H; ι6 is D or V; and ι8 is Y or W.
In some embodiments, the Tim-3 antibody comprises a CDR-L3 sequence defined by the consensus sequence Q-Q-H-Y-T-T-P-P-T.
2.9.7. CDR-L2 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a CDR-L2 sequence defined by the consensus sequence λ1-λ2-S-N-λ5-λ6-S, where λ1 is A or K; λ2 is A or V; λ5 is L or R; λ6 is E or F.
In some embodiments, the Tim-3 antibody comprises a CDR-L2 sequence defined by the consensus sequence π1-π2-π3-π4-L-π6-π7, where π1 is S or D; π2 is A or D; π3 is S or D; π4 is F or D; π6 is Y or D; and π7 is D or S.
2.9.8. CDR-L1 Consensus Sequences
In some embodiments, the Tim-3 antibody comprises a CDR-L1 sequence defined by the consensus sequence μ1-μ2-S-Q-S-μ6-μ7-μ8-μ9-μ10-μ11-μ12-μ13-μ14-μ15-μ16, where μ1 is K or R; μ2 is A or S; μ6 is V or I; μ7 is D or V; μ8 is Y or H; μ9 is D or T; μ10 is absent or N; μ11 is G; μ12 is N; μ13 is S or T; μ14 is Y; μ15 is V or L; and μ16 is N, A, or E.
In some embodiments, the Tim-3 antibody comprises a CDR-L1 sequence defined by the consensus sequence K-A-S-S-Q-V-D-Y-D-G-N-S-Y-V-μ16, where μ16 is N or A.
In some embodiments, the Tim-3 antibody comprises a CDR-L1 sequence defined by the consensus sequence R-A-S-Q-D-V-N-T-A-V-A.
Provided herein are PD-1 antibodies that selectively bind human PD-1. In some aspects, the antibody selectively binds to the extracellular domain of human PD-1. In some aspects, the antibody selectively binds to one or more of full-length human PD-1, PD-1Δex2, PD-1Δex3, PD-1Δex2,3, and PD-1Δex2,3,4. See Nielsen et al., Cellular Immunology, 2005, 235:109-116, incorporated by reference in its entirety.
In some embodiments, the PD-1 antibody binds to a homolog of human PD-1. In some aspects, the antibody binds to a homolog of human Tim-3 from a species selected from monkeys, mice, dogs, cats, rats, cows, horses, goats and sheep. In some aspects, the homolog is a cynomolgus monkey homolog. In some aspects, the homolog is a murine homolog.
In some embodiments, the PD-1 antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.
In some embodiments, the PD-1 antibody comprises a heavy chain. In some aspects, the heavy chain is an IgA. In some aspects, the heavy chain is an IgD. In some aspects, the heavy chain is an IgE. In some aspects, the heavy chain is an IgG. In some aspects, the heavy chain is an IgM. In some aspects, the heavy chain is an IgG1. In some aspects, the heavy chain is an IgG2. In some aspects, the heavy chain is an IgG3. In some aspects, the heavy chain is an IgG4. In some aspects, the heavy chain is an IgA1. In some aspects, the heavy chain is an IgA2.
In some embodiments, the PD-1 antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab′)2 fragment. In some aspects, the antibody fragment is a Fab′ fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.
In some embodiments, the PD-1 antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.
In some embodiments, the PD-1 antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.
In some embodiments, the PD-1 antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from an illustrative sequence provided in this disclosure or in, e.g., WO 2016/077397, which is incorporated herein by reference in its entirety.
In some embodiments, the PD-1 antibody inhibits the binding of PD-1 to its ligands. In some aspects, the antibody inhibits the binding of PD-1 to PD-L1. In some aspects, the antibody inhibits the binding of PD-1 to PD-L2. In some aspects, the antibody inhibits the binding of PD-1 to PD-L1 and PD-L2.
In some embodiments, the PD-1 antibody is provided as a single arm binder. For example, the PD-1 antibody can be provided as part of a bi-specific antibody or bi-specific antibody construct as disclosed here.
The PD-1 antibodies provided herein may be useful for the treatment of a variety of diseases and conditions, including cancers, autoimmune diseases, and infections.
3.1 PD-1 CDR-H3 Sequences
In some embodiments, the PD-1 antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the CDR-H3 sequence is a CDR-H3 sequence of a VH sequence provided in SEQ ID NOs.: 181-220. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some embodiments, the PD-1 antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence selected from SEQ ID NOs.: 182-220. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 182. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 183. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 184. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 185. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 186. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 187. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 188. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 189. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 190. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 191. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 192. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 193. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 194. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 195. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 196. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 197. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 198. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 199.
In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 200. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 201. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 202. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 203. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 204. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 205. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 206. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 207. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 208. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 209. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 210. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 211. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 212. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 213. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 214. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 215. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 216. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 217. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 218. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 219. In some aspects, the antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of a VH sequence of SEQ ID NO: 220. In some embodiments, the PD-1 antibody comprises a CDR-H3 sequence comprising, consisting of, or consisting essentially of a CDR-H3 sequence of an illustrative antibody or VH sequence provided in WO 2016/077397.
In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.2 PD-1 VH Sequences Comprising Illustrative CDRs
In some embodiments, the PD-1 antibody comprises a VH sequence comprising one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-H sequences provided in this disclosure, and variants thereof. In some embodiments, the CDR-H sequences comprise, consist of, or consist essentially of one or more CDR-H sequences provided in a VH sequence selected from SEQ ID NOs: 181-220. In some embodiments, the PD-1 antibody comprises a VH sequence comprising one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-H sequences provided in WO 2016/077397.
3.3.1 VH Sequences Comprising Illustrative Kabat CDRs
In some embodiments, the PD-1 antibody comprises a VH sequence comprising one or more Kabat CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-H sequences provided in this disclosure, and variants thereof. In some embodiments, the CDR-H sequences comprise, consist of, or consist essentially of one or more CDR-H sequences provided in a VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.1 Kabat CDR-H3
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H3 sequence, wherein the CDR-H3 sequence comprises, consists of, or consists essentially of a Kabat CDR-H3 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Kabat CDR-H3 sequence is a Kabat CDR-H3 sequence of a VH sequence provided in SEQ ID NOs.: 181-220. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H3 sequence, wherein the CDR-H3 sequence comprises, consists of, or consists essentially of a Kabat CDR-H3 sequence of an illustrative antibody or VH sequence provided in WO 2016/077397.
In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence selected from SEQ ID NOs.: 182-220. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 182. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 183. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 184. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 185. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 186. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 187. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 188. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 189. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 190. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 191. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 192. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 193. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 194. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 195. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 196. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 197. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 198. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 199.
In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 200. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 201. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 202. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 203. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 204. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 205. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 206. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 207. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 208. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 209. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 210. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 211. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 212. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 213. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 214. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 215. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 216. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 217. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 218. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 219. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H3 sequence of a VH sequence of SEQ ID NO: 220.
3.2.2.2 Kabat CDR-H2
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H2 sequence, wherein the CDR-H2 sequence comprises, consists of, or consists essentially of a Kabat CDR-H2 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Kabat CDR-H2 sequence is a Kabat CDR-H2 sequence of a VH sequence provided in SEQ ID NOs.: 181-220. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H2 sequence, wherein the CDR-H2 sequence comprises, consists of, or consists essentially of a Kabat CDR-H2 sequence of an illustrative antibody or VH sequence provided in WO 2016/077397.
In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence selected from SEQ ID NOs.: 182-220. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 182. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 183. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 184. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 185. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 186. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 187. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 188. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 189. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 190. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 191. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 192. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 193. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 194. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 195. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 196. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 197. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 198. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 199.
In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 200. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 201. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 202. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 203. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 204. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 205. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 206. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 207. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 208. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 209. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 210. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 211. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 212. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 213. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 214. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 215. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 216. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 217. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 218. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 219. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H2 sequence of a VH sequence of SEQ ID NO: 220.
3.2.2.3 Kabat CDR-H1
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H1 sequence, wherein the CDR-H1 sequence comprises, consists of, or consists essentially of a Kabat CDR-H1 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Kabat CDR-H1 sequence is a Kabat CDR-H1 sequence of a VH sequence provided in SEQ ID NOs.: 181-220. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H1 sequence, wherein the CDR-H1 sequence comprises, consists of, or consists essentially of a Kabat CDR-H1 sequence of an illustrative antibody or VH sequence provided in WO 2016/077397.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 57-62. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 57. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 58. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 59. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 60. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 61. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 62.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence selected from SEQ ID NOs.: 182-220. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 182. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 183. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 184. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 185. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 186. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 187. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 188. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 189. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 190. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 191. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 192. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 193. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 194. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 195. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 196. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 197. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 198. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 199.
In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 200. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 201. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 202. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 203. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 204. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 205. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 206. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 207. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 208. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 209. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 210. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 211. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 212. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 213. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 214. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 215. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 216. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 217. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 218. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 219. In some aspects, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a Kabat CDR-H1 sequence of a VH sequence of SEQ ID NO: 220.
3.2.2.4 Kabat CDR-H3+Kabat CDR-H2
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H3 sequence of a VH sequence selected from SEQ ID NOs.: 181-220, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H2 sequence of a VH sequence selected from SEQ ID NOs.: 181-220. In some aspects, the Kabat CDR-H3 sequence and the Kabat CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H3 and Kabat CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.5 Kabat CDR-H3+Kabat CDR-H1
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119, and a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 57-62. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H3 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220, and a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H1 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220. In some aspects, the Kabat CDR-H3 sequence and the Kabat CDR-H1 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H3 and Kabat CDR-H1 are both from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.6 Kabat CDR-H1+Kabat CDR-H2
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 57-62, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H1 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220, and a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H2 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220. In some aspects, the Kabat CDR-H1 sequence and the Kabat CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1 and Kabat CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.7 Kabat CDR-H1+Kabat CDR-H2+Kabat CDR-H3
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 57-62, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H1 sequence of a VH sequence selected from SEQ ID NOs.: 181-220, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H2 sequence of a VH sequence selected from SEQ ID NOs.: 181-220, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Kabat CDR-H3 sequence of a VH sequence selected from SEQ ID NOs.: 181-220. In some aspects, the Kabat CDR-H1 sequence, Kabat CDR-H2 sequence, and Kabat CDR-H3 are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.8 Variants of VH Sequences Comprising Illustrative Kabat CDRs
In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure. In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in WO 2016/077397.
In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H3 sequences provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.3.2 VH Sequences Comprising Illustrative Chothia CDRs
In some embodiments, the PD-1 antibody comprises a VH sequence comprising one or more Chothia CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-H sequences provided in this disclosure, and variants thereof. In some embodiments, the PD-1 antibody comprises a VH sequence comprising one or more Chothia CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-H sequences provided in WO 2016/077397.
3.2.2.1 Chothia CDR-H3
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H3 sequence, wherein the CDR-H3 sequence comprises, consists of, or consists essentially of a Chothia CDR-H3 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Chothia CDR-H3 sequence is a Chothia CDR-H3 sequence of a VH sequence provided in SEQ ID NOs.: 181-220. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H3 sequence, wherein the CDR-H3 sequence comprises, consists of, or consists essentially of a Chothia CDR-H3 sequence of an illustrative antibody or VH sequence provided in WO 2016/077397.
In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence selected from SEQ ID NOs.: 182-220. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 182. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 183. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 184. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 185. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 186. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 187. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 188. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 189. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 190. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 191. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 192. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 193. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 194. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 195. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 196. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 197. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 198. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 199.
In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 200. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 201. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 202. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 203. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 204. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 205. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 206. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 207. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 208. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 209. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 210. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 211. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 212. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 213. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 214. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 215. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 216. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 217. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 218. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 219. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H3 sequence of a VH sequence of SEQ ID NO: 220.
3.2.2.2 Chothia CDR-H2
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H2 sequence, wherein the CDR-H2 sequence comprises, consists of, or consists essentially of a Chothia CDR-H2 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Chothia CDR-H2 sequence is a Chothia CDR-H2 sequence of a VH sequence provided in SEQ ID NOs.: 181-220. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H2 sequence, wherein the CDR-H2 sequence comprises, consists of, or consists essentially of a Chothia CDR-H2 sequence of an illustrative antibody or VH sequence provided in WO 2016/077397.
In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 81.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence selected from SEQ ID NOs.: 182-220. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 182. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 183. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 184. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 185. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 186. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 187. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 188. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 189. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 190. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 191. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 192. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 193. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 194. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 195. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 196. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 197. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 198. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 199.
In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 200. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 201. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 202. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 203. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 204. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 205. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 206. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 207. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 208. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 209. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 210. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 211. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 212. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 213. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 214. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 215. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 216. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 217. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 218. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 219. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H2 sequence of a VH sequence of SEQ ID NO: 220.
3.2.2.3 Chothia CDR-H1
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H1 sequence, wherein the CDR-H1 sequence comprises, consists of, or consists essentially of a Chothia CDR-H1 sequence of an illustrative antibody or VH sequence provided herein. In some aspects, the Chothia CDR-H1 sequence is a Chothia CDR-H1 sequence of a VH sequence provided in SEQ ID NOs.: 181-220. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a CDR-H1 sequence, wherein the CDR-H1 sequence comprises, consists of, or consists essentially of a Chothia CDR-H1 sequence of an illustrative antibody or VH sequence provided in WO 2016/077397.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 24-38. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 24. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 25. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 26. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 27. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 28. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 29. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 30. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 31. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 32. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 33. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 34. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 35. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 36. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 37. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 38.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence selected from SEQ ID NOs.: 182-220. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 182. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 183. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 184. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 185. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 186. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 187. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 188. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 189. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 190. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 191. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 192. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 193. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 194. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 195. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 196. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 197. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 198. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 199.
In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 200. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 201. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 202. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 203. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 204. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 205. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 206. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 207. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 208. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 209. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 210. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 211. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 212. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 213. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 214. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 215. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 216. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 217. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 218. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 219. In some aspects, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a Chothia CDR-H1 sequence of a VH sequence of SEQ ID NO: 220.
3.2.2.4 Chothia CDR-H3+Chothia CDR-H2
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 81. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H3 sequence of a VH sequence selected from SEQ ID NOs.: 181-220, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H2 sequence of a VH sequence selected from SEQ ID NOs.: 181-220. In some aspects, the Chothia CDR-H3 sequence and the Chothia CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H3 and Chothia CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.5 Chothia CDR-H3+Chothia CDR-H1
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119, and a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 24-38. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H3 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220, and a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H1 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220. In some aspects, the Chothia CDR-H3 sequence and the Chothia CDR-H1 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H3 and Chothia CDR-H1 are both from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.6 Chothia CDR-H1+Chothia CDR-H2
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 24-38 and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 81. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H1 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220, and a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H2 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220. In some aspects, the Chothia CDR-H1 sequence and the Chothia CDR-H2 sequence are both from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1 and Chothia CDR-H2 are both from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.7 Chothia CDR-H1+Chothia CDR-H2+Chothia CDR-H3
In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs:24-38, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 81, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119. In some embodiments, the PD-1 antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H1 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H2 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a Chothia CDR-H3 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220. In some aspects, the Chothia CDR-H1 sequence, Chothia CDR-H2 sequence, and Chothia CDR-H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 181-220.
3.2.2.8 Variants of VH Sequences Comprising Illustrative Chothia CDRs
In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-H3, CDR-H2, and/or CDR-H1 sequence provided in this disclosure.
In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H3 sequences provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H2 sequences provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia CDR-H1 sequences provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.3 PD-1 VH Sequences
In some embodiments, the PD-1 antibody comprises, consists of, or consists essentially of a VH sequence provided in SEQ ID NOs.: 181-220.
In some embodiments, the PD-1 antibody comprises a VH sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 181-220. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 181. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 182. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 183. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 184. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 185. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 186. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 187. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 188. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 189. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 190. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 191. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 192. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 193. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 194. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 195. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 196. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 197. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 198. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 199.
In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 200. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 201. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 202. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 203. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 204. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 205. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 206. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 207. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 208. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 209. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 210. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 211. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 212. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 213. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 214. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 215. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 216. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 217. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 218. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 219. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 220.
3.3.1 Variants of VH Sequences
In some embodiments, the VH sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VH sequence provided in this disclosure. In some embodiments, the VH sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VH sequence provided in WO 2016/077397.
In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VH sequences provided in this disclosure.
In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.4 PD-1 CDR-L3 Sequences
In some embodiments, the PD-1 antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L3 sequence is a CDR-L3 sequence of a VL sequence provided in SEQ ID NOs.: 236-269. In some embodiments, the PD-1 antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of an illustrative antibody or VL sequence provided in WO 2016/077397.
In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143.
In some embodiments, the PD-1 antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence selected from SEQ ID NOs.: 237-269. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 237. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 238. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 239. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 240. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 241. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 242. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 243. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 244. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 245. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 246. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 247. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 248. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 249.
In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 250. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 251. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 252. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 253. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 254. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 255. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 256. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 257. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 258. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 259. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 260. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 261. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 262. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 263. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 264. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 265. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 266. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 267. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 268. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 269.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.5 PD-1 VL Sequences Comprising Illustrative CDRs
In some embodiments, the PD-1 antibody comprises a VL sequence comprising one or more CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-L sequences provided in this disclosure, and variants thereof
3.5.1 CDR-L3
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L3 sequence, wherein the CDR-L3 sequence comprises, consists of, or consists essentially of a CDR-L3 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L3 sequence is a CDR-L3 sequence of a VL sequence provided in SEQ ID NOs.: 236-269. In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L3 sequence, wherein the CDR-L3 sequence comprises, consists of, or consists essentially of a CDR-L3 sequence of an illustrative antibody or VL sequence provided in WO 2016/077397.
In some embodiments, the antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143.
In some embodiments, the PD-1 antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence selected from SEQ ID NOs.: 237-269. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 237. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 238. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 239. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 240. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 241. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 242. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 243. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 244. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 245. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 246. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 247. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 248. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 249.
In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 250. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 251. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 252. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 253. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 254. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 255. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 256. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 257. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 258. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 259. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 260. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 261. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 262. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 263. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 264. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 265. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 266. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 267. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 268. In some aspects, the antibody comprises a CDR-L3 sequence comprising, consisting of, or consisting essentially of a CDR-L3 sequence of a VL sequence of SEQ ID NO: 269.
3.5.2 CDR-L2
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L2 sequence, wherein the CDR-L2 sequence comprises, consists of, or consists essentially of a CDR-L2 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L2 sequence is a CDR-L2 sequence of a VL sequence provided in SEQ ID NOs.: 236-269. In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L2 sequence, wherein the CDR-L2 sequence comprises, consists of, or consists essentially of a CDR-L2 sequence of an illustrative antibody or VL sequence provided in WO 2016/077397.
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 134-139. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 134. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 135. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 136. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 137. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 138. In some aspects, the antibody comprises a VL sequence comprising a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 139.
In some embodiments, the PD-1 antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence selected from SEQ ID NOs.: 237-269. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 237. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 238. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 239. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 240. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 241. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 242. In some aspects, the antibody comprises a CDR L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 243. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 244. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 245. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 246. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 247. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 248. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 249.
In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 250. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 251. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 252. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 253. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 254. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 255. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 256. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 257. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 258. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 259. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 260. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 261. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 262. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 263. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 264. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 265. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 266. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 267. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 268. In some aspects, the antibody comprises a CDR-L2 sequence comprising, consisting of, or consisting essentially of a CDR-L2 sequence of a VL sequence of SEQ ID NO: 269.
3.5.3 CDR-L1
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L1 sequence, wherein the CDR-L1 sequence comprises, consists of, or consists essentially of a CDR-L1 sequence of an illustrative antibody or VL sequence provided herein. In some aspects, the CDR-L1 sequence is a CDR-L1 sequence of a VL sequence provided in SEQ ID NOs.: 236-269. In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L1 sequence, wherein the CDR-L1 sequence comprises, consists of, or consists essentially of a CDR-L1 sequence of an illustrative antibody or VL sequence provided in WO 2016/077397.
In some embodiments, the antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124.
In some embodiments, the PD-1 antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence selected from SEQ ID NOs.: 237-269. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 237. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 238. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 239. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 240. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 241. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 242. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 243. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 244. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 245. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 246. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 247. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 248. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 249.
In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 250. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 251. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 252. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 253. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 254. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 255. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 256. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 257. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 258. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 259. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 260. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 261. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 262. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 263. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 264. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 265. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 266. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 267. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 268. In some aspects, the antibody comprises a CDR-L1 sequence comprising, consisting of, or consisting essentially of a CDR-L1 sequence of a VL sequence of SEQ ID NO: 269.
3.5.4 CDR-L3+CDR-L2
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 134-139. In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L3 sequence of a VL sequence selected from SEQ ID NOs.: 236-269, and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L2 sequence of a VL sequence selected from SEQ ID NOs.: 236-269. In some aspects, the CDR-L3 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L3 and CDR-L2 are both from a single illustrative VL sequence selected from SEQ ID NOs: 236-269. In some aspects, the CDR-L3 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in WO 2016/077397.
3.5.5 CDR-L3+CDR-L1
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143 and a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124. In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L3 sequence of a VL sequence selected from SEQ ID NOs.: 236-269, and a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L1 sequence of a VL sequence selected from SEQ ID NOs.: 236-269. In some aspects, the CDR-L3 sequence and the CDR-L1 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L3 and CDR-L1 are both from a single illustrative VL sequence selected from SEQ ID NOs: 236-269. In some aspects, the CDR-L3 sequence and the CDR-L1 sequence are both from a single illustrative VL sequence provided in WO 2016/077397.
3.5.6 CDR-L1+CDR-L2
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124 and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 134-139. In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L1 sequence of a VL sequence selected from SEQ ID NOs.: 236-269, and a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L2 sequence of a VL sequence selected from SEQ ID NOs.: 236-269. In some aspects, the CDR-L1 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L1 and CDR-L2 are both from a single illustrative VL sequence selected from SEQ ID NOs: 236-269. In some aspects, the CDR-L1 sequence and the CDR-L2 sequence are both from a single illustrative VL sequence provided in WO 2016/077397.
3.5.7 CDR-L1+CDR-L2+CDR-L3
In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 134-139, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143. In some embodiments, the PD-1 antibody comprises a VL sequence comprising a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L1 sequence of a VL sequence selected from SEQ ID NOs.: 236-269, a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L2 sequence of a VL sequence selected from SEQ ID NOs.: 236-269, and a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from a CDR-L3 sequence of a VL sequence selected from SEQ ID NOs.: 236-269. In some aspects, the CDR-L1 sequence, CDR-L2 sequence, and CDR-L3 sequence are all from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the CDR-L1, CDR-L2, and CDR-L3 are all from a single illustrative VL sequence selected from SEQ ID NOs: 236-269. In some aspects, the CDR-L1 sequence, CDR-L2 sequence, and CDR-L3 sequence are all from a single illustrative VL sequence provided in WO 2016/077397.
3.5.8 Variants of VL Sequences Comprising Illustrative CDR-Ls
In some embodiments, the VL sequences provided herein comprise a variant of an illustrative CDR-L3, CDR-L2, and/or CDR-L1 sequence provided in this disclosure.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.6 PD-1 VL Sequences
In some embodiments, the PD-1 antibody comprises, consists of, or consists essentially of a VL sequence provided in SEQ ID NOs.: 236-269.
In some embodiments, the PD-1 antibody comprises a VL sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 236-269. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 236. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 237. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 238. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 239. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 240. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 241. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 242. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 243. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 244. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 245. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 246. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 247. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 248. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 249.
In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 250. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 251. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 252. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 253. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 254. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 255. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 256. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 257. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 258. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 259. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 260. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 261. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 262. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 263. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 264. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 265. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 266. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 267. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 268. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 269.
3.6.1 Variants of VL Sequences
In some embodiments, the VL sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VL sequence provided in this disclosure. In some embodiments, the VL sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VL sequence provided in WO 2016/077397.
In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.7 PD-1 Pairs
3.7.1 CDR-H3-CDR-L3 Pairs
In some embodiments, the PD-1 antibody comprises a CDR-H3 sequence and a CDR-L3 sequence. In some aspects, the CDR-H3 sequence is part of a VH and the CDR-L3 sequence is part of a VL.
In some aspects, the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 119 and a CDR-H3 sequence of a a VH sequence selected from SEQ ID NOs.: 182-220, and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 143 and a CDR-L3 sequence of a a VL sequence selected from SEQ ID NOs.: 237-269.
3.7.1.1 Variants of CDR-H3-CDR-L3 Pairs
In some embodiments, the CDR-H3-CDR-L3 pairs provided herein comprise a variant of an illustrative CDR-H3 and/or CDR-L1 sequence provided in this disclosure.
In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.7.2 CDR-H1-CDR-L1 Pairs
In some embodiments, the PD-1 antibody comprises a CDR-H1 sequence and a CDR-L1 sequence. In some aspects, the CDR-H1 sequence is part of a VH and the CDR-L1 sequence is part of a VL.
In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 24-38 and a Chothia CDR-H1 sequence of a a VH sequence selected from SEQ ID NOs.: 182-220, and the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 124 and a CDR-L1 sequence of a a VL sequence selected from SEQ ID NOs.: 237-269.
In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 57-62 and a Kabat CDR-H1 sequence of a a VH sequence selected from SEQ ID NOs.: 182-220, and the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 124 and a CDR-L1 sequence of a a VL sequence selected from SEQ ID NOs.: 237-269.
3.7.2.1 Variants of CDR-H1-CDR-L1 Pairs
In some embodiments, the CDR-H1-CDR-L1 pairs provided herein comprise a variant of an illustrative CDR-H1 and/or CDR-L1 sequence provided in this disclosure.
In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.7.3 CDR-H2-CDR-L2 Pairs
In some embodiments, the PD-1 antibody comprises a CDR-H2 sequence and a CDR-L2 sequence. In some aspects, the CDR-H2 sequence is part of a VH and the CDR-L2 sequence is part of a VL.
In some aspects, the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 81 and a Chothia CDR-H2 sequence of a a VH sequence selected from SEQ ID NOs.: 182-220, and the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 134-139 and a CDR-L2 sequence of a a VL sequence selected from SEQ ID NOs.: 237-269.
In some aspects, the CDR-H1 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NO: 110 and a Kabat CDR-H2 sequence of a a VH sequence selected from SEQ ID NOs.: 182-220, and the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 134-139 and a CDR-L2 sequence of a a VL sequence selected from SEQ ID NOs.: 237-269.
3.7.3.1 Variants of CDR-H2-CDR-L2 Pairs
In some embodiments, the CDR-H2-CDR-L2 pairs provided herein comprise a variant of an illustrative CDR-H2 and/or CDR-L2 sequence provided in this disclosure.
In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H2 sequence provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H2 sequences provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.7.4 VH-VL Pairs
In some embodiments, the PD-1 antibody comprises a VH sequence and a VL sequence.
In some aspects, the VH sequence is a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 181-220, and the VL sequence is a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 236-269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 181 and SEQ ID NO: 236; SEQ ID NO: 181 and SEQ ID NO: 325; SEQ ID NO: 181 and SEQ ID NO: 237; SEQ ID NO: 181 and SEQ ID NO: 238; SEQ ID NO: 181 and SEQ ID NO: 239; SEQ ID NO: 181 and SEQ ID NO: 240; SEQ ID NO: 181 and SEQ ID NO: 241; SEQ ID NO: 181 and SEQ ID NO: 242; SEQ ID NO: 181 and SEQ ID NO: 243; SEQ ID NO: 181 and SEQ ID NO: 244; SEQ ID NO: 181 and SEQ ID NO: 245; SEQ ID NO: 181 and SEQ ID NO: 246; SEQ ID NO: 181 and SEQ ID NO: 247; SEQ ID NO: 181 and SEQ ID NO: 248; SEQ ID NO: 181 and SEQ ID NO: 249; SEQ ID NO: 181 and SEQ ID NO: 250; SEQ ID NO: 181 and SEQ ID NO: 251; SEQ ID NO: 181 and SEQ ID NO: 252; SEQ ID NO: 181 and SEQ ID NO: 253; SEQ ID NO: 181 and SEQ ID NO: 254; SEQ ID NO: 181 and SEQ ID NO: 255; SEQ ID NO: 181 and SEQ ID NO: 256; SEQ ID NO: 181 and SEQ ID NO: 257; SEQ ID NO: 181 and SEQ ID NO: 258; SEQ ID NO: 181 and SEQ ID NO: 259; SEQ ID NO: 181 and SEQ ID NO: 260; SEQ ID NO: 181 and SEQ ID NO: 261; SEQ ID NO: 181 and SEQ ID NO: 262; SEQ ID NO: 181 and SEQ ID NO: 263; SEQ ID NO: 181 and SEQ ID NO: 264; SEQ ID NO: 181 and SEQ ID NO: 265; SEQ ID NO: 181 and SEQ ID NO: 266; SEQ ID NO: 181 and SEQ ID NO: 267; SEQ ID NO: 181 and SEQ ID NO: 268; and SEQ ID NO: 181 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 182 and SEQ ID NO: 236; SEQ ID NO: 182 and SEQ ID NO: 325; SEQ ID NO: 182 and SEQ ID NO: 237; SEQ ID NO: 182 and SEQ ID NO: 238; SEQ ID NO: 182 and SEQ ID NO: 239; SEQ ID NO: 182 and SEQ ID NO: 240; SEQ ID NO: 182 and SEQ ID NO: 241; SEQ ID NO: 182 and SEQ ID NO: 242; SEQ ID NO: 182 and SEQ ID NO: 243; SEQ ID NO: 182 and SEQ ID NO: 244; SEQ ID NO: 182 and SEQ ID NO: 245; SEQ ID NO: 182 and SEQ ID NO: 246; SEQ ID NO: 182 and SEQ ID NO: 247; SEQ ID NO: 182 and SEQ ID NO: 248; SEQ ID NO: 182 and SEQ ID NO: 249; SEQ ID NO: 182 and SEQ ID NO: 250; SEQ ID NO: 182 and SEQ ID NO: 251; SEQ ID NO: 182 and SEQ ID NO: 252; SEQ ID NO: 182 and SEQ ID NO: 253; SEQ ID NO: 182 and SEQ ID NO: 254; SEQ ID NO: 182 and SEQ ID NO: 255; SEQ ID NO: 182 and SEQ ID NO: 256; SEQ ID NO: 182 and SEQ ID NO: 257; SEQ ID NO: 182 and SEQ ID NO: 258; SEQ ID NO: 182 and SEQ ID NO: 259; SEQ ID NO: 182 and SEQ ID NO: 260; SEQ ID NO: 182 and SEQ ID NO: 261; SEQ ID NO: 182 and SEQ ID NO: 262; SEQ ID NO: 182 and SEQ ID NO: 263; SEQ ID NO: 182 and SEQ ID NO: 264; SEQ ID NO: 182 and SEQ ID NO: 265; SEQ ID NO: 182 and SEQ ID NO: 266; SEQ ID NO: 182 and SEQ ID NO: 267; SEQ ID NO: 182 and SEQ ID NO: 268; and SEQ ID NO: 182 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 183 and SEQ ID NO: 236; SEQ ID NO: 183 and SEQ ID NO: 325; SEQ ID NO: 183 and SEQ ID NO: 237; SEQ ID NO: 183 and SEQ ID NO: 238; SEQ ID NO: 183 and SEQ ID NO: 239; SEQ ID NO: 183 and SEQ ID NO: 240; SEQ ID NO: 183 and SEQ ID NO: 241; SEQ ID NO: 183 and SEQ ID NO: 242; SEQ ID NO: 183 and SEQ ID NO: 243; SEQ ID NO: 183 and SEQ ID NO: 244; SEQ ID NO: 183 and SEQ ID NO: 245; SEQ ID NO: 183 and SEQ ID NO: 246; SEQ ID NO: 183 and SEQ ID NO: 247; SEQ ID NO: 183 and SEQ ID NO: 248; SEQ ID NO: 183 and SEQ ID NO: 249; SEQ ID NO: 183 and SEQ ID NO: 250; SEQ ID NO: 183 and SEQ ID NO: 251; SEQ ID NO: 183 and SEQ ID NO: 252; SEQ ID NO: 183 and SEQ ID NO: 253; SEQ ID NO: 183 and SEQ ID NO: 254; SEQ ID NO: 183 and SEQ ID NO: 255; SEQ ID NO: 183 and SEQ ID NO: 256; SEQ ID NO: 183 and SEQ ID NO: 257; SEQ ID NO: 183 and SEQ ID NO: 258; SEQ ID NO: 183 and SEQ ID NO: 259; SEQ ID NO: 183 and SEQ ID NO: 260; SEQ ID NO: 183 and SEQ ID NO: 261; SEQ ID NO: 183 and SEQ ID NO: 262; SEQ ID NO: 183 and SEQ ID NO: 263; SEQ ID NO: 183 and SEQ ID NO: 264; SEQ ID NO: 183 and SEQ ID NO: 265; SEQ ID NO: 183 and SEQ ID NO: 266; SEQ ID NO: 183 and SEQ ID NO: 267; SEQ ID NO: 183 and SEQ ID NO: 268; and SEQ ID NO: 183 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 184 and SEQ ID NO: 236; SEQ ID NO: 184 and SEQ ID NO: 325; SEQ ID NO: 184 and SEQ ID NO: 237; SEQ ID NO: 184 and SEQ ID NO: 238; SEQ ID NO: 184 and SEQ ID NO: 239; SEQ ID NO: 184 and SEQ ID NO: 240; SEQ ID NO: 184 and SEQ ID NO: 241; SEQ ID NO: 184 and SEQ ID NO: 242; SEQ ID NO: 184 and SEQ ID NO: 243; SEQ ID NO: 184 and SEQ ID NO: 244; SEQ ID NO: 184 and SEQ ID NO: 245; SEQ ID NO: 184 and SEQ ID NO: 246; SEQ ID NO: 184 and SEQ ID NO: 247; SEQ ID NO: 184 and SEQ ID NO: 248; SEQ ID NO: 184 and SEQ ID NO: 249; SEQ ID NO: 184 and SEQ ID NO: 250; SEQ ID NO: 184 and SEQ ID NO: 251; SEQ ID NO: 184 and SEQ ID NO: 252; SEQ ID NO: 184 and SEQ ID NO: 253; SEQ ID NO: 184 and SEQ ID NO: 254; SEQ ID NO: 184 and SEQ ID NO: 255; SEQ ID NO: 184 and SEQ ID NO: 256; SEQ ID NO: 184 and SEQ ID NO: 257; SEQ ID NO: 184 and SEQ ID NO: 258; SEQ ID NO: 184 and SEQ ID NO: 259; SEQ ID NO: 184 and SEQ ID NO: 260; SEQ ID NO: 184 and SEQ ID NO: 261; SEQ ID NO: 184 and SEQ ID NO: 262; SEQ ID NO: 184 and SEQ ID NO: 263; SEQ ID NO: 184 and SEQ ID NO: 264; SEQ ID NO: 184 and SEQ ID NO: 265; SEQ ID NO: 184 and SEQ ID NO: 266; SEQ ID NO: 184 and SEQ ID NO: 267; SEQ ID NO: 184 and SEQ ID NO: 268; and SEQ ID NO: 184 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 185 and SEQ ID NO: 236; SEQ ID NO: 185 and SEQ ID NO: 325; SEQ ID NO: 185 and SEQ ID NO: 237; SEQ ID NO: 185 and SEQ ID NO: 238; SEQ ID NO: 185 and SEQ ID NO: 239; SEQ ID NO: 185 and SEQ ID NO: 240; SEQ ID NO: 185 and SEQ ID NO: 241; SEQ ID NO: 185 and SEQ ID NO: 242; SEQ ID NO: 185 and SEQ ID NO: 243; SEQ ID NO: 185 and SEQ ID NO: 244; SEQ ID NO: 185 and SEQ ID NO: 245; SEQ ID NO: 185 and SEQ ID NO: 246; SEQ ID NO: 185 and SEQ ID NO: 247; SEQ ID NO: 185 and SEQ ID NO: 248; SEQ ID NO: 185 and SEQ ID NO: 249; SEQ ID NO: 185 and SEQ ID NO: 250; SEQ ID NO: 185 and SEQ ID NO: 251; SEQ ID NO: 185 and SEQ ID NO: 252; SEQ ID NO: 185 and SEQ ID NO: 253; SEQ ID NO: 185 and SEQ ID NO: 254; SEQ ID NO: 185 and SEQ ID NO: 255; SEQ ID NO: 185 and SEQ ID NO: 256; SEQ ID NO: 185 and SEQ ID NO: 257; SEQ ID NO: 185 and SEQ ID NO: 258; SEQ ID NO: 185 and SEQ ID NO: 259; SEQ ID NO: 185 and SEQ ID NO: 260; SEQ ID NO: 185 and SEQ ID NO: 261; SEQ ID NO: 185 and SEQ ID NO: 262; SEQ ID NO: 185 and SEQ ID NO: 263; SEQ ID NO: 185 and SEQ ID NO: 264; SEQ ID NO: 185 and SEQ ID NO: 265; SEQ ID NO: 185 and SEQ ID NO: 266; SEQ ID NO: 185 and SEQ ID NO: 267; SEQ ID NO: 185 and SEQ ID NO: 268; and SEQ ID NO: 185 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 186 and SEQ ID NO: 236; SEQ ID NO: 186 and SEQ ID NO: 325; SEQ ID NO: 186 and SEQ ID NO: 237; SEQ ID NO: 186 and SEQ ID NO: 238; SEQ ID NO: 186 and SEQ ID NO: 239; SEQ ID NO: 186 and SEQ ID NO: 240; SEQ ID NO: 186 and SEQ ID NO: 241; SEQ ID NO: 186 and SEQ ID NO: 242; SEQ ID NO: 186 and SEQ ID NO: 243; SEQ ID NO: 186 and SEQ ID NO: 244; SEQ ID NO: 186 and SEQ ID NO: 245; SEQ ID NO: 186 and SEQ ID NO: 246; SEQ ID NO: 186 and SEQ ID NO: 247; SEQ ID NO: 186 and SEQ ID NO: 248; SEQ ID NO: 186 and SEQ ID NO: 249; SEQ ID NO: 186 and SEQ ID NO: 250; SEQ ID NO: 186 and SEQ ID NO: 251; SEQ ID NO: 186 and SEQ ID NO: 252; SEQ ID NO: 186 and SEQ ID NO: 253; SEQ ID NO: 186 and SEQ ID NO: 254; SEQ ID NO: 186 and SEQ ID NO: 255; SEQ ID NO: 186 and SEQ ID NO: 256; SEQ ID NO: 186 and SEQ ID NO: 257; SEQ ID NO: 186 and SEQ ID NO: 258; SEQ ID NO: 186 and SEQ ID NO: 259; SEQ ID NO: 186 and SEQ ID NO: 260; SEQ ID NO: 186 and SEQ ID NO: 261; SEQ ID NO: 186 and SEQ ID NO: 262; SEQ ID NO: 186 and SEQ ID NO: 263; SEQ ID NO: 186 and SEQ ID NO: 264; SEQ ID NO: 186 and SEQ ID NO: 265; SEQ ID NO: 186 and SEQ ID NO: 266; SEQ ID NO: 186 and SEQ ID NO: 267; SEQ ID NO: 186 and SEQ ID NO: 268; and SEQ ID NO: 186 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 187 and SEQ ID NO: 236; SEQ ID NO: 187 and SEQ ID NO: 325; SEQ ID NO: 187 and SEQ ID NO: 237; SEQ ID NO: 187 and SEQ ID NO: 238; SEQ ID NO: 187 and SEQ ID NO: 239; SEQ ID NO: 187 and SEQ ID NO: 240; SEQ ID NO: 187 and SEQ ID NO: 241; SEQ ID NO: 187 and SEQ ID NO: 242; SEQ ID NO: 187 and SEQ ID NO: 243; SEQ ID NO: 187 and SEQ ID NO: 244; SEQ ID NO: 187 and SEQ ID NO: 245; SEQ ID NO: 187 and SEQ ID NO: 246; SEQ ID NO: 187 and SEQ ID NO: 247; SEQ ID NO: 187 and SEQ ID NO: 248; SEQ ID NO: 187 and SEQ ID NO: 249; SEQ ID NO: 187 and SEQ ID NO: 250; SEQ ID NO: 187 and SEQ ID NO: 251; SEQ ID NO: 187 and SEQ ID NO: 252; SEQ ID NO: 187 and SEQ ID NO: 253; SEQ ID NO: 187 and SEQ ID NO: 254; SEQ ID NO: 187 and SEQ ID NO: 255; SEQ ID NO: 187 and SEQ ID NO: 256; SEQ ID NO: 187 and SEQ ID NO: 257; SEQ ID NO: 187 and SEQ ID NO: 258; SEQ ID NO: 187 and SEQ ID NO: 259; SEQ ID NO: 187 and SEQ ID NO: 260; SEQ ID NO: 187 and SEQ ID NO: 261; SEQ ID NO: 187 and SEQ ID NO: 262; SEQ ID NO: 187 and SEQ ID NO: 263; SEQ ID NO: 187 and SEQ ID NO: 264; SEQ ID NO: 187 and SEQ ID NO: 265; SEQ ID NO: 187 and SEQ ID NO: 266; SEQ ID NO: 187 and SEQ ID NO: 267; SEQ ID NO: 187 and SEQ ID NO: 268; and SEQ ID NO: 187 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 188 and SEQ ID NO: 236; SEQ ID NO: 188 and SEQ ID NO: 325; SEQ ID NO: 188 and SEQ ID NO: 237; SEQ ID NO: 188 and SEQ ID NO: 238; SEQ ID NO: 188 and SEQ ID NO: 239; SEQ ID NO: 188 and SEQ ID NO: 240; SEQ ID NO: 188 and SEQ ID NO: 241; SEQ ID NO: 188 and SEQ ID NO: 242; SEQ ID NO: 188 and SEQ ID NO: 243; SEQ ID NO: 188 and SEQ ID NO: 244; SEQ ID NO: 188 and SEQ ID NO: 245; SEQ ID NO: 188 and SEQ ID NO: 246; SEQ ID NO: 188 and SEQ ID NO: 247; SEQ ID NO: 188 and SEQ ID NO: 248; SEQ ID NO: 188 and SEQ ID NO: 249; SEQ ID NO: 188 and SEQ ID NO: 250; SEQ ID NO: 188 and SEQ ID NO: 251; SEQ ID NO: 188 and SEQ ID NO: 252; SEQ ID NO: 188 and SEQ ID NO: 253; SEQ ID NO: 188 and SEQ ID NO: 254; SEQ ID NO: 188 and SEQ ID NO: 255; SEQ ID NO: 188 and SEQ ID NO: 256; SEQ ID NO: 188 and SEQ ID NO: 257; SEQ ID NO: 188 and SEQ ID NO: 258; SEQ ID NO: 188 and SEQ ID NO: 259; SEQ ID NO: 188 and SEQ ID NO: 260; SEQ ID NO: 188 and SEQ ID NO: 261; SEQ ID NO: 188 and SEQ ID NO: 262; SEQ ID NO: 188 and SEQ ID NO: 263; SEQ ID NO: 188 and SEQ ID NO: 264; SEQ ID NO: 188 and SEQ ID NO: 265; SEQ ID NO: 188 and SEQ ID NO: 266; SEQ ID NO: 188 and SEQ ID NO: 267; SEQ ID NO: 188 and SEQ ID NO: 268; and SEQ ID NO: 188 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 189 and SEQ ID NO: 236; SEQ ID NO: 189 and SEQ ID NO: 325; SEQ ID NO: 189 and SEQ ID NO: 237; SEQ ID NO: 189 and SEQ ID NO: 238; SEQ ID NO: 189 and SEQ ID NO: 239; SEQ ID NO: 189 and SEQ ID NO: 240; SEQ ID NO: 189 and SEQ ID NO: 241; SEQ ID NO: 189 and SEQ ID NO: 242; SEQ ID NO: 189 and SEQ ID NO: 243; SEQ ID NO: 189 and SEQ ID NO: 244; SEQ ID NO: 189 and SEQ ID NO: 245; SEQ ID NO: 189 and SEQ ID NO: 246; SEQ ID NO: 189 and SEQ ID NO: 247; SEQ ID NO: 189 and SEQ ID NO: 248; SEQ ID NO: 189 and SEQ ID NO: 249; SEQ ID NO: 189 and SEQ ID NO: 250; SEQ ID NO: 189 and SEQ ID NO: 251; SEQ ID NO: 189 and SEQ ID NO: 252; SEQ ID NO: 189 and SEQ ID NO: 253; SEQ ID NO: 189 and SEQ ID NO: 254; SEQ ID NO: 189 and SEQ ID NO: 255; SEQ ID NO: 189 and SEQ ID NO: 256; SEQ ID NO: 189 and SEQ ID NO: 257; SEQ ID NO: 189 and SEQ ID NO: 258; SEQ ID NO: 189 and SEQ ID NO: 259; SEQ ID NO: 189 and SEQ ID NO: 260; SEQ ID NO: 189 and SEQ ID NO: 261; SEQ ID NO: 189 and SEQ ID NO: 262; SEQ ID NO: 189 and SEQ ID NO: 263; SEQ ID NO: 189 and SEQ ID NO: 264; SEQ ID NO: 189 and SEQ ID NO: 265; SEQ ID NO: 189 and SEQ ID NO: 266; SEQ ID NO: 189 and SEQ ID NO: 267; SEQ ID NO: 189 and SEQ ID NO: 268; and SEQ ID NO: 189 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 190 and SEQ ID NO: 236; SEQ ID NO: 190 and SEQ ID NO: 325; SEQ ID NO: 190 and SEQ ID NO: 237; SEQ ID NO: 190 and SEQ ID NO: 238; SEQ ID NO: 190 and SEQ ID NO: 239; SEQ ID NO: 190 and SEQ ID NO: 240; SEQ ID NO: 190 and SEQ ID NO: 241; SEQ ID NO: 190 and SEQ ID NO: 242; SEQ ID NO: 190 and SEQ ID NO: 243; SEQ ID NO: 190 and SEQ ID NO: 244; SEQ ID NO: 190 and SEQ ID NO: 245; SEQ ID NO: 190 and SEQ ID NO: 246; SEQ ID NO: 190 and SEQ ID NO: 247; SEQ ID NO: 190 and SEQ ID NO: 248; SEQ ID NO: 190 and SEQ ID NO: 249; SEQ ID NO: 190 and SEQ ID NO: 250; SEQ ID NO: 190 and SEQ ID NO: 251; SEQ ID NO: 190 and SEQ ID NO: 252; SEQ ID NO: 190 and SEQ ID NO: 253; SEQ ID NO: 190 and SEQ ID NO: 254; SEQ ID NO: 190 and SEQ ID NO: 255; SEQ ID NO: 190 and SEQ ID NO: 256; SEQ ID NO: 190 and SEQ ID NO: 257; SEQ ID NO: 190 and SEQ ID NO: 258; SEQ ID NO: 190 and SEQ ID NO: 259; SEQ ID NO: 190 and SEQ ID NO: 260; SEQ ID NO: 190 and SEQ ID NO: 261; SEQ ID NO: 190 and SEQ ID NO: 262; SEQ ID NO: 190 and SEQ ID NO: 263; SEQ ID NO: 190 and SEQ ID NO: 264; SEQ ID NO: 190 and SEQ ID NO: 265; SEQ ID NO: 190 and SEQ ID NO: 266; SEQ ID NO: 190 and SEQ ID NO: 267; SEQ ID NO: 190 and SEQ ID NO: 268; and SEQ ID NO: 190 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 191 and SEQ ID NO: 236; SEQ ID NO: 191 and SEQ ID NO: 325; SEQ ID NO: 191 and SEQ ID NO: 237; SEQ ID NO: 191 and SEQ ID NO: 238; SEQ ID NO: 191 and SEQ ID NO: 239; SEQ ID NO: 191 and SEQ ID NO: 240; SEQ ID NO: 191 and SEQ ID NO: 241; SEQ ID NO: 191 and SEQ ID NO: 242; SEQ ID NO: 191 and SEQ ID NO: 243; SEQ ID NO: 191 and SEQ ID NO: 244; SEQ ID NO: 191 and SEQ ID NO: 245; SEQ ID NO: 191 and SEQ ID NO: 246; SEQ ID NO: 191 and SEQ ID NO: 247; SEQ ID NO: 191 and SEQ ID NO: 248; SEQ ID NO: 191 and SEQ ID NO: 249; SEQ ID NO: 191 and SEQ ID NO: 250; SEQ ID NO: 191 and SEQ ID NO: 251; SEQ ID NO: 191 and SEQ ID NO: 252; SEQ ID NO: 191 and SEQ ID NO: 253; SEQ ID NO: 191 and SEQ ID NO: 254; SEQ ID NO: 191 and SEQ ID NO: 255; SEQ ID NO: 191 and SEQ ID NO: 256; SEQ ID NO: 191 and SEQ ID NO: 257; SEQ ID NO: 191 and SEQ ID NO: 258; SEQ ID NO: 191 and SEQ ID NO: 259; SEQ ID NO: 191 and SEQ ID NO: 260; SEQ ID NO: 191 and SEQ ID NO: 261; SEQ ID NO: 191 and SEQ ID NO: 262; SEQ ID NO: 191 and SEQ ID NO: 263; SEQ ID NO: 191 and SEQ ID NO: 264; SEQ ID NO: 191 and SEQ ID NO: 265; SEQ ID NO: 191 and SEQ ID NO: 266; SEQ ID NO: 191 and SEQ ID NO: 267; SEQ ID NO: 191 and SEQ ID NO: 268; and SEQ ID NO: 191 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 192 and SEQ ID NO: 236; SEQ ID NO: 192 and SEQ ID NO: 325; SEQ ID NO: 192 and SEQ ID NO: 237; SEQ ID NO: 192 and SEQ ID NO: 238; SEQ ID NO: 192 and SEQ ID NO: 239; SEQ ID NO: 192 and SEQ ID NO: 240; SEQ ID NO: 192 and SEQ ID NO: 241; SEQ ID NO: 192 and SEQ ID NO: 242; SEQ ID NO: 192 and SEQ ID NO: 243; SEQ ID NO: 192 and SEQ ID NO: 244; SEQ ID NO: 192 and SEQ ID NO: 245; SEQ ID NO: 192 and SEQ ID NO: 246; SEQ ID NO: 192 and SEQ ID NO: 247; SEQ ID NO: 192 and SEQ ID NO: 248; SEQ ID NO: 192 and SEQ ID NO: 249; SEQ ID NO: 192 and SEQ ID NO: 250; SEQ ID NO: 192 and SEQ ID NO: 251; SEQ ID NO: 192 and SEQ ID NO: 252; SEQ ID NO: 192 and SEQ ID NO: 253; SEQ ID NO: 192 and SEQ ID NO: 254; SEQ ID NO: 192 and SEQ ID NO: 255; SEQ ID NO: 192 and SEQ ID NO: 256; SEQ ID NO: 192 and SEQ ID NO: 257; SEQ ID NO: 192 and SEQ ID NO: 258; SEQ ID NO: 192 and SEQ ID NO: 259; SEQ ID NO: 192 and SEQ ID NO: 260; SEQ ID NO: 192 and SEQ ID NO: 261; SEQ ID NO: 192 and SEQ ID NO: 262; SEQ ID NO: 192 and SEQ ID NO: 263; SEQ ID NO: 192 and SEQ ID NO: 264; SEQ ID NO: 192 and SEQ ID NO: 265; SEQ ID NO: 192 and SEQ ID NO: 266; SEQ ID NO: 192 and SEQ ID NO: 267; SEQ ID NO: 192 and SEQ ID NO: 268; and SEQ ID NO: 192 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 193 and SEQ ID NO: 236; SEQ ID NO: 193 and SEQ ID NO: 325; SEQ ID NO: 193 and SEQ ID NO: 237; SEQ ID NO: 193 and SEQ ID NO: 238; SEQ ID NO: 193 and SEQ ID NO: 239; SEQ ID NO: 193 and SEQ ID NO: 240; SEQ ID NO: 193 and SEQ ID NO: 241; SEQ ID NO: 193 and SEQ ID NO: 242; SEQ ID NO: 193 and SEQ ID NO: 243; SEQ ID NO: 193 and SEQ ID NO: 244; SEQ ID NO: 193 and SEQ ID NO: 245; SEQ ID NO: 193 and SEQ ID NO: 246; SEQ ID NO: 193 and SEQ ID NO: 247; SEQ ID NO: 193 and SEQ ID NO: 248; SEQ ID NO: 193 and SEQ ID NO: 249; SEQ ID NO: 193 and SEQ ID NO: 250; SEQ ID NO: 193 and SEQ ID NO: 251; SEQ ID NO: 193 and SEQ ID NO: 252; SEQ ID NO: 193 and SEQ ID NO: 253; SEQ ID NO: 193 and SEQ ID NO: 254; SEQ ID NO: 193 and SEQ ID NO: 255; SEQ ID NO: 193 and SEQ ID NO: 256; SEQ ID NO: 193 and SEQ ID NO: 257; SEQ ID NO: 193 and SEQ ID NO: 258; SEQ ID NO: 193 and SEQ ID NO: 259; SEQ ID NO: 193 and SEQ ID NO: 260; SEQ ID NO: 193 and SEQ ID NO: 261; SEQ ID NO: 193 and SEQ ID NO: 262; SEQ ID NO: 193 and SEQ ID NO: 263; SEQ ID NO: 193 and SEQ ID NO: 264; SEQ ID NO: 193 and SEQ ID NO: 265; SEQ ID NO: 193 and SEQ ID NO: 266; SEQ ID NO: 193 and SEQ ID NO: 267; SEQ ID NO: 193 and SEQ ID NO: 268; and SEQ ID NO: 193 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 194 and SEQ ID NO: 236; SEQ ID NO: 194 and SEQ ID NO: 325; SEQ ID NO: 194 and SEQ ID NO: 237; SEQ ID NO: 194 and SEQ ID NO: 238; SEQ ID NO: 194 and SEQ ID NO: 239; SEQ ID NO: 194 and SEQ ID NO: 240; SEQ ID NO: 194 and SEQ ID NO: 241; SEQ ID NO: 194 and SEQ ID NO: 242; SEQ ID NO: 194 and SEQ ID NO: 243; SEQ ID NO: 194 and SEQ ID NO: 244; SEQ ID NO: 194 and SEQ ID NO: 245; SEQ ID NO: 194 and SEQ ID NO: 246; SEQ ID NO: 194 and SEQ ID NO: 247; SEQ ID NO: 194 and SEQ ID NO: 248; SEQ ID NO: 194 and SEQ ID NO: 249; SEQ ID NO: 194 and SEQ ID NO: 250; SEQ ID NO: 194 and SEQ ID NO: 251; SEQ ID NO: 194 and SEQ ID NO: 252; SEQ ID NO: 194 and SEQ ID NO: 253; SEQ ID NO: 194 and SEQ ID NO: 254; SEQ ID NO: 194 and SEQ ID NO: 255; SEQ ID NO: 194 and SEQ ID NO: 256; SEQ ID NO: 194 and SEQ ID NO: 257; SEQ ID NO: 194 and SEQ ID NO: 258; SEQ ID NO: 194 and SEQ ID NO: 259; SEQ ID NO: 194 and SEQ ID NO: 260; SEQ ID NO: 194 and SEQ ID NO: 261; SEQ ID NO: 194 and SEQ ID NO: 262; SEQ ID NO: 194 and SEQ ID NO: 263; SEQ ID NO: 194 and SEQ ID NO: 264; SEQ ID NO: 194 and SEQ ID NO: 265; SEQ ID NO: 194 and SEQ ID NO: 266; SEQ ID NO: 194 and SEQ ID NO: 267; SEQ ID NO: 194 and SEQ ID NO: 268; and SEQ ID NO: 194 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 195 and SEQ ID NO: 236; SEQ ID NO: 195 and SEQ ID NO: 325; SEQ ID NO: 195 and SEQ ID NO: 237; SEQ ID NO: 195 and SEQ ID NO: 238; SEQ ID NO: 195 and SEQ ID NO: 239; SEQ ID NO: 195 and SEQ ID NO: 240; SEQ ID NO: 195 and SEQ ID NO: 241; SEQ ID NO: 195 and SEQ ID NO: 242; SEQ ID NO: 195 and SEQ ID NO: 243; SEQ ID NO: 195 and SEQ ID NO: 244; SEQ ID NO: 195 and SEQ ID NO: 245; SEQ ID NO: 195 and SEQ ID NO: 246; SEQ ID NO: 195 and SEQ ID NO: 247; SEQ ID NO: 195 and SEQ ID NO: 248; SEQ ID NO: 195 and SEQ ID NO: 249; SEQ ID NO: 195 and SEQ ID NO: 250; SEQ ID NO: 195 and SEQ ID NO: 251; SEQ ID NO: 195 and SEQ ID NO: 252; SEQ ID NO: 195 and SEQ ID NO: 253; SEQ ID NO: 195 and SEQ ID NO: 254; SEQ ID NO: 195 and SEQ ID NO: 255; SEQ ID NO: 195 and SEQ ID NO: 256; SEQ ID NO: 195 and SEQ ID NO: 257; SEQ ID NO: 195 and SEQ ID NO: 258; SEQ ID NO: 195 and SEQ ID NO: 259; SEQ ID NO: 195 and SEQ ID NO: 260; SEQ ID NO: 195 and SEQ ID NO: 261; SEQ ID NO: 195 and SEQ ID NO: 262; SEQ ID NO: 195 and SEQ ID NO: 263; SEQ ID NO: 195 and SEQ ID NO: 264; SEQ ID NO: 195 and SEQ ID NO: 265; SEQ ID NO: 195 and SEQ ID NO: 266; SEQ ID NO: 195 and SEQ ID NO: 267; SEQ ID NO: 195 and SEQ ID NO: 268; and SEQ ID NO: 195 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 196 and SEQ ID NO: 236; SEQ ID NO: 196 and SEQ ID NO: 325; SEQ ID NO: 196 and SEQ ID NO: 237; SEQ ID NO: 196 and SEQ ID NO: 238; SEQ ID NO: 196 and SEQ ID NO: 239; SEQ ID NO: 196 and SEQ ID NO: 240; SEQ ID NO: 196 and SEQ ID NO: 241; SEQ ID NO: 196 and SEQ ID NO: 242; SEQ ID NO: 196 and SEQ ID NO: 243; SEQ ID NO: 196 and SEQ ID NO: 244; SEQ ID NO: 196 and SEQ ID NO: 245; SEQ ID NO: 196 and SEQ ID NO: 246; SEQ ID NO: 196 and SEQ ID NO: 247; SEQ ID NO: 196 and SEQ ID NO: 248; SEQ ID NO: 196 and SEQ ID NO: 249; SEQ ID NO: 196 and SEQ ID NO: 250; SEQ ID NO: 196 and SEQ ID NO: 251; SEQ ID NO: 196 and SEQ ID NO: 252; SEQ ID NO: 196 and SEQ ID NO: 253; SEQ ID NO: 196 and SEQ ID NO: 254; SEQ ID NO: 196 and SEQ ID NO: 255; SEQ ID NO: 196 and SEQ ID NO: 256; SEQ ID NO: 196 and SEQ ID NO: 257; SEQ ID NO: 196 and SEQ ID NO: 258; SEQ ID NO: 196 and SEQ ID NO: 259; SEQ ID NO: 196 and SEQ ID NO: 260; SEQ ID NO: 196 and SEQ ID NO: 261; SEQ ID NO: 196 and SEQ ID NO: 262; SEQ ID NO: 196 and SEQ ID NO: 263; SEQ ID NO: 196 and SEQ ID NO: 264; SEQ ID NO: 196 and SEQ ID NO: 265; SEQ ID NO: 196 and SEQ ID NO: 266; SEQ ID NO: 196 and SEQ ID NO: 267; SEQ ID NO: 196 and SEQ ID NO: 268; and SEQ ID NO: 196 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 197 and SEQ ID NO: 236; SEQ ID NO: 197 and SEQ ID NO: 325; SEQ ID NO: 197 and SEQ ID NO: 237; SEQ ID NO: 197 and SEQ ID NO: 238; SEQ ID NO: 197 and SEQ ID NO: 239; SEQ ID NO: 197 and SEQ ID NO: 240; SEQ ID NO: 197 and SEQ ID NO: 241; SEQ ID NO: 197 and SEQ ID NO: 242; SEQ ID NO: 197 and SEQ ID NO: 243; SEQ ID NO: 197 and SEQ ID NO: 244; SEQ ID NO: 197 and SEQ ID NO: 245; SEQ ID NO: 197 and SEQ ID NO: 246; SEQ ID NO: 197 and SEQ ID NO: 247; SEQ ID NO: 197 and SEQ ID NO: 248; SEQ ID NO: 197 and SEQ ID NO: 249; SEQ ID NO: 197 and SEQ ID NO: 250; SEQ ID NO: 197 and SEQ ID NO: 251; SEQ ID NO: 197 and SEQ ID NO: 252; SEQ ID NO: 197 and SEQ ID NO: 253; SEQ ID NO: 197 and SEQ ID NO: 254; SEQ ID NO: 197 and SEQ ID NO: 255; SEQ ID NO: 197 and SEQ ID NO: 256; SEQ ID NO: 197 and SEQ ID NO: 257; SEQ ID NO: 197 and SEQ ID NO: 258; SEQ ID NO: 197 and SEQ ID NO: 259; SEQ ID NO: 197 and SEQ ID NO: 260; SEQ ID NO: 197 and SEQ ID NO: 261; SEQ ID NO: 197 and SEQ ID NO: 262; SEQ ID NO: 197 and SEQ ID NO: 263; SEQ ID NO: 197 and SEQ ID NO: 264; SEQ ID NO: 197 and SEQ ID NO: 265; SEQ ID NO: 197 and SEQ ID NO: 266; SEQ ID NO: 197 and SEQ ID NO: 267; SEQ ID NO: 197 and SEQ ID NO: 268; and SEQ ID NO: 197 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 198 and SEQ ID NO: 236; SEQ ID NO: 198 and SEQ ID NO: 325; SEQ ID NO: 198 and SEQ ID NO: 237; SEQ ID NO: 198 and SEQ ID NO: 238; SEQ ID NO: 198 and SEQ ID NO: 239; SEQ ID NO: 198 and SEQ ID NO: 240; SEQ ID NO: 198 and SEQ ID NO: 241; SEQ ID NO: 198 and SEQ ID NO: 242; SEQ ID NO: 198 and SEQ ID NO: 243; SEQ ID NO: 198 and SEQ ID NO: 244; SEQ ID NO: 198 and SEQ ID NO: 245; SEQ ID NO: 198 and SEQ ID NO: 246; SEQ ID NO: 198 and SEQ ID NO: 247; SEQ ID NO: 198 and SEQ ID NO: 248; SEQ ID NO: 198 and SEQ ID NO: 249; SEQ ID NO: 198 and SEQ ID NO: 250; SEQ ID NO: 198 and SEQ ID NO: 251; SEQ ID NO: 198 and SEQ ID NO: 252; SEQ ID NO: 198 and SEQ ID NO: 253; SEQ ID NO: 198 and SEQ ID NO: 254; SEQ ID NO: 198 and SEQ ID NO: 255; SEQ ID NO: 198 and SEQ ID NO: 256; SEQ ID NO: 198 and SEQ ID NO: 257; SEQ ID NO: 198 and SEQ ID NO: 258; SEQ ID NO: 198 and SEQ ID NO: 259; SEQ ID NO: 198 and SEQ ID NO: 260; SEQ ID NO: 198 and SEQ ID NO: 261; SEQ ID NO: 198 and SEQ ID NO: 262; SEQ ID NO: 198 and SEQ ID NO: 263; SEQ ID NO: 198 and SEQ ID NO: 264; SEQ ID NO: 198 and SEQ ID NO: 265; SEQ ID NO: 198 and SEQ ID NO: 266; SEQ ID NO: 198 and SEQ ID NO: 267; SEQ ID NO: 198 and SEQ ID NO: 268; and SEQ ID NO: 198 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 199 and SEQ ID NO: 236; SEQ ID NO: 199 and SEQ ID NO: 325; SEQ ID NO: 199 and SEQ ID NO: 237; SEQ ID NO: 199 and SEQ ID NO: 238; SEQ ID NO: 199 and SEQ ID NO: 239; SEQ ID NO: 199 and SEQ ID NO: 240; SEQ ID NO: 199 and SEQ ID NO: 241; SEQ ID NO: 199 and SEQ ID NO: 242; SEQ ID NO: 199 and SEQ ID NO: 243; SEQ ID NO: 199 and SEQ ID NO: 244; SEQ ID NO: 199 and SEQ ID NO: 245; SEQ ID NO: 199 and SEQ ID NO: 246; SEQ ID NO: 199 and SEQ ID NO: 247; SEQ ID NO: 199 and SEQ ID NO: 248; SEQ ID NO: 199 and SEQ ID NO: 249; SEQ ID NO: 199 and SEQ ID NO: 250; SEQ ID NO: 199 and SEQ ID NO: 251; SEQ ID NO: 199 and SEQ ID NO: 252; SEQ ID NO: 199 and SEQ ID NO: 253; SEQ ID NO: 199 and SEQ ID NO: 254; SEQ ID NO: 199 and SEQ ID NO: 255; SEQ ID NO: 199 and SEQ ID NO: 256; SEQ ID NO: 199 and SEQ ID NO: 257; SEQ ID NO: 199 and SEQ ID NO: 258; SEQ ID NO: 199 and SEQ ID NO: 259; SEQ ID NO: 199 and SEQ ID NO: 260; SEQ ID NO: 199 and SEQ ID NO: 261; SEQ ID NO: 199 and SEQ ID NO: 262; SEQ ID NO: 199 and SEQ ID NO: 263; SEQ ID NO: 199 and SEQ ID NO: 264; SEQ ID NO: 199 and SEQ ID NO: 265; SEQ ID NO: 199 and SEQ ID NO: 266; SEQ ID NO: 199 and SEQ ID NO: 267; SEQ ID NO: 199 and SEQ ID NO: 268; and SEQ ID NO: 199 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 200 and SEQ ID NO: 236; SEQ ID NO: 200 and SEQ ID NO: 325; SEQ ID NO: 200 and SEQ ID NO: 237; SEQ ID NO: 200 and SEQ ID NO: 238; SEQ ID NO: 200 and SEQ ID NO: 239; SEQ ID NO: 200 and SEQ ID NO: 240; SEQ ID NO: 200 and SEQ ID NO: 241; SEQ ID NO: 200 and SEQ ID NO: 242; SEQ ID NO: 200 and SEQ ID NO: 243; SEQ ID NO: 200 and SEQ ID NO: 244; SEQ ID NO: 200 and SEQ ID NO: 245; SEQ ID NO: 200 and SEQ ID NO: 246; SEQ ID NO: 200 and SEQ ID NO: 247; SEQ ID NO: 200 and SEQ ID NO: 248; SEQ ID NO: 200 and SEQ ID NO: 249; SEQ ID NO: 200 and SEQ ID NO: 250; SEQ ID NO: 200 and SEQ ID NO: 251; SEQ ID NO: 200 and SEQ ID NO: 252; SEQ ID NO: 200 and SEQ ID NO: 253; SEQ ID NO: 200 and SEQ ID NO: 254; SEQ ID NO: 200 and SEQ ID NO: 255; SEQ ID NO: 200 and SEQ ID NO: 256; SEQ ID NO: 200 and SEQ ID NO: 257; SEQ ID NO: 200 and SEQ ID NO: 258; SEQ ID NO: 200 and SEQ ID NO: 259; SEQ ID NO: 200 and SEQ ID NO: 260; SEQ ID NO: 200 and SEQ ID NO: 261; SEQ ID NO: 200 and SEQ ID NO: 262; SEQ ID NO: 200 and SEQ ID NO: 263; SEQ ID NO: 200 and SEQ ID NO: 264; SEQ ID NO: 200 and SEQ ID NO: 265; SEQ ID NO: 200 and SEQ ID NO: 266; SEQ ID NO: 200 and SEQ ID NO: 267; SEQ ID NO: 200 and SEQ ID NO: 268; and SEQ ID NO: 200 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 201 and SEQ ID NO: 236; SEQ ID NO: 201 and SEQ ID NO: 325; SEQ ID NO: 201 and SEQ ID NO: 237; SEQ ID NO: 201 and SEQ ID NO: 238; SEQ ID NO: 201 and SEQ ID NO: 239; SEQ ID NO: 201 and SEQ ID NO: 240; SEQ ID NO: 201 and SEQ ID NO: 241; SEQ ID NO: 201 and SEQ ID NO: 242; SEQ ID NO: 201 and SEQ ID NO: 243; SEQ ID NO: 201 and SEQ ID NO: 244; SEQ ID NO: 201 and SEQ ID NO: 245; SEQ ID NO: 201 and SEQ ID NO: 246; SEQ ID NO: 201 and SEQ ID NO: 247; SEQ ID NO: 201 and SEQ ID NO: 248; SEQ ID NO: 201 and SEQ ID NO: 249; SEQ ID NO: 201 and SEQ ID NO: 250; SEQ ID NO: 201 and SEQ ID NO: 251; SEQ ID NO: 201 and SEQ ID NO: 252; SEQ ID NO: 201 and SEQ ID NO: 253; SEQ ID NO: 201 and SEQ ID NO: 254; SEQ ID NO: 201 and SEQ ID NO: 255; SEQ ID NO: 201 and SEQ ID NO: 256; SEQ ID NO: 201 and SEQ ID NO: 257; SEQ ID NO: 201 and SEQ ID NO: 258; SEQ ID NO: 201 and SEQ ID NO: 259; SEQ ID NO: 201 and SEQ ID NO: 260; SEQ ID NO: 201 and SEQ ID NO: 261; SEQ ID NO: 201 and SEQ ID NO: 262; SEQ ID NO: 201 and SEQ ID NO: 263; SEQ ID NO: 201 and SEQ ID NO: 264; SEQ ID NO: 201 and SEQ ID NO: 265; SEQ ID NO: 201 and SEQ ID NO: 266; SEQ ID NO: 201 and SEQ ID NO: 267; SEQ ID NO: 201 and SEQ ID NO: 268; and SEQ ID NO: 201 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 202 and SEQ ID NO: 236; SEQ ID NO: 202 and SEQ ID NO: 325; SEQ ID NO: 202 and SEQ ID NO: 237; SEQ ID NO: 202 and SEQ ID NO: 238; SEQ ID NO: 202 and SEQ ID NO: 239; SEQ ID NO: 202 and SEQ ID NO: 240; SEQ ID NO: 202 and SEQ ID NO: 241; SEQ ID NO: 202 and SEQ ID NO: 242; SEQ ID NO: 202 and SEQ ID NO: 243; SEQ ID NO: 202 and SEQ ID NO: 244; SEQ ID NO: 202 and SEQ ID NO: 245; SEQ ID NO: 202 and SEQ ID NO: 246; SEQ ID NO: 202 and SEQ ID NO: 247; SEQ ID NO: 202 and SEQ ID NO: 248; SEQ ID NO: 202 and SEQ ID NO: 249; SEQ ID NO: 202 and SEQ ID NO: 250; SEQ ID NO: 202 and SEQ ID NO: 251; SEQ ID NO: 202 and SEQ ID NO: 252; SEQ ID NO: 202 and SEQ ID NO: 253; SEQ ID NO: 202 and SEQ ID NO: 254; SEQ ID NO: 202 and SEQ ID NO: 255; SEQ ID NO: 202 and SEQ ID NO: 256; SEQ ID NO: 202 and SEQ ID NO: 257; SEQ ID NO: 202 and SEQ ID NO: 258; SEQ ID NO: 202 and SEQ ID NO: 259; SEQ ID NO: 202 and SEQ ID NO: 260; SEQ ID NO: 202 and SEQ ID NO: 261; SEQ ID NO: 202 and SEQ ID NO: 262; SEQ ID NO: 202 and SEQ ID NO: 263; SEQ ID NO: 202 and SEQ ID NO: 264; SEQ ID NO: 202 and SEQ ID NO: 265; SEQ ID NO: 202 and SEQ ID NO: 266; SEQ ID NO: 202 and SEQ ID NO: 267; SEQ ID NO: 202 and SEQ ID NO: 268; and SEQ ID NO: 202 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 203 and SEQ ID NO: 236; SEQ ID NO: 203 and SEQ ID NO: 325; SEQ ID NO: 203 and SEQ ID NO: 237; SEQ ID NO: 203 and SEQ ID NO: 238; SEQ ID NO: 203 and SEQ ID NO: 239; SEQ ID NO: 203 and SEQ ID NO: 240; SEQ ID NO: 203 and SEQ ID NO: 241; SEQ ID NO: 203 and SEQ ID NO: 242; SEQ ID NO: 203 and SEQ ID NO: 243; SEQ ID NO: 203 and SEQ ID NO: 244; SEQ ID NO: 203 and SEQ ID NO: 245; SEQ ID NO: 203 and SEQ ID NO: 246; SEQ ID NO: 203 and SEQ ID NO: 247; SEQ ID NO: 203 and SEQ ID NO: 248; SEQ ID NO: 203 and SEQ ID NO: 249; SEQ ID NO: 203 and SEQ ID NO: 250; SEQ ID NO: 203 and SEQ ID NO: 251; SEQ ID NO: 203 and SEQ ID NO: 252; SEQ ID NO: 203 and SEQ ID NO: 253; SEQ ID NO: 203 and SEQ ID NO: 254; SEQ ID NO: 203 and SEQ ID NO: 255; SEQ ID NO: 203 and SEQ ID NO: 256; SEQ ID NO: 203 and SEQ ID NO: 257; SEQ ID NO: 203 and SEQ ID NO: 258; SEQ ID NO: 203 and SEQ ID NO: 259; SEQ ID NO: 203 and SEQ ID NO: 260; SEQ ID NO: 203 and SEQ ID NO: 261; SEQ ID NO: 203 and SEQ ID NO: 262; SEQ ID NO: 203 and SEQ ID NO: 263; SEQ ID NO: 203 and SEQ ID NO: 264; SEQ ID NO: 203 and SEQ ID NO: 265; SEQ ID NO: 203 and SEQ ID NO: 266; SEQ ID NO: 203 and SEQ ID NO: 267; SEQ ID NO: 203 and SEQ ID NO: 268; and SEQ ID NO: 203 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 204 and SEQ ID NO: 236; SEQ ID NO: 204 and SEQ ID NO: 325; SEQ ID NO: 204 and SEQ ID NO: 237; SEQ ID NO: 204 and SEQ ID NO: 238; SEQ ID NO: 204 and SEQ ID NO: 239; SEQ ID NO: 204 and SEQ ID NO: 240; SEQ ID NO: 204 and SEQ ID NO: 241; SEQ ID NO: 204 and SEQ ID NO: 242; SEQ ID NO: 204 and SEQ ID NO: 243; SEQ ID NO: 204 and SEQ ID NO: 244; SEQ ID NO: 204 and SEQ ID NO: 245; SEQ ID NO: 204 and SEQ ID NO: 246; SEQ ID NO: 204 and SEQ ID NO: 247; SEQ ID NO: 204 and SEQ ID NO: 248; SEQ ID NO: 204 and SEQ ID NO: 249; SEQ ID NO: 204 and SEQ ID NO: 250; SEQ ID NO: 204 and SEQ ID NO: 251; SEQ ID NO: 204 and SEQ ID NO: 252; SEQ ID NO: 204 and SEQ ID NO: 253; SEQ ID NO: 204 and SEQ ID NO: 254; SEQ ID NO: 204 and SEQ ID NO: 255; SEQ ID NO: 204 and SEQ ID NO: 256; SEQ ID NO: 204 and SEQ ID NO: 257; SEQ ID NO: 204 and SEQ ID NO: 258; SEQ ID NO: 204 and SEQ ID NO: 259; SEQ ID NO: 204 and SEQ ID NO: 260; SEQ ID NO: 204 and SEQ ID NO: 261; SEQ ID NO: 204 and SEQ ID NO: 262; SEQ ID NO: 204 and SEQ ID NO: 263; SEQ ID NO: 204 and SEQ ID NO: 264; SEQ ID NO: 204 and SEQ ID NO: 265; SEQ ID NO: 204 and SEQ ID NO: 266; SEQ ID NO: 204 and SEQ ID NO: 267; SEQ ID NO: 204 and SEQ ID NO: 268; and SEQ ID NO: 204 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 205 and SEQ ID NO: 236; SEQ ID NO: 205 and SEQ ID NO: 325; SEQ ID NO: 205 and SEQ ID NO: 237; SEQ ID NO: 205 and SEQ ID NO: 238; SEQ ID NO: 205 and SEQ ID NO: 239; SEQ ID NO: 205 and SEQ ID NO: 240; SEQ ID NO: 205 and SEQ ID NO: 241; SEQ ID NO: 205 and SEQ ID NO: 242; SEQ ID NO: 205 and SEQ ID NO: 243; SEQ ID NO: 205 and SEQ ID NO: 244; SEQ ID NO: 205 and SEQ ID NO: 245; SEQ ID NO: 205 and SEQ ID NO: 246; SEQ ID NO: 205 and SEQ ID NO: 247; SEQ ID NO: 205 and SEQ ID NO: 248; SEQ ID NO: 205 and SEQ ID NO: 249; SEQ ID NO: 205 and SEQ ID NO: 250; SEQ ID NO: 205 and SEQ ID NO: 251; SEQ ID NO: 205 and SEQ ID NO: 252; SEQ ID NO: 205 and SEQ ID NO: 253; SEQ ID NO: 205 and SEQ ID NO: 254; SEQ ID NO: 205 and SEQ ID NO: 255; SEQ ID NO: 205 and SEQ ID NO: 256; SEQ ID NO: 205 and SEQ ID NO: 257; SEQ ID NO: 205 and SEQ ID NO: 258; SEQ ID NO: 205 and SEQ ID NO: 259; SEQ ID NO: 205 and SEQ ID NO: 260; SEQ ID NO: 205 and SEQ ID NO: 261; SEQ ID NO: 205 and SEQ ID NO: 262; SEQ ID NO: 205 and SEQ ID NO: 263; SEQ ID NO: 205 and SEQ ID NO: 264; SEQ ID NO: 205 and SEQ ID NO: 265; SEQ ID NO: 205 and SEQ ID NO: 266; SEQ ID NO: 205 and SEQ ID NO: 267; SEQ ID NO: 205 and SEQ ID NO: 268; and SEQ ID NO: 205 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 206 and SEQ ID NO: 236; SEQ ID NO: 206 and SEQ ID NO: 325; SEQ ID NO: 206 and SEQ ID NO: 237; SEQ ID NO: 206 and SEQ ID NO: 238; SEQ ID NO: 206 and SEQ ID NO: 239; SEQ ID NO: 206 and SEQ ID NO: 240; SEQ ID NO: 206 and SEQ ID NO: 241; SEQ ID NO: 206 and SEQ ID NO: 242; SEQ ID NO: 206 and SEQ ID NO: 243; SEQ ID NO: 206 and SEQ ID NO: 244; SEQ ID NO: 206 and SEQ ID NO: 245; SEQ ID NO: 206 and SEQ ID NO: 246; SEQ ID NO: 206 and SEQ ID NO: 247; SEQ ID NO: 206 and SEQ ID NO: 248; SEQ ID NO: 206 and SEQ ID NO: 249; SEQ ID NO: 206 and SEQ ID NO: 250; SEQ ID NO: 206 and SEQ ID NO: 251; SEQ ID NO: 206 and SEQ ID NO: 252; SEQ ID NO: 206 and SEQ ID NO: 253; SEQ ID NO: 206 and SEQ ID NO: 254; SEQ ID NO: 206 and SEQ ID NO: 255; SEQ ID NO: 206 and SEQ ID NO: 256; SEQ ID NO: 206 and SEQ ID NO: 257; SEQ ID NO: 206 and SEQ ID NO: 258; SEQ ID NO: 206 and SEQ ID NO: 259; SEQ ID NO: 206 and SEQ ID NO: 260; SEQ ID NO: 206 and SEQ ID NO: 261; SEQ ID NO: 206 and SEQ ID NO: 262; SEQ ID NO: 206 and SEQ ID NO: 263; SEQ ID NO: 206 and SEQ ID NO: 264; SEQ ID NO: 206 and SEQ ID NO: 265; SEQ ID NO: 206 and SEQ ID NO: 266; SEQ ID NO: 206 and SEQ ID NO: 267; SEQ ID NO: 206 and SEQ ID NO: 268; and SEQ ID NO: 206 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 207 and SEQ ID NO: 236; SEQ ID NO: 207 and SEQ ID NO: 325; SEQ ID NO: 207 and SEQ ID NO: 237; SEQ ID NO: 207 and SEQ ID NO: 238; SEQ ID NO: 207 and SEQ ID NO: 239; SEQ ID NO: 207 and SEQ ID NO: 240; SEQ ID NO: 207 and SEQ ID NO: 241; SEQ ID NO: 207 and SEQ ID NO: 242; SEQ ID NO: 207 and SEQ ID NO: 243; SEQ ID NO: 207 and SEQ ID NO: 244; SEQ ID NO: 207 and SEQ ID NO: 245; SEQ ID NO: 207 and SEQ ID NO: 246; SEQ ID NO: 207 and SEQ ID NO: 247; SEQ ID NO: 207 and SEQ ID NO: 248; SEQ ID NO: 207 and SEQ ID NO: 249; SEQ ID NO: 207 and SEQ ID NO: 250; SEQ ID NO: 207 and SEQ ID NO: 251; SEQ ID NO: 207 and SEQ ID NO: 252; SEQ ID NO: 207 and SEQ ID NO: 253; SEQ ID NO: 207 and SEQ ID NO: 254; SEQ ID NO: 207 and SEQ ID NO: 255; SEQ ID NO: 207 and SEQ ID NO: 256; SEQ ID NO: 207 and SEQ ID NO: 257; SEQ ID NO: 207 and SEQ ID NO: 258; SEQ ID NO: 207 and SEQ ID NO: 259; SEQ ID NO: 207 and SEQ ID NO: 260; SEQ ID NO: 207 and SEQ ID NO: 261; SEQ ID NO: 207 and SEQ ID NO: 262; SEQ ID NO: 207 and SEQ ID NO: 263; SEQ ID NO: 207 and SEQ ID NO: 264; SEQ ID NO: 207 and SEQ ID NO: 265; SEQ ID NO: 207 and SEQ ID NO: 266; SEQ ID NO: 207 and SEQ ID NO: 267; SEQ ID NO: 207 and SEQ ID NO: 268; and SEQ ID NO: 207 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 208 and SEQ ID NO: 236; SEQ ID NO: 208 and SEQ ID NO: 325; SEQ ID NO: 208 and SEQ ID NO: 237; SEQ ID NO: 208 and SEQ ID NO: 238; SEQ ID NO: 208 and SEQ ID NO: 239; SEQ ID NO: 208 and SEQ ID NO: 240; SEQ ID NO: 208 and SEQ ID NO: 241; SEQ ID NO: 208 and SEQ ID NO: 242; SEQ ID NO: 208 and SEQ ID NO: 243; SEQ ID NO: 208 and SEQ ID NO: 244; SEQ ID NO: 208 and SEQ ID NO: 245; SEQ ID NO: 208 and SEQ ID NO: 246; SEQ ID NO: 208 and SEQ ID NO: 247; SEQ ID NO: 208 and SEQ ID NO: 248; SEQ ID NO: 208 and SEQ ID NO: 249; SEQ ID NO: 208 and SEQ ID NO: 250; SEQ ID NO: 208 and SEQ ID NO: 251; SEQ ID NO: 208 and SEQ ID NO: 252; SEQ ID NO: 208 and SEQ ID NO: 253; SEQ ID NO: 208 and SEQ ID NO: 254; SEQ ID NO: 208 and SEQ ID NO: 255; SEQ ID NO: 208 and SEQ ID NO: 256; SEQ ID NO: 208 and SEQ ID NO: 257; SEQ ID NO: 208 and SEQ ID NO: 258; SEQ ID NO: 208 and SEQ ID NO: 259; SEQ ID NO: 208 and SEQ ID NO: 260; SEQ ID NO: 208 and SEQ ID NO: 261; SEQ ID NO: 208 and SEQ ID NO: 262; SEQ ID NO: 208 and SEQ ID NO: 263; SEQ ID NO: 208 and SEQ ID NO: 264; SEQ ID NO: 208 and SEQ ID NO: 265; SEQ ID NO: 208 and SEQ ID NO: 266; SEQ ID NO: 208 and SEQ ID NO: 267; SEQ ID NO: 208 and SEQ ID NO: 268; and SEQ ID NO: 208 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 209 and SEQ ID NO: 236; SEQ ID NO: 209 and SEQ ID NO: 325; SEQ ID NO: 209 and SEQ ID NO: 237; SEQ ID NO: 209 and SEQ ID NO: 238; SEQ ID NO: 209 and SEQ ID NO: 239; SEQ ID NO: 209 and SEQ ID NO: 240; SEQ ID NO: 209 and SEQ ID NO: 241; SEQ ID NO: 209 and SEQ ID NO: 242; SEQ ID NO: 209 and SEQ ID NO: 243; SEQ ID NO: 209 and SEQ ID NO: 244; SEQ ID NO: 209 and SEQ ID NO: 245; SEQ ID NO: 209 and SEQ ID NO: 246; SEQ ID NO: 209 and SEQ ID NO: 247; SEQ ID NO: 209 and SEQ ID NO: 248; SEQ ID NO: 209 and SEQ ID NO: 249; SEQ ID NO: 209 and SEQ ID NO: 250; SEQ ID NO: 209 and SEQ ID NO: 251; SEQ ID NO: 209 and SEQ ID NO: 252; SEQ ID NO: 209 and SEQ ID NO: 253; SEQ ID NO: 209 and SEQ ID NO: 254; SEQ ID NO: 209 and SEQ ID NO: 255; SEQ ID NO: 209 and SEQ ID NO: 256; SEQ ID NO: 209 and SEQ ID NO: 257; SEQ ID NO: 209 and SEQ ID NO: 258; SEQ ID NO: 209 and SEQ ID NO: 259; SEQ ID NO: 209 and SEQ ID NO: 260; SEQ ID NO: 209 and SEQ ID NO: 261; SEQ ID NO: 209 and SEQ ID NO: 262; SEQ ID NO: 209 and SEQ ID NO: 263; SEQ ID NO: 209 and SEQ ID NO: 264; SEQ ID NO: 209 and SEQ ID NO: 265; SEQ ID NO: 209 and SEQ ID NO: 266; SEQ ID NO: 209 and SEQ ID NO: 267; SEQ ID NO: 209 and SEQ ID NO: 268; and SEQ ID NO: 209 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 210 and SEQ ID NO: 236; SEQ ID NO: 210 and SEQ ID NO: 325; SEQ ID NO: 210 and SEQ ID NO: 237; SEQ ID NO: 210 and SEQ ID NO: 238; SEQ ID NO: 210 and SEQ ID NO: 239; SEQ ID NO: 210 and SEQ ID NO: 240; SEQ ID NO: 210 and SEQ ID NO: 241; SEQ ID NO: 210 and SEQ ID NO: 242; SEQ ID NO: 210 and SEQ ID NO: 243; SEQ ID NO: 210 and SEQ ID NO: 244; SEQ ID NO: 210 and SEQ ID NO: 245; SEQ ID NO: 210 and SEQ ID NO: 246; SEQ ID NO: 210 and SEQ ID NO: 247; SEQ ID NO: 210 and SEQ ID NO: 248; SEQ ID NO: 210 and SEQ ID NO: 249; SEQ ID NO: 210 and SEQ ID NO: 250; SEQ ID NO: 210 and SEQ ID NO: 251; SEQ ID NO: 210 and SEQ ID NO: 252; SEQ ID NO: 210 and SEQ ID NO: 253; SEQ ID NO: 210 and SEQ ID NO: 254; SEQ ID NO: 210 and SEQ ID NO: 255; SEQ ID NO: 210 and SEQ ID NO: 256; SEQ ID NO: 210 and SEQ ID NO: 257; SEQ ID NO: 210 and SEQ ID NO: 258; SEQ ID NO: 210 and SEQ ID NO: 259; SEQ ID NO: 210 and SEQ ID NO: 260; SEQ ID NO: 210 and SEQ ID NO: 261; SEQ ID NO: 210 and SEQ ID NO: 262; SEQ ID NO: 210 and SEQ ID NO: 263; SEQ ID NO: 210 and SEQ ID NO: 264; SEQ ID NO: 210 and SEQ ID NO: 265; SEQ ID NO: 210 and SEQ ID NO: 266; SEQ ID NO: 210 and SEQ ID NO: 267; SEQ ID NO: 210 and SEQ ID NO: 268; and SEQ ID NO: 210 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 211 and SEQ ID NO: 236; SEQ ID NO: 211 and SEQ ID NO: 325; SEQ ID NO: 211 and SEQ ID NO: 237; SEQ ID NO: 211 and SEQ ID NO: 238; SEQ ID NO: 211 and SEQ ID NO: 239; SEQ ID NO: 211 and SEQ ID NO: 240; SEQ ID NO: 211 and SEQ ID NO: 241; SEQ ID NO: 211 and SEQ ID NO: 242; SEQ ID NO: 211 and SEQ ID NO: 243; SEQ ID NO: 211 and SEQ ID NO: 244; SEQ ID NO: 211 and SEQ ID NO: 245; SEQ ID NO: 211 and SEQ ID NO: 246; SEQ ID NO: 211 and SEQ ID NO: 247; SEQ ID NO: 211 and SEQ ID NO: 248; SEQ ID NO: 211 and SEQ ID NO: 249; SEQ ID NO: 211 and SEQ ID NO: 250; SEQ ID NO: 211 and SEQ ID NO: 251; SEQ ID NO: 211 and SEQ ID NO: 252; SEQ ID NO: 211 and SEQ ID NO: 253; SEQ ID NO: 211 and SEQ ID NO: 254; SEQ ID NO: 211 and SEQ ID NO: 255; SEQ ID NO: 211 and SEQ ID NO: 256; SEQ ID NO: 211 and SEQ ID NO: 257; SEQ ID NO: 211 and SEQ ID NO: 258; SEQ ID NO: 211 and SEQ ID NO: 259; SEQ ID NO: 211 and SEQ ID NO: 260; SEQ ID NO: 211 and SEQ ID NO: 261; SEQ ID NO: 211 and SEQ ID NO: 262; SEQ ID NO: 211 and SEQ ID NO: 263; SEQ ID NO: 211 and SEQ ID NO: 264; SEQ ID NO: 211 and SEQ ID NO: 265; SEQ ID NO: 211 and SEQ ID NO: 266; SEQ ID NO: 211 and SEQ ID NO: 267; SEQ ID NO: 211 and SEQ ID NO: 268; and SEQ ID NO: 211 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 212 and SEQ ID NO: 236; SEQ ID NO: 212 and SEQ ID NO: 325; SEQ ID NO: 212 and SEQ ID NO: 237; SEQ ID NO: 212 and SEQ ID NO: 238; SEQ ID NO: 212 and SEQ ID NO: 239; SEQ ID NO: 212 and SEQ ID NO: 240; SEQ ID NO: 212 and SEQ ID NO: 241; SEQ ID NO: 212 and SEQ ID NO: 242; SEQ ID NO: 212 and SEQ ID NO: 243; SEQ ID NO: 212 and SEQ ID NO: 244; SEQ ID NO: 212 and SEQ ID NO: 245; SEQ ID NO: 212 and SEQ ID NO: 246; SEQ ID NO: 212 and SEQ ID NO: 247; SEQ ID NO: 212 and SEQ ID NO: 248; SEQ ID NO: 212 and SEQ ID NO: 249; SEQ ID NO: 212 and SEQ ID NO: 250; SEQ ID NO: 212 and SEQ ID NO: 251; SEQ ID NO: 212 and SEQ ID NO: 252; SEQ ID NO: 212 and SEQ ID NO: 253; SEQ ID NO: 212 and SEQ ID NO: 254; SEQ ID NO: 212 and SEQ ID NO: 255; SEQ ID NO: 212 and SEQ ID NO: 256; SEQ ID NO: 212 and SEQ ID NO: 257; SEQ ID NO: 212 and SEQ ID NO: 258; SEQ ID NO: 212 and SEQ ID NO: 259; SEQ ID NO: 212 and SEQ ID NO: 260; SEQ ID NO: 212 and SEQ ID NO: 261; SEQ ID NO: 212 and SEQ ID NO: 262; SEQ ID NO: 212 and SEQ ID NO: 263; SEQ ID NO: 212 and SEQ ID NO: 264; SEQ ID NO: 212 and SEQ ID NO: 265; SEQ ID NO: 212 and SEQ ID NO: 266; SEQ ID NO: 212 and SEQ ID NO: 267; SEQ ID NO: 212 and SEQ ID NO: 268; and SEQ ID NO: 212 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 213 and SEQ ID NO: 236; SEQ ID NO: 213 and SEQ ID NO: 325; SEQ ID NO: 213 and SEQ ID NO: 237; SEQ ID NO: 213 and SEQ ID NO: 238; SEQ ID NO: 213 and SEQ ID NO: 239; SEQ ID NO: 213 and SEQ ID NO: 240; SEQ ID NO: 213 and SEQ ID NO: 241; SEQ ID NO: 213 and SEQ ID NO: 242; SEQ ID NO: 213 and SEQ ID NO: 243; SEQ ID NO: 213 and SEQ ID NO: 244; SEQ ID NO: 213 and SEQ ID NO: 245; SEQ ID NO: 213 and SEQ ID NO: 246; SEQ ID NO: 213 and SEQ ID NO: 247; SEQ ID NO: 213 and SEQ ID NO: 248; SEQ ID NO: 213 and SEQ ID NO: 249; SEQ ID NO: 213 and SEQ ID NO: 250; SEQ ID NO: 213 and SEQ ID NO: 251; SEQ ID NO: 213 and SEQ ID NO: 252; SEQ ID NO: 213 and SEQ ID NO: 253; SEQ ID NO: 213 and SEQ ID NO: 254; SEQ ID NO: 213 and SEQ ID NO: 255; SEQ ID NO: 213 and SEQ ID NO: 256; SEQ ID NO: 213 and SEQ ID NO: 257; SEQ ID NO: 213 and SEQ ID NO: 258; SEQ ID NO: 213 and SEQ ID NO: 259; SEQ ID NO: 213 and SEQ ID NO: 260; SEQ ID NO: 213 and SEQ ID NO: 261; SEQ ID NO: 213 and SEQ ID NO: 262; SEQ ID NO: 213 and SEQ ID NO: 263; SEQ ID NO: 213 and SEQ ID NO: 264; SEQ ID NO: 213 and SEQ ID NO: 265; SEQ ID NO: 213 and SEQ ID NO: 266; SEQ ID NO: 213 and SEQ ID NO: 267; SEQ ID NO: 213 and SEQ ID NO: 268; and SEQ ID NO: 213 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 214 and SEQ ID NO: 236; SEQ ID NO: 214 and SEQ ID NO: 325; SEQ ID NO: 214 and SEQ ID NO: 237; SEQ ID NO: 214 and SEQ ID NO: 238; SEQ ID NO: 214 and SEQ ID NO: 239; SEQ ID NO: 214 and SEQ ID NO: 240; SEQ ID NO: 214 and SEQ ID NO: 241; SEQ ID NO: 214 and SEQ ID NO: 242; SEQ ID NO: 214 and SEQ ID NO: 243; SEQ ID NO: 214 and SEQ ID NO: 244; SEQ ID NO: 214 and SEQ ID NO: 245; SEQ ID NO: 214 and SEQ ID NO: 246; SEQ ID NO: 214 and SEQ ID NO: 247; SEQ ID NO: 214 and SEQ ID NO: 248; SEQ ID NO: 214 and SEQ ID NO: 249; SEQ ID NO: 214 and SEQ ID NO: 250; SEQ ID NO: 214 and SEQ ID NO: 251; SEQ ID NO: 214 and SEQ ID NO: 252; SEQ ID NO: 214 and SEQ ID NO: 253; SEQ ID NO: 214 and SEQ ID NO: 254; SEQ ID NO: 214 and SEQ ID NO: 255; SEQ ID NO: 214 and SEQ ID NO: 256; SEQ ID NO: 214 and SEQ ID NO: 257; SEQ ID NO: 214 and SEQ ID NO: 258; SEQ ID NO: 214 and SEQ ID NO: 259; SEQ ID NO: 214 and SEQ ID NO: 260; SEQ ID NO: 214 and SEQ ID NO: 261; SEQ ID NO: 214 and SEQ ID NO: 262; SEQ ID NO: 214 and SEQ ID NO: 263; SEQ ID NO: 214 and SEQ ID NO: 264; SEQ ID NO: 214 and SEQ ID NO: 265; SEQ ID NO: 214 and SEQ ID NO: 266; SEQ ID NO: 214 and SEQ ID NO: 267; SEQ ID NO: 214 and SEQ ID NO: 268; and SEQ ID NO: 214 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 215 and SEQ ID NO: 236; SEQ ID NO: 215 and SEQ ID NO: 325; SEQ ID NO: 215 and SEQ ID NO: 237; SEQ ID NO: 215 and SEQ ID NO: 238; SEQ ID NO: 215 and SEQ ID NO: 239; SEQ ID NO: 215 and SEQ ID NO: 240; SEQ ID NO: 215 and SEQ ID NO: 241; SEQ ID NO: 215 and SEQ ID NO: 242; SEQ ID NO: 215 and SEQ ID NO: 243; SEQ ID NO: 215 and SEQ ID NO: 244; SEQ ID NO: 215 and SEQ ID NO: 245; SEQ ID NO: 215 and SEQ ID NO: 246; SEQ ID NO: 215 and SEQ ID NO: 247; SEQ ID NO: 215 and SEQ ID NO: 248; SEQ ID NO: 215 and SEQ ID NO: 249; SEQ ID NO: 215 and SEQ ID NO: 250; SEQ ID NO: 215 and SEQ ID NO: 251; SEQ ID NO: 215 and SEQ ID NO: 252; SEQ ID NO: 215 and SEQ ID NO: 253; SEQ ID NO: 215 and SEQ ID NO: 254; SEQ ID NO: 215 and SEQ ID NO: 255; SEQ ID NO: 215 and SEQ ID NO: 256; SEQ ID NO: 215 and SEQ ID NO: 257; SEQ ID NO: 215 and SEQ ID NO: 258; SEQ ID NO: 215 and SEQ ID NO: 259; SEQ ID NO: 215 and SEQ ID NO: 260; SEQ ID NO: 215 and SEQ ID NO: 261; SEQ ID NO: 215 and SEQ ID NO: 262; SEQ ID NO: 215 and SEQ ID NO: 263; SEQ ID NO: 215 and SEQ ID NO: 264; SEQ ID NO: 215 and SEQ ID NO: 265; SEQ ID NO: 215 and SEQ ID NO: 266; SEQ ID NO: 215 and SEQ ID NO: 267; SEQ ID NO: 215 and SEQ ID NO: 268; and SEQ ID NO: 215 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 216 and SEQ ID NO: 236; SEQ ID NO: 216 and SEQ ID NO: 325; SEQ ID NO: 216 and SEQ ID NO: 237; SEQ ID NO: 216 and SEQ ID NO: 238; SEQ ID NO: 216 and SEQ ID NO: 239; SEQ ID NO: 216 and SEQ ID NO: 240; SEQ ID NO: 216 and SEQ ID NO: 241; SEQ ID NO: 216 and SEQ ID NO: 242; SEQ ID NO: 216 and SEQ ID NO: 243; SEQ ID NO: 216 and SEQ ID NO: 244; SEQ ID NO: 216 and SEQ ID NO: 245; SEQ ID NO: 216 and SEQ ID NO: 246; SEQ ID NO: 216 and SEQ ID NO: 247; SEQ ID NO: 216 and SEQ ID NO: 248; SEQ ID NO: 216 and SEQ ID NO: 249; SEQ ID NO: 216 and SEQ ID NO: 250; SEQ ID NO: 216 and SEQ ID NO: 251; SEQ ID NO: 216 and SEQ ID NO: 252; SEQ ID NO: 216 and SEQ ID NO: 253; SEQ ID NO: 216 and SEQ ID NO: 254; SEQ ID NO: 216 and SEQ ID NO: 255; SEQ ID NO: 216 and SEQ ID NO: 256; SEQ ID NO: 216 and SEQ ID NO: 257; SEQ ID NO: 216 and SEQ ID NO: 258; SEQ ID NO: 216 and SEQ ID NO: 259; SEQ ID NO: 216 and SEQ ID NO: 260; SEQ ID NO: 216 and SEQ ID NO: 261; SEQ ID NO: 216 and SEQ ID NO: 262; SEQ ID NO: 216 and SEQ ID NO: 263; SEQ ID NO: 216 and SEQ ID NO: 264; SEQ ID NO: 216 and SEQ ID NO: 265; SEQ ID NO: 216 and SEQ ID NO: 266; SEQ ID NO: 216 and SEQ ID NO: 267; SEQ ID NO: 216 and SEQ ID NO: 268; and SEQ ID NO: 216 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 217 and SEQ ID NO: 236; SEQ ID NO: 217 and SEQ ID NO: 325; SEQ ID NO: 217 and SEQ ID NO: 237; SEQ ID NO: 217 and SEQ ID NO: 238; SEQ ID NO: 217 and SEQ ID NO: 239; SEQ ID NO: 217 and SEQ ID NO: 240; SEQ ID NO: 217 and SEQ ID NO: 241; SEQ ID NO: 217 and SEQ ID NO: 242; SEQ ID NO: 217 and SEQ ID NO: 243; SEQ ID NO: 217 and SEQ ID NO: 244; SEQ ID NO: 217 and SEQ ID NO: 245; SEQ ID NO: 217 and SEQ ID NO: 246; SEQ ID NO: 217 and SEQ ID NO: 247; SEQ ID NO: 217 and SEQ ID NO: 248; SEQ ID NO: 217 and SEQ ID NO: 249; SEQ ID NO: 217 and SEQ ID NO: 250; SEQ ID NO: 217 and SEQ ID NO: 251; SEQ ID NO: 217 and SEQ ID NO: 252; SEQ ID NO: 217 and SEQ ID NO: 253; SEQ ID NO: 217 and SEQ ID NO: 254; SEQ ID NO: 217 and SEQ ID NO: 255; SEQ ID NO: 217 and SEQ ID NO: 256; SEQ ID NO: 217 and SEQ ID NO: 257; SEQ ID NO: 217 and SEQ ID NO: 258; SEQ ID NO: 217 and SEQ ID NO: 259; SEQ ID NO: 217 and SEQ ID NO: 260; SEQ ID NO: 217 and SEQ ID NO: 261; SEQ ID NO: 217 and SEQ ID NO: 262; SEQ ID NO: 217 and SEQ ID NO: 263; SEQ ID NO: 217 and SEQ ID NO: 264; SEQ ID NO: 217 and SEQ ID NO: 265; SEQ ID NO: 217 and SEQ ID NO: 266; SEQ ID NO: 217 and SEQ ID NO: 267; SEQ ID NO: 217 and SEQ ID NO: 268; and SEQ ID NO: 217 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 218 and SEQ ID NO: 236; SEQ ID NO: 218 and SEQ ID NO: 325; SEQ ID NO: 218 and SEQ ID NO: 237; SEQ ID NO: 218 and SEQ ID NO: 238; SEQ ID NO: 218 and SEQ ID NO: 239; SEQ ID NO: 218 and SEQ ID NO: 240; SEQ ID NO: 218 and SEQ ID NO: 241; SEQ ID NO: 218 and SEQ ID NO: 242; SEQ ID NO: 218 and SEQ ID NO: 243; SEQ ID NO: 218 and SEQ ID NO: 244; SEQ ID NO: 218 and SEQ ID NO: 245; SEQ ID NO: 218 and SEQ ID NO: 246; SEQ ID NO: 218 and SEQ ID NO: 247; SEQ ID NO: 218 and SEQ ID NO: 248; SEQ ID NO: 218 and SEQ ID NO: 249; SEQ ID NO: 218 and SEQ ID NO: 250; SEQ ID NO: 218 and SEQ ID NO: 251; SEQ ID NO: 218 and SEQ ID NO: 252; SEQ ID NO: 218 and SEQ ID NO: 253; SEQ ID NO: 218 and SEQ ID NO: 254; SEQ ID NO: 218 and SEQ ID NO: 255; SEQ ID NO: 218 and SEQ ID NO: 256; SEQ ID NO: 218 and SEQ ID NO: 257; SEQ ID NO: 218 and SEQ ID NO: 258; SEQ ID NO: 218 and SEQ ID NO: 259; SEQ ID NO: 218 and SEQ ID NO: 260; SEQ ID NO: 218 and SEQ ID NO: 261; SEQ ID NO: 218 and SEQ ID NO: 262; SEQ ID NO: 218 and SEQ ID NO: 263; SEQ ID NO: 218 and SEQ ID NO: 264; SEQ ID NO: 218 and SEQ ID NO: 265; SEQ ID NO: 218 and SEQ ID NO: 266; SEQ ID NO: 218 and SEQ ID NO: 267; SEQ ID NO: 218 and SEQ ID NO: 268; and SEQ ID NO: 218 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 219 and SEQ ID NO: 236; SEQ ID NO: 219 and SEQ ID NO: 325; SEQ ID NO: 219 and SEQ ID NO: 237; SEQ ID NO: 219 and SEQ ID NO: 238; SEQ ID NO: 219 and SEQ ID NO: 239; SEQ ID NO: 219 and SEQ ID NO: 240; SEQ ID NO: 219 and SEQ ID NO: 241; SEQ ID NO: 219 and SEQ ID NO: 242; SEQ ID NO: 219 and SEQ ID NO: 243; SEQ ID NO: 219 and SEQ ID NO: 244; SEQ ID NO: 219 and SEQ ID NO: 245; SEQ ID NO: 219 and SEQ ID NO: 246; SEQ ID NO: 219 and SEQ ID NO: 247; SEQ ID NO: 219 and SEQ ID NO: 248; SEQ ID NO: 219 and SEQ ID NO: 249; SEQ ID NO: 219 and SEQ ID NO: 250; SEQ ID NO: 219 and SEQ ID NO: 251; SEQ ID NO: 219 and SEQ ID NO: 252; SEQ ID NO: 219 and SEQ ID NO: 253; SEQ ID NO: 219 and SEQ ID NO: 254; SEQ ID NO: 219 and SEQ ID NO: 255; SEQ ID NO: 219 and SEQ ID NO: 256; SEQ ID NO: 219 and SEQ ID NO: 257; SEQ ID NO: 219 and SEQ ID NO: 258; SEQ ID NO: 219 and SEQ ID NO: 259; SEQ ID NO: 219 and SEQ ID NO: 260; SEQ ID NO: 219 and SEQ ID NO: 261; SEQ ID NO: 219 and SEQ ID NO: 262; SEQ ID NO: 219 and SEQ ID NO: 263; SEQ ID NO: 219 and SEQ ID NO: 264; SEQ ID NO: 219 and SEQ ID NO: 265; SEQ ID NO: 219 and SEQ ID NO: 266; SEQ ID NO: 219 and SEQ ID NO: 267; SEQ ID NO: 219 and SEQ ID NO: 268; and SEQ ID NO: 219 and SEQ ID NO: 269.
In some aspects, the VH-VL pairs are selected from SEQ ID NO: 220 and SEQ ID NO: 236; SEQ ID NO: 220 and SEQ ID NO: 325; SEQ ID NO: 220 and SEQ ID NO: 237; SEQ ID NO: 220 and SEQ ID NO: 238; SEQ ID NO: 220 and SEQ ID NO: 239; SEQ ID NO: 220 and SEQ ID NO: 240; SEQ ID NO: 220 and SEQ ID NO: 241; SEQ ID NO: 220 and SEQ ID NO: 242; SEQ ID NO: 220 and SEQ ID NO: 243; SEQ ID NO: 220 and SEQ ID NO: 244; SEQ ID NO: 220 and SEQ ID NO: 245; SEQ ID NO: 220 and SEQ ID NO: 246; SEQ ID NO: 220 and SEQ ID NO: 247; SEQ ID NO: 220 and SEQ ID NO: 248; SEQ ID NO: 220 and SEQ ID NO: 249; SEQ ID NO: 220 and SEQ ID NO: 250; SEQ ID NO: 220 and SEQ ID NO: 251; SEQ ID NO: 220 and SEQ ID NO: 252; SEQ ID NO: 220 and SEQ ID NO: 253; SEQ ID NO: 220 and SEQ ID NO: 254; SEQ ID NO: 220 and SEQ ID NO: 255; SEQ ID NO: 220 and SEQ ID NO: 256; SEQ ID NO: 220 and SEQ ID NO: 257; SEQ ID NO: 220 and SEQ ID NO: 258; SEQ ID NO: 220 and SEQ ID NO: 259; SEQ ID NO: 220 and SEQ ID NO: 260; SEQ ID NO: 220 and SEQ ID NO: 261; SEQ ID NO: 220 and SEQ ID NO: 262; SEQ ID NO: 220 and SEQ ID NO: 263; SEQ ID NO: 220 and SEQ ID NO: 264; SEQ ID NO: 220 and SEQ ID NO: 265; SEQ ID NO: 220 and SEQ ID NO: 266; SEQ ID NO: 220 and SEQ ID NO: 267; SEQ ID NO: 220 and SEQ ID NO: 268; and SEQ ID NO: 220 and SEQ ID NO: 269.
3.7.4.1 Variants of VH-VL Pairs
In some embodiments, the VH-VL pairs provided herein comprise a variant of an illustrative VH and/or VL sequence provided in this disclosure.
In some aspects, the VH sequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identity with any of the illustrative VH sequences provided in this disclosure.
In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VH sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.
In some embodiments, the VL sequence comprises, consists of, or consists essentially of any of the illustrative VL sequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
3.8 PD-1 Antibodies Comprising all Six CDRs
In some embodiments, the PD-1 antibody comprises a CDR-H1 sequence, a CDR-H2 sequence, a CDR-H3 sequence, a CDR-L1 sequence, a CDR-L2 sequence, and a CDR-L3 sequence. In some aspects, the CDR sequences are part of a VH (for CDR-H) or VL (for CDR-L).
In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 24-38 or a Chothia CDR-H1 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 81 or a Chothia CDR-H2 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119 or a CDR-H3 sequence of a VH sequence provided in any one of SEQ ID NOs.: 181-220; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124 or a CDR-L1 sequence of a VL sequence selected from SEQ ID NOs.: 236-269; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 134-139 or a CDR-L2 sequence of a VL sequence selected from SEQ ID NOs.: 236-269; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143 or a CDR-L3 sequence of a VL sequence selected from SEQ ID NOs.: 236-269.
In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 57-62 or a Kabat CDR-H1 sequence of a VH sequence selected from SEQ ID NOs.: 181-220; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 110 or a Kabat CDR-H2 sequence of a VH sequence selected from SEQ ID NOs.: 181-220; the CDR-H3 sequence is a CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 119 or a Kabat CDR-H3 sequence of a VH sequence selected from SEQ ID NOs.: 181-220; the CDR-L1 sequence is a CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 124 or a CDR-L1 sequence of a VL sequence selected from SEQ ID NOs.: 236-269; the CDR-L2 sequence is a CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 134-139 or a CDR-L2 sequence of a VL sequence selected from SEQ ID NOs.: 236-269; and the CDR-L3 sequence is a CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NO: 143 or or a CDR-L3 sequence of a VL sequence selected from SEQ ID NOs.: 236-269.
3.8.1 Variants of Antibodies Comprising all Six CDRs
In some embodiments, the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 provided herein comprise a variant of an illustrative CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and/or CDR-L3 sequence provided in this disclosure.
In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.
Provided herein are bi-specific antigen-binding constructs, e.g., antibodies, that bind Tim-3 and PD-1. The bi-specific antigen-binding construct includes two antigen-binding polypeptide constructs, e.g., antigen binding domains, that specifically binding to Tim-3 and/or PD-1. In some embodiments, the antigen-binding construct is derived from known antibodies or antigen-binding constructs. In some embodiments, the antigen-binding polypeptide constructs comprise two antigen binding domains that comprise antibody fragments. In some embodiments, the first antigen binding domain and second antigen binding domain each independently comprises an antibody fragment selected from the group of: an scFv, a Fab, and an Fc domain. The antibody fragments may be the same format or different formats from each other. For example, in some embodiments, the antigen-binding polypeptide constructs comprise a first antigen binding domain comprising an scFv and a second antigen binding domain comprising a Fab. In some embodiments, the antigen-binding polypeptide constructs comprise a first antigen binding domain and a second antigen binding domain, wherein both antigen binding domains comprise an scFv. In other embodiments, the first and second antigen binding domains each comprise a Fab. In some embodiments, the first and second antigen binding domains each comprise an Fc domain. Any combination of antibody formats is suitable for the bi-specific antibody constructs disclosed herein.
In some embodiments, in the bi-specific antibodies disclosed herein, the first and second antigen-binding polypeptide constructs independently comprise different light chains. For example, in some embodiments, the first antigen-binding polypeptide construct comprises a VL sequence selected from any one of SEQ ID NOs: 221-235, and the second antigen-binding polypeptide construct comprises a VL sequence selected from any one of SEQ ID NOs: 236-269. In some embodiments, the first antigen-binding polypeptide construct comprises a VL sequence selected from any one of SEQ ID NOs: 236-269, and the second antigen-binding polypeptide construct comprises a VL sequence selected from any one of SEQ ID NOs: 221-235. In some embodiments, the first and second antigen-binding polypeptide constructs comprise the same light chain. For example, in some embodiments, the first and second antigen-binding polypeptide constructs comprise a same VL sequence selected from any one of SEQ ID NOs: 221-269. In some embodiments, the first and second antigen-binding polypeptide constructs further comprise a CL sequence selected from any one of SEQ ID NOs: 327-338 and 346-347. In some embodiments, the first and second antigen-binding polypeptide constructs comprise the same CL sequence. In some embodiments, the first and second antigen-binding polypeptide constructs comprise different CL sequences.
The term “antigen-binding construct” refers to any agent, e.g., polypeptide or polypeptide complex capable of binding to an antigen. In some aspects an antigen-binding construct is a polypeptide that specifically binds to an antigen of interest. An antigen-binding construct can be a monomer, dimer, multimer, a protein, a peptide, or a protein or peptide complex; an antibody, an antibody fragment, or an antigen-binding fragment thereof; an scFv and the like. An antigen-binding construct can be a polypeptide construct that is monospecific, bi-specific, or multispecific. In some aspects, an antigen-binding construct can include, e.g., one or more antigen-binding components (e.g., Fabs or scFvs) linked to one or more Fc. Further examples of antigen-binding constructs are described below and provided in the Examples.
The term “bi-specific” includes any agent, e.g., an antigen-binding construct, which has two antigen-binding moieties (e.g. antigen-binding polypeptide constructs), each with a unique binding specificity. For example, a first antigen-binding moiety binds to an epitope on a first antigen, and a second antigen-binding moiety binds to an epitope on a second antigen, where the first antigen is different from the second antigen.
For example, in some embodiments, a bi-specific agent can bind to, or interact with, (a) a cell surface target molecule and (b) an Fc receptor on the surface of an effector cell. In some embodiments, the agent can bind to, or interact with (a) a first cell surface target molecule and (b) a second cell surface target molecule that is different from the first cell surface target molecule. In some embodiments, the agent can bind to and bridge two cells, i.e. interact with (a) a first cell surface target molecule on a first call and (b) a second cell surface target molecule on a second cell that is different from the first cells surface target molecule on the first cell.
In contrast, a monospecific antigen-binding construct refers to an antigen-binding construct with a single binding specificity. In other words, both antigen-binding moieties bind to the same epitope on the same antigen. Examples of monospecific antigen-binding constructs include the anti-CD19 antibody HD37 and the anti-CD3 antibody OKT3 for example.
An antigen-binding construct can be an antibody or antigen-binding portion thereof as disclosed herein.
Methods of generating bi-specific antibodies and bi-specific antigen-binding constructs are described, for example, in Brinkmann, U., and R. E. Kontermann. 2017. mAbs 9(2):182-212; and in Yang, et al. 2017. Int. J. Mol. Sci. 18(1):48 (21 pages), each of which is incorporated herein by reference in its entirety.
4.1 Antigen-Binding Polypeptide Construct-Format
The bi-specific antigen-binding construct comprises at least two antigen-binding polypeptide constructs, e.g., antigen binding domains. The format of the antigen-binding polypeptide construct determines certain functional characteristics of the bi-specific antigen-binding construct. In some embodiments, the bi-specific antigen-binding construct has an scFv-scFv format, i.e. both antigen-binding polypeptide constructs are scFvs. In some embodiments, the bi-specific antigen-binding construct has a Fab-Fab format, i.e. both antigen-binding polypeptide constructs are Fabs. In some embodiments, the bi-specific antigen-binding construct has an scFv-Fab format, i.e. a first antigen-binding polypeptide construct is an scFv, and a second antigen-binding polypeptide construct is an Fab. The bi-specific antibody or antigen-binding construct can have any form suitable for the antibody or antigen-binding construct, so long as it comprises a first antigen binding domain and a second antigen binding domain that bind to distinct targets.
In some embodiments, the bi-specific antibody or antigen-binding construct is provided, comprising a first antigen binding domain that specifically binds Tim-3 and a second antigen binding domain that specifically binds PD-1. In some embodiments, a bi-specific antigen construct is provided, comprising a first scFv that specifically binds Tim-3 and a second scFv that specifically binds PD-1. In some embodiments, a bi-specific antigen construct is provided, comprising a first Fab that specifically binds Tim-3 and a second Fab that specifically binds PD-1. In some embodiments, a bi-specific antigen construct is provided, comprising an scFv that specifically binds Tim-3 and a Fab that specifically binds PD-1. In some embodiments, a bi-specific antigen construct is provided, comprising a Fab that specifically binds Tim-3 and an scFv that specifically binds PD-1.
In some embodiments, the bi-specific antibody or bi-specific antigen-binding construct can be generated as a dual-variable domain antibody. A “dual-variable domain antibody” (also referred to as a DVD-Ig) refers to fusion of an additional VH domain and VL domain of a second specificity to a given IgG heavy chain and light chain. Generation of dual-variable domain antibody formats are described, for example, in Wu et al. 2007. Nature Biotechnology 25:1290-1297 and U.S. 2007/0071675, each of which is incorporated herein by reference in its entirety.
In some embodiments, the bi-specific antibody or bi-specific antigen-binding construct is generated as a cross-over dual-variable domain antibody. A “cross-over dual-variable domain antibody” (also referred to as a CODV-Ig) refers to a format related to the dual-variable domain antibody format wherein the two VH domains and two VL domains are linked to allow cross-over pairing of the variable VH-VL domains. Generation of cross-over dual-variable domain antibody formats are described, for example, in Steinmetz et al. 2016. mAbs 8:867-878, which is incorporated herein by reference in its entirety.
Other formats for synthesis and use in bi-specific antibodies or bi-specific antigen-binding constructs are contemplated and described below.
The format “Single-chain Fv” or “scFv” includes the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In some embodiments, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains. See, e.g., Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
The “Fab fragment” (also referred to as fragment antigen-binding) contains the constant domain (CL) of the light chain and the first constant domain (CH1) of the heavy chain along with the variable domains VL and VH on the light and heavy chains respectively. The variable domains comprise the complementarity determining loops (CDR, also referred to as hypervariable region) that are involved in antigen-binding. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.
The “Single domain antibodies” or “sdAb” format is an individual immunoglobulin domain. SdAbs are fairly stable and easy to express as fusion partner with the Fc chain of an antibody (see Harmsen M M, De Haard H J (2007). “Properties, production, and applications of camelid single-domain antibody fragments.” Appl. Microbiol Biotechnol. 77(1): 13-22).
4.1.1 Format scFv
Embodiments are directed to bi-specific antigen-binding constructs comprising two antigen-binding polypeptide constructs that are each capable of specific binding to a distinct antigen. In some embodiments, each antigen-binding polypeptide construct is in an scFv format. (i.e., antigen-binding domains composed of a heavy chain variable domain and a light chain variable domain, connected with a polypeptide linker). In some embodiments, the scFv molecules are human. In some embodiments, the scFv molecules are humanized. The scFvs can be optimized for protein expression and yield by the modifications disclosed herein.
In some embodiments, the scFv is optimized by changing the order of the variable domains VL and VH in the scFv. In some embodiments, in the scFv, the C-terminus of the light chain variable region can be linked to the N-terminus of the heavy chain variable region. In some embodiments, in the scFv, the C-terminus of the heavy chain variable region can be linked to the N-terminus of the light chain variable region.
The variable regions of the scFv can be connected via a linker peptide, or scFv linker, that allows the formation of a functional antigen-binding moiety. In some embodiments, the scFv can be optimized for protein expression and yield by changing composition and/or length of the scFv linker polypeptide. Typical peptide linkers comprise about 2-20 amino acids, and are described herein or known in the art. Suitable, non-immunogenic linker peptides include, for example, (G4S)n, (SG4)n, (G4S)n, G4(SG4)n or G2(SG2)n linker peptides, wherein n is generally a number between 1 and 10. In some embodiments, n is a number between 4 and 8. In some embodiments, n is a number between 3 and 6. In some embodiments, n is a number between 2 and 4. Other linkers are described, for example, in Bird et al. 1988. Science 242:423-426; Huston et al. 1988. PNAS 85:5879-5883; and McCafferty et al. 1990. Nature 348:552-554.
The scFv molecule can be optimized for protein expression and yield by including stabilizing disulfide bridges between the heavy and light chain variable domains, for example as described in Reiter et al. (Nat Biotechnol 14, 1239-1245 (1996)). Accordingly, in some embodiments, the bi-specific antigen-binding molecule disclosed herein can comprise an scFv molecule wherein an amino acid in the heavy chain variable domain and an amino acid in the light chain variable domain have been replaced by cysteine so that a disulfide bridge can be formed between the heavy and light chain variable domain.
ScFvs can also be stabilized by mutation of CDR sequences, as described in the art (Miller et al., Protein Eng Des Sel. 2010 July; 23(7):549-57; Igawa et al., MAbs. 2011 May-June; 3(3):243-5; Perchiacca & Tessier, Annu Rev Chem Biomol Eng. 2012; 3:263-286, each of which is incorporated herein by reference in its entirety.) and as disclosed herein in exemplary embodiments.
4.1.2 Fc Domains of Antigen-Binding Constructs
In some embodiments, the antigen-binding constructs described herein comprise an Fc domain, e.g., a dimeric Fc. The Fc domain is a heterodimeric Fc comprising first and second Fc polypeptides each comprising a modified CH3 sequence, wherein each modified CH3 sequence comprises asymmetric amino acid modifications that promote the formation of a heterodimeric Fc and the dimerized CH3 domains have a melting temperature (Tm) of about 68° C. or higher, and wherein the first Fc polypeptide is linked to the first antigen-binding polypeptide construct, with a first hinge linker, and the second Fc polypeptide is linked to the second antigen-binding polypeptide construct with a second hinge linker.
The term “Fc domain” or “Fc region” herein refers to a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions and is used interchangeably with “Fc.” Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. An “Fc polypeptide” of a dimeric Fc as used herein refers to one of the two polypeptides forming the dimeric Fc domain, i.e. a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self-association. For example, an Fc polypeptide of a dimeric IgG Fc comprises an IgG CH2 and an IgG CH3 constant domain sequence.
An Fc domain comprises either a CH3 domain or a CH3 and a CH2 domain. The CH3 domain comprises two CH3 sequences, one from each of the two Fc polypeptides of the dimeric Fc. The CH2 domain comprises two CH2 sequences, one from each of the two Fc polypeptides of the dimeric Fc.
In some embodiments, the Fc comprises at least one or two CH3 sequences. In some aspects, the Fc is coupled, with or without one or more linkers, to a first antigen-binding construct and/or a second antigen-binding construct. In some embodiments, the Fc is a human Fc. In some embodiments, the Fc is a human IgG or IgG1 Fc. In some embodiments, the Fc is a heterodimeric Fc. In some embodiments, the Fc comprises at least one or two CH2 sequences.
In some embodiments, the Fc comprises one or more modifications in at least one of the CH3 sequences. In some embodiments, the Fc comprises one or more modifications in at least one of the CH2 sequences. For example, the Fc can include one or modifications selected from the group consisting of: V262E, V262D, V262K, V262R, V262S, V264S, V303R, and V305R. In some embodiments, an Fc is a single polypeptide. In some embodiments, an Fc is multiple peptides, e.g., two polypeptides.
4.1.3 Modified CH3 Domains
In some embodiments, the antigen-binding construct described herein comprises a heterodimeric Fc comprising a modified CH3 domain that has been asymmetrically modified. The heterodimeric Fc can comprise two heavy chain constant domain polypeptides: a first Fc polypeptide and a second Fc polypeptide, which can be used interchangeably provided that Fc comprises one first Fc polypeptide and one second Fc polypeptide. Generally, the first Fc polypeptide comprises a first CH3 sequence and the second Fc polypeptide comprises a second CH3 sequence.
Two CH3 sequences that comprise one or more amino acid modifications introduced in an asymmetric fashion generally results in a heterodimeric Fc, rather than a homodimer, when the two CH3 sequences dimerize. As used herein, “asymmetric amino acid modifications” refers to any modification where an amino acid at a specific position on a first CH3 sequence is different from the amino acid on a second CH3 sequence at the same position, and the first and second CH3 sequence preferentially pair to form a heterodimer, rather than a homodimer. This heterodimerization can be a result of modification of one of the two amino acids at the same respective amino acid position on each sequence; or modification of both amino acids on each sequence at the same respective position on each of the first and second CH3 sequences. The first and second CH3 sequence of a heterodimeric Fc can comprise one or more than one asymmetric amino acid modification.
Typically an Fc can include two contiguous heavy chain sequences (A and B) that are capable of dimerizing. With respect to the antigen binding constructs described herein, in some embodiments the first scFv is linked to chain A of the heterodimeric Fc and the second scFv is linked to chain B of the heterodimeric Fc. In some embodiments the second scFv is linked to chain A of the heterodimeric Fc and the first scFv is linked to chain B of the heterodimeric Fc.
In some embodiments, one or both sequences of an Fc include one or more mutations or modifications at the following locations: L351, L368, F405, Y407, T366, K392, T394, T350, S400, and/or N390, using EU numbering. In some embodiments, an Fc includes the mutations as disclosed in the art (see Von Kreudenstein et al. 2013. mAbs 5(5):646-654; Von Kreudenstein et al. 2014. Methods 65:77-94; U.S. 2013/0195849; Ridgway et al. 1996. Protein Eng 9(7):617-621; and Brinkmann, U., and R. E. Kontermann. 2017. mAbs 9(2):182-212, each of which is incorporated herein by reference in its entirety.)
The first and second CH3 sequences can comprise amino acid mutations as described herein. In some embodiments, the heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having one or more amino acid modifications selected from L351Y, F405A, and Y407V, and the second CH3 sequence having one or more amino acid modifications selected from T366L, T366I, K392L, K392M, and T394W. In some embodiments, the heterodimeric Fc comprises a modified CH3 domain with a first CH3 sequence having amino acid modifications T350V/T366L/K392L/T394W, and a second CH3 sequence having amino acid modifications T350V/L351Y/F405A/Y407V.
Additional modifications within the first and second CH3, or within the amino acid sequence of human IgG1 Fc, can be found, for example, at U.S. 2016/0326249, which is incorporated herein by reference in its entirety.
4.1.4 Modified VH/VL and/or CH1/CL1 Interactions
In some embodiments, the bi-specific antibodies or bi-specific antigen-binding constructs disclosed herein comprise one or more light chains. In some embodiments, the bi-specific antibody or bi-specific antigen-binding construct comprises two light chains. In some embodiments, the two light chains are different. In some embodiments, the two light chains are the same.
In embodiments wherein the two light chains are different, one or more modifications can be introduced into one or both light chains to allow for pairing of a cognate heavy chain and light chain. Accordingly, in some embodiments, the interaction between the variable domain a first light chain and the variable domain of a corresponding first heavy chain (i.e., VH-VL interaction) is modified. In some embodiments, the interaction the constant domain of a first light chain and the first constant domain of a corresponding first heavy chain (i.e., CH1-CL interaction) is modified. In some embodiments, the modification comprises genetically engineering or genetically modifying residues that are involved in the VH-VL and/or the CH1-CL interaction. In some embodiments, the modification involves mutating residues to modify electrostatic interactions between the VH-VL pairs and/or the CH1-CL pairs. The result of modification to the VH-VL and/or the CH1-CL interactions can result in improved accuracy (or improved “steering”) in pairing of cognate heavy and light chains. Exemplary modifications in these domains are described, for example, in Lewis et al. 2014. Nature Biotechnology 32:191-198 and WO 2014/082179, each of which is incorporated herein by reference in its entirety.
4.1.5 Hinge Linkers
In some embodiments, in the bi-specific antigen-binding constructs disclosed herein, the first Fc polypeptide is linked to the first antigen-binding polypeptide construct with a first hinge linker, and the second Fc polypeptide is linked to the second antigen-binding polypeptide construct with a second hinge linker. Examples of hinge linker sequences are well-known to one of skill in the art and can be used in the antigen-binding constructs described herein. Alternatively, modified versions of known hinge linkers can be used.
The hinge linker polypeptides are selected such that they maintain or optimize the functional activity of the antigen-binding construct. Suitable linker polypeptides include IgG hinge regions such as, for example those from IgG1, IgG2, or IgG4, including the upper hinge sequences and core hinge sequences. The amino acid residues corresponding to the upper and core hinge sequences vary depending on the IgG type, as is known in the art and one of skill in the art would readily be able to identify such sequences for a given IgG type. Modified versions of these exemplary linkers can also be used. For example, modifications to improve the stability of the IgG4 hinge are known in the art (see for example, Labrijn et al. (2009) Nature Biotechnology 27, 767-771). Examples of hinge linker sequences are found, for example, in U.S. 2016/0326249.
4.1.6. Bispecific Scaffold arrangements
The bi-specific antigen-binding construct can have a variety of different arrangements. For example, the bi-specific antigen-binding construct can comprise a 2-chain scFvFc, a 3-chain Fab×scFvFc, or a 4-chain IgG-like bispecific construct as described below.
4.1.6.1. Generation of a PD1/Tim-3 Bi-Specific Antigen-binding Construct (Two-Chain scFvFc)
A general scheme for generating embodiments of scFvs for use in a PD-1/Tim3 bi-specific antigen-binding construct is provided below in Tables 5 and 6. In some embodiments, the bi-specific antigen-binding construct comprises a 2-chain scFvFc HC/LC pairing maintained by genetically fusing the VH to the VL of both antibodies to form an scFv. In some embodiments, the order of the HC/LC pairing is VH/VL. In some embodiments, the order of the HC/LC pairing is VL/VH. In any of the foregoing embodiments, the HC/LC pairing can comprise a linker sequence. In some embodiments, the linker sequence comprises a Gly/Ser-rich linker of the sequence (GGGGS)n where n=3, 4, 5, or 6 to provide linkers with lengths of 15, 20, 25, or 30 residues, respectively.
In some embodiments, the scFv is arranged in a VH-VL arrangement. In some embodiments, the scFv comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245. In some embodiments, the scFv comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235.
In some embodiments, the scFv is arranged in a VL-VH arrangement. In some embodiments, the scFv comprises a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197. In some embodiments, the scFv comprises a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180.
4.1.6.2. Generation of a PD-1/Tim-3 Bi-Specific Antigen-Binding Construct (Two-Chain scFvFc with Knob-in-Hole Mutations)
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a two-chain scFvFc arrangement, wherein the scFvFc pairing comprises knob-in-hole mutations, is provided. In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising an anti-PD-1 scFvFc knob paired with an anti-Tim-3 scFvFc hole. In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising an anti-PD-1 scFvFc hole paired with an anti-Tim-3 scFvFc knob. The scFvFcs include scFvs generated in accordance with Section 4.1.6.1.
A general scheme for scFvFcs useful in a PD-1/Tim-3 bi-specific antigen-binding construct comprising a two-chain scFv arrangement with knob-in-hole mutations is provided below in Table 7.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a two-chain scFvFc arrangement is prepared using the following arrangement: an anti-PD-1 scFvFc knob (Table 12, design (a)) paired with an anti-Tim-3 scFvFc hole (Table 12, design (d)). In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a two-chain scFvFc arrangement is prepared using the following arrangement: an anti-PD-1 scFvFc hole (Table 12, design (c)) paired with an anti-Tim-3 scFvFc knob (Table 12, design (b)).
In some embodiments, the anti-PD-1 scFvFc knob is constructed from: (1) an anti-PD-1 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-PD-1 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245. In some embodiments, the anti-PD-1 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 236-245; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 181-197. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO:285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 295-299.
In some embodiments, the anti-PD-1 scFvFc hole is constructed from: (1) an anti-PD-1 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-PD-1 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245. In some embodiments, the anti-PD-1 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 236-245; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 181-197. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO:285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 300-304.
In some embodiments, the anti-Tim-3 scFvFc knob is constructed from: (1) an anti-Tim-3 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-Tim-3 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235. In some embodiments, the anti-Tim-3 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 221-235; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 144-180. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO: 285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 295-299.
In some embodiments, the anti-Tim-3 scFvFc hole is constructed from: (1) an anti-Tim-3 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-Tim-3 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235. In some embodiments, the anti-Tim-3 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 221-235; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 144-180. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO: 285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 300-304.
4.1.6.3. Generation of a PD-1/Tim-3 Bi-Specific Antigen-Binding Construct (Three-Chain Fab×scFvFc with Knob-in-Hole Mutations)
In some embodiments, the bi-specific antigen-binding construct comprises a 3-chain Fab×scFvFc scaffolds in which an scFv is replaced with a Fab domain. In these embodiments, the asymmetry of the scaffold facilitates correct HC/LC pairing as there is only one HC/LC pairing that can correctly form the Fab domain; the other arm is an scFv.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a three-chain Fab×scFvFc structure can be prepared using the following arrangements: (1) an anti-PD-1 scFvFc knob paired with an anti-Tim-3 half IgG (HC+LC) hole, (2) an anti-PD-1 scFvFc hole paired with an anti-Tim-3 half IgG (HC+LC) knob, (3) an anti-PD-1 half IgG (HC+LC) knob paired with an anti-Tim-3 scFvFc hole, and (4) an anti-PD-1 half IgG (HC+LC) hole paired with an anti-Tim-3 scFvFc knob. The scFvs included within such scFvFc arrangements can be generated in accordance with Section 4.1.6.1.
A general scheme for anti-PD-1 half IgGs (HC+LC, knob or hole) and anti-Tim 3 half IgGs (HC+LC, knob or hole) for use in a PD-1/Tim-3 bi-specific antigen-binding construct comprising a three-chain Fab×scFv arrangement with knob-in-hole mutations is provided below in Tables 8 and 9.
In some embodiments, the anti-PD-1 half IgG knob comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 295-299, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245 and a CL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs:346-347.
In some embodiments, the anti-PD-1 half IgG hole comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 300-304, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245 and a CL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 346-347.
In some embodiments, the anti-Tim-3 half IgG knob comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 295-299, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235 and a CL comprising, consisting of, or consisting essentially of SEQ ID NO: 346.
In some embodiments, the anti-Tim-3 half IgG hole comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 300-304, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235 and a CL comprising, consisting of, or consisting essentially of SEQ ID NO: 346.
In some embodiments, the anti-Tim-3 scFvFc hole is constructed from: (1) an anti-Tim-3 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-Tim-3 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235. In some embodiments, the anti-Tim-3 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 221-235; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 144-180. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO: 285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 300-304.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a three-chain Fab×scFvFc arrangement is prepared using the following arrangement: an anti-PD-1 scFvFc knob (Table 7, design (a)) paired with an anti-Tim-3 half IgG hole (HC=Table 8, design (d), LC=Table 9, design (c)).
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a three-chain Fab×scFvFc arrangement is prepared using the following arrangement: an anti-PD-1 scFvFc hole (Table 7, design (c)) paired with an anti-Tim-3 half IgG knob (HC=Table 8, design (b), LC=Table 9, design (c)).
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a three-chain Fab×scFvFc arrangement is prepared using the following arrangement: an anti-PD-1 half IgG knob (HC=Table 8, design (a), LC=Table 9, design (a) or (b)) paired with an anti-Tim-3 scFvFc hole (Table 7, design (d)).
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct comprising a three-chain Fab×scFvFc arrangement is prepared using the following arrangement: an anti-PD-1 half IgG hole (HC=Table 8, design (c), LC=Table 9, design (a) or (b)) hole paired with an anti-Tim-3 scFvFc knob (Table 7, design (b)).
4.1.6.4. Generation of a PD-1/Tim-3 Bi-Specific Antigen-Binding Construct (Three-Chain Fab×scFvFc with Zw Mutations)
In some embodiments, the bi-specific antigen-binding construct comprises a three-chain Fab×scFvFc scaffold, wherein the Fab and scFvFc structures comprise knob-in-hole mutations. In these embodiments, the asymmetry of the scaffold facilitates correct HC/LC pairing as there is only one HC/LC pairing that can correctly form the Fab domain; the other arm is an scFv.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising a three-chain Fab×scFvFc structure comprising an anti-PD-1 scFvFc with zwA mutations paired with an anti-Tim-3 half IgG (HC+LC) with zwB mutations. In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising a three-chain Fab×scFvFc structure comprising an anti-PD-1 scFvFc with zwB mutations paired with an anti-Tim-3 half IgG (HC+LC) with zwA mutations. In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising a three-chain Fab×scFvFc structure comprising an anti-PD-1 half IgG (HC+LC) with zwA mutations paired with an anti-Tim-3 scFvFc with zwB mutations. In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising a three-chain Fab×scFvFc structure comprising an anti-PD-1 half IgG (HC+LC) with zwB mutations paired with an anti-Tim-3 scFvFc with zwA mutations. The mutations encompassed by “zwA” mutations include T350V/L351Y/F405A/Y407V in the CH3 domain. The mutations encompassed by “zwB” mutations include T350V/T366L/K392L/T394W in the CH3 domain.
A general scheme for scFvFcs with zw mutations and for anti-PD-1 half IgGs (HC+LC) and anti-Tim-3 half IgGs (HC+LC) with zw mutations for use in a PD-1/Tim-3 bi-specific antigen-binding construct comprising a three-chain Fab×scFv arrangement is provided below in Tables 10 and 11. Exemplary LC embodiments for the half IgGs correspond to those in Table 9 above.
In some embodiments, the anti-PD-1 scFvFc zwA is constructed from: (1) an anti-PD-1 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-PD-1 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245. In some embodiments, the anti-PD-1 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 236-245; a linker selected from SEQ ID NOs:278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 181-197. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO: 285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 305-307.
In some embodiments, the anti-PD-1 scFvFc zwB is constructed from: (1) an anti-PD-1 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-PD-1 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245. In some embodiments, the anti-PD-1 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 236-245; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 181-197. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO: 285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 308-310.
In some embodiments, the anti-Tim-3 scFvFc zwA is constructed from: (1) an anti-Tim-3 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-Tim-3 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235. In some embodiments, the anti-Tim-3 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 221-235; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 144-180. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO: 285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 305-307.
In some embodiments, the anti-Tim-3 scFvFc zwB is constructed from: (1) an anti-Tim-3 scFv; (2) a linker-hinge; and (3) a CH2-CH3 region. In some embodiments, the anti-Tim-3 scFv comprises a VH-VL arrangement and comprises a VH sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a linker selected from SEQ ID NOs: 278-281; and a VL sequence comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235. In some embodiments, the anti-Tim-3 scFv comprises a VL-VH arrangement and comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 221-235; a linker selected from SEQ ID NOs: 278-281; and a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 144-180. In some embodiments, the linker-hinge comprises, consists of, or consists essentially of SEQ ID NO: 285. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs.: 308-310.
In some embodiments, the anti-PD-1 half IgG with zwA mutations comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 305-307, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245 and a CL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 346-347.
In some embodiments, the anti-PD-1 half IgG with zwB mutations comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 181-197; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 308-310, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 236-245 and a CL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 346-347.
In some embodiments, the anti-Tim-3 half IgG with zwA mutations comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 305-307, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235 and a CL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 346-347.
In some embodiments, the anti-Tim-3 half IgG with zwB mutations comprises a heavy chain and a light chain, wherein the heavy chain comprises: a VH comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 144-180; a CH1 region comprising, consisting of, or consisting essentially of SEQ ID NO: 345; a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286; and a CH2-CH3 region comprising, consisting of, or consisting essentially of any one of SEQ ID NOs.: 308-310, and wherein the light chain comprises: a VL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 221-235 and a CL comprising, consisting of, or consisting essentially of any one of SEQ ID NOs: 346-347.
4.1.6.5. Generation of a PD-1/Tim-3 Bi-Specific Antigen-Binding Construct (Four-Chain Fab-Fc×Fab-Fc (IgG-Like) with Zw Mutations)
In some embodiments, the bi-specific antigen-binding construct comprises a four-chain IgG-like scaffold comprising a Fab domain fused to the N-termini of a heterodimeric Fc. In such embodiments, this bispecific format comprises four chains: heavy chain 1 (HC1), light chain 1 (LC1), heavy chain 2 (HC2), and light chain 2 (LC2). In some embodiments, the HC and LC sequences are mutated as described herein in sections 4.1.2-4.1.4 to facilitate correct pairing between HCs and LCs. For example, the HC/LC pairing designs listed in Tables 12-14 can be incorporated into the construct to facilitate correct HC/LC pairing. HC1 is designed such that it pairs specifically with LC1 rather than LC2. HC2 is designed such this it pairs specifically with LC2 rather than LC1. Six designs are shown below in Tables 12 and 13 that enforce correct light-chain pairing: (a), (b) (c), (d), (e), and (f). Designs (a) and (b) in Table 12 can be incorporated for an embodiment in which one light chain is a kappa chain (LC1) and the second light chain is a lambda chain (LC2). Designs (c), (d), (e) and (f) in Table 13 can be incorporated for embodiments in which the first and second light chains (LC1, LC2) are kappa chains.
In some embodiments, the HCs and LCs for a kappa×kappa bi-specific construct can be switched around. For example, in some embodiments, the (c), (d), (e), and (f) designs of Table 13 can be swapped such that the Tim-3 HC1+LC1 and PD-1 HC2+LC2 use the opposite light-chain pairing mutations, as illustrated in Table 14.
In some embodiments, HC1 and HC2 incorporate complementary Zymeworks mutations A (T350V/L351Y/F405A/Y407V; “zwA”) and B (T350V/T366L/K392L/T394W; “zwB”) to enforce heterodimerization of HC1 with HC2 (see, e.g., Von Kreudenstein et al. 2013. mAbs 5(5):646-654; Von Kreudenstein et al. 2014. Methods 65:77-94; U.S. 2013/0195849, each of which is incorporated herein by reference in its entirety). Accordingly, if HC1 has zwA then HC2 must have zwB; if HC1 has zwB then HC2 must have zwA. Many alternatives to these CH3 pairing mutations, e.g., knobs-in-holes mutations, can be used instead. Some of these alternatives are described, for example, in Brinkmann, U., and R. E. Kontermann. 2017. mAbs 9(2):182-212; and Yang, et al. 2017. Int. J. Mol. Sci. 18(1):48 (21 pages), each of which is incorporated herein by reference in its entirety. The CH2 domains can either be wild-type or have stability/solubility/assembly/yield enhancing mutations V262E or V264S.
4.1.6.5.1 Tim-3 Heavy Chains (HC1 or HC2)
A full-length antibody Tim-3 heavy chain typically includes a VH domain, a CH1 domain, a linker, and a CH2-CH3 region. In some embodiments, the VH domain comprises, consists, or consists essentially of any one of SEQ ID NOs: 144-180. In some embodiments, the CH1 domain is selected from SEQ ID NOs: 317-326. In some embodiments, the linker comprises, consists of, or consists essentially of SEQ ID NO: 286. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs: 305-310. For example, in an embodiment where the anti-Tim-3 arm is antibody “1” in the bi-specific antibody, an anti-Tim-3 heavy chain with design (a) (“HC1(a)”) can be constructed from: (1) a VH sequence of 1649-A01 (SEQ ID NO: 151); (2) CH1-(a)1; (3) a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286, and (4) a CH2-CH3 region comprising, consisting of, or consisting essentially of Fc-zwA. Table 15 provides various exemplary components for the VH domain, CH1 domain, linker, and CH2-CH3 region that are contemplated for generation of a Tim-3 heavy chain sequence.
In some embodiments, the VH sequence can be selected from the group consisting of: the VH sequence of 1649-A01 (SEQ ID NO: 151), the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), and the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO:305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 (SEQ ID NO: 151), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO:305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D (SEQ ID NO: 179), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO:305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D (SEQ ID NO: 167), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO:305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/Y56D (SEQ ID NO: 166), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO:305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-Tim-3 heavy chain comprises a VH sequence comprising the VH sequence of 1649-A01 S30D/R31D/Y56D (SEQ ID NO: 165), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
4.1.6.5.2 Tim-3 Light Chains (LC1 or LC2)
A full-length anti-Tim-3 light chain typically includes a VL domain and a CL domain. In some embodiments, the VL domain comprises, consists of, or consists essentially of any one of SEQ ID NOs: 221-235. In some embodiments, the CL domain comprises, consists of, or consists essentially of any one of SEQ ID NOs: 327-338. For example, in an embodiment where the anti-Tim-3 arm is antibody “1” in the bi-specific antibody, an anti-Tim-3 light chain with design (a) (“LC1(a)”) can be constructed from: (1) VL sequence 1649-A01 (SEQ ID NO: 235); and (2) Ck-(a)1. Table 16 provides various exemplary components for the VL domain and CL domain for generation of a Tim-3 light chain sequence.
In some embodiments, the VL sequence can be selected from the group consisting of: the VL sequence of 1649-A01 and the VL sequence of 1649-A01 T56D.
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(a)1 (SEQ ID NO: 327).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(b)1 (SEQ ID NO: 328).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(c)1 (SEQ ID NO: 329). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(c)2 (SEQ ID NO: 334).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(d)1 (SEQ ID NO: 330). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(d)2 (SEQ ID NO: 335).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(e)(f)1 (SEQ ID NO: 331). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(e)2 (SEQ ID NO: 336). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 (SEQ ID NO: 235) and a CL sequence comprising the sequence of Ck-(f)2 (SEQ ID NO: 337).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(a)1 (SEQ ID NO: 327).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(b)1 (SEQ ID NO: 328).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(c)1 (SEQ ID NO: 329). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(c)2 (SEQ ID NO: 334).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(d)1 (SEQ ID NO: 330). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(d)2 (SEQ ID NO: 335).
In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(e)(f)1 (SEQ ID NO: 331). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(e)2 (SEQ ID NO: 336). In some embodiments, the anti-Tim-3 light chain comprises a VL sequence comprising the VL sequence of 1649-A01 T56D (SEQ ID NO: 229) and a CL sequence comprising the sequence of Ck-(f)2 (SEQ ID NO: 337).
4.1.6.5.3 PD-1 Heavy Chains (HC1 or HC2)
A full-length anti-PD-1 heavy chain typically includes includes a VH domain, a CH1 domain, a linker, and a CH2-CH3 region. In some embodiments, the VH domain comprises, consists, or consists essentially of any one of SEQ ID NOs: 181-197. In some embodiments, the CH1 domain is selected from SEQ ID NOs: 317-326. In some embodiments, the linker comprises, consists of, or consists essentially of SEQ ID NO: 286. In some embodiments, the CH2-CH3 region comprises, consists of, or consists essentially of any one of SEQ ID NOs: 305-310. For example, in an embodiment where the anti-PD-1 arm is antibody “2” in the bi-specific antibody, an anti-PD-1 heavy chain with design (a) (“HC2a”) can be constructed from: (1) VH sequence 1353-G10R28T/P30D/H31S (SEQ ID NO: 197); (2) CH1(a)2; and (3) a linker comprising, consisting of, or consisting essentially of SEQ ID NO: 286, and (4) a CH2-CH3 region comprising, consisting of, or consisting essentially of Fc-zwA. Table 17 provides various exemplary components for the VH domain, CH1 domain, linker, and CH2-CH3 region that are contemplated for generation of a PD-1 heavy chain sequence.
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)1 (SEQ ID NO: 317), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(a)2 (SEQ ID NO: 322), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)1 (SEQ ID NO: 318), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(b)2 (SEQ ID NO: 323), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)1 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(01 (SEQ ID NO: 319), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(c)2 (SEQ ID NO: 324), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)1 (SEQ ID NO: 320), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(d)2 (SEQ ID NO: 325), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA (SEQ ID NO: 305).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V262E (SEQ ID NO: 306).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwA V264S (SEQ ID NO: 307).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB (SEQ ID NO: 308).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V262E (SEQ ID NO: 309).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)1 (SEQ ID NO: 321), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-wt (SEQ ID NO: 181), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310). In some embodiments, the anti-PD-1 heavy chain comprises a VH sequence comprising the VH sequence of 1353-G10-R28T/P30D/H31S (SEQ ID NO: 197), a CH1 sequence comprising the sequence of CH1-(e)(f)2 (SEQ ID NO: 326), a linker of hinge-wt (SEQ ID NO: 286), and a CH2-CH3 region comprising the sequence of Fc-zwB V264S (SEQ ID NO: 310).
4.1.6.5.4 PD-1 Light Chains (LC1 or LC2)
A full-length anti-PD-1 light chain typically includes a VL domain and a CL domain. In some embodiments, the VL domain comprises, consists of, or consists essentially of any one of SEQ ID NOs: 236-245. In some embodiments, the CL domain comprises, consists of, or consists essentially of any one of SEQ ID NOs: 327-338. For example, in an embodiment where the anti-PD-1 arm is antibody “2” in the bi-specific antibody, an anti-PD-1 light chain with design (a) (“LC2a”) can be constructed from: (1) VL sequence 1353-G10 wt (SEQ ID NO: 236); and (2) Cl-(a)2. Table 18 provides various exemplary components for the VL domain and CL domain for generation of a PD-1 light chain sequence.
In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 wt (SEQ ID NO: 236) and a CL sequence comprising the sequence of Cl-(a)2 (SEQ ID NO: 332).
In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 wt (SEQ ID NO: 236) and a CL sequence comprising the sequence of Cl-(b)2 (SEQ ID NO: 333).
In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 Vk1-39 (κ) (also referred to as “1353-G10-kappa”, SEQ ID NO: 244) and a CL sequence comprising the sequence of Ck-(c)1 (SEQ ID NO: 329). In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 Vk1-39 (κ) (also referred to as “1353-G10-kappa”, SEQ ID NO: 244) and a CL sequence comprising the sequence of Ck-(c)2 (SEQ ID NO: 334).
In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 Vk1-39 (κ) (also referred to as “1353-G10-kappa”, SEQ ID NO: 244) and a CL sequence comprising the sequence of Ck-(d)1 (SEQ ID NO: 330). In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 Vk1-39 (κ) (also referred to as “1353-G10-kappa”, SEQ ID NO: 244) and a CL sequence comprising the sequence of Ck-(d)2 (SEQ ID NO: 335).
In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 Vk1-39 (κ) (also referred to as “1353-G10-kappa”, SEQ ID NO: 244) and a CL sequence comprising the sequence of Ck-(e)(f)1 (SEQ ID NO: 331). In some embodiments, the anti-PD-1 light chain comprises a VL sequence comprising the VL sequence of 1353-G10 Vk1-39 (κ) (also referred to as “1353-G10-kappa”, SEQ ID NO: 244) and a CL sequence comprising the sequence of Ck-(e)(f)2 (SEQ ID NO: 338).
4.1.6.5.5 Hybrid Light Chains (LC1 or LC2=Vλ, +Cκ)
In some embodiments, the anti-Tim-3 or anti-PD-1 light chain comprises a VL lambda sequence (“Vλ”) and a CL kappa sequence (“Cκ”). In such embodiments, the Vλ, sequence comprises one or more mutations selected from the group consisting of: E38F, D85T, T105E, V106I, and L106K. In some embodiments, the light chain is an anti-PD-1 light chain comprising, consisting of, or consisting essentially of SEQ ID NOs: 351 or 352.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising a hybrid light chain comprising a Vλ, and a Cκ sequence, wherein HC1, LC1, HC2, and LC2 comprise one or more mutations selected from the Table 19:
In some embodiments, HC1 and LC1 indicate PD-1 heavy chain and light chain sequences, respectively, and HC2 and LC2 indicate Tim-3 heavy chain and light chain sequences, respectively. In some embodiments, HC1 and LC1 indicate Tim-3 heavy chain and light chain sequences, respectively, and HC2 and LC2 indicate PD-1 heavy chain and light chain sequences, respectively.
In some embodiments, the VH and VL sequences of HC1, HC2, LC1 and LC2 comprise the following mutations from Table 20:
In some embodiments, HC1 comprises, consists of, or consists essentially of SEQ ID NO:353; LC1 comprises, consists of, or consists essentially of SEQ ID NO: 352; HC2 comprises, consists of, or consists essentially of SEQ ID NO: 151; and LC2 comprises, consists of, or consists essentially of SEQ ID NO: 228.
The sequences of the various components contemplated for VH, CH1, linker, CH2-CH3, VL, and CL in Section 4.1.6 can be found in Table 30.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 181, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 236, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 228.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 197, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 236, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 228.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 181, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 244, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 228.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 197, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 244, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 228.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 181, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 236, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 235.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 197, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 236, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 235.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 181, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 244, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 235.
In some embodiments, a PD-1/Tim-3 bi-specific antigen-binding construct is provided, comprising: (i) an anti-PD-1 VH sequence of SEQ ID NO: 197, (ii) an anti-PD-1 VL sequence of SEQ ID NO: 244, and (iii) an anti-Tim-3 VH sequence of SEQ ID NO: 179. In some embodiments, the bi-specific antigen-binding construct further comprises a VL sequence of SEQ ID NO: 235.
4.1.7. Additional Mutations
In some embodiments, an bi-specific antibody or antigen-binding construct as disclosed herein can include additional mutations. In some embodiments, the bi-specific antibody or antigen-binding construct can include a mutation to remove a methionine start residue. In some embodiments, the bi-specific antibody or antigen-binding construct can include a mutation to remove glycosylation (e.g. N297A). In some embodiments, the bi-specific antibody or antigen-binding construct can include a mutation to remove effector function (e.g., AAS mutation, as described in U.S. Patent Publicaiton No. 2016/0075792, which is incorporated herein by reference in its entirety). For example, in some embodiments, one or more of the additional mutations disclosed herein can be used to improve production of bi-specific antibody constructs or bi-specific antibody components in a host cell.
In some embodiments, an antibody or bi-specific antibody as disclosed herein that specifically binds Tim-3 is an antibody comprising a variable region that is encoded by a particular germline gene, or a variant thereof. The illustrative antibodies provided herein comprise variable regions that are encoded by the heavy chain variable region germline genes VH3-23 and VH5-51, or variants thereof and the light chain variable region germline genes Vκ3-20 and Vκ4-1, or variants thereof.
One of skill in the art would recognize that the CDR sequences provided herein may also be useful when combined with variable regions encoded by other variable region germline genes, or variants thereof. In particular, the CDR sequences provided herein may be useful when combined with variable regions encoded by variable region germline genes, or variants thereof, that are structurally similar to the variable region germline genes recited above. For example, in some embodiments, a CDR-H sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the VH3 or VH5 families, or a variant thereof. In some embodiments, a CDR-L sequence provided herein may be combined with a variable region encoded by a variable region germline gene selected from the Vκ3 or Vκ4 families, or a variant thereof.
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for Tim-3 as indicated by KD, is less than about 10−5 M, less than about 10−6M, less than about 10−7 M, less than about 10−8 M, less than about 10−9 M, less than about 10−10 M, less than about 10−11 M, or less than about 10−12 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−11 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−10 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−9 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−8 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−8M and 10−11M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−8 M and 10−10 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−9 M and 10−11 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−10 M and 10−11 M.
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for human Tim-3, as determined by surface plasmon resonance at 25° C., and as indicated by KD, is between about 9.1×10−9 M and about 4.3×10−9 M. In some embodiments, the affinity of the antibody or bi-specific antibody for human Tim-3 is about 9.1×10−9 M, about 8.1×10−9M, about 7.9×10−9M, about 7.6×10−9M, about 7.46×10−9M, about 7.2×10−9M, about 6.8×10−9M, about 6.7×10−9M, about 6.69×10−9M, about 6.2×10−9M, about 6.0×10−9M, about 5.9×10−9 M, about 5.7×10−9 M, about 5.6×10−9 M, about 5.5×10−9 M, about 5.4×10−9 M, about 5.3×10−9 M, about 5.0×10−9 M, about 4.97×10−9 M, about 4.9×10−9 M, about 4.8×10−9 M, or about 4.3×10−9 M.
In some embodiments an antibody or bi-specific antibody as disclosed herein has a ka of at least about 104 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of at least about 105 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of at least about 106 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of between about 104 M−1×sec−1 and about 105 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of between about 105 M−1×sec−1 and about 106 M−1×sec−1.
In some embodiments an antibody or bi-specific antibody as disclosed herein has a ka when associating with human Tim-3, as determined by surface plasmon resonance at 25° C., of between about 6.71×104 M−1×sec−1 and about 2.81×105 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka when associating with human Tim-3 of about 6.71×104 M−1×sec−1, 1.21×105 M−1×sec−1, about 1.33×105 M−1×sec−1, about 1.35×105 M−1×sec−1, about 1.50×105 M−1×sec−1, about 1.57×105 M−1×sec−1, about 1.85×105 M−1×sec−1, about 1.89×105 M−1×sec−1, about 1.91×105 M−1×sec−1, about 1.97×105 M−1×sec−1, about 2.02×105 M−1×sec−1, about 2.27×105 M−1×sec−1, about 2.75×105 M−1×sec−1, or about 2.81×105 M−1×sec−1.
In some embodiments an antibody or bi-specific antibody as disclosed herein has a kd of about 10−5 sec−1 or less. In some embodiments the antibody or bi-specific antibody has a kd of about 10−4 sec−1 or less. In some embodiments the antibody or bi-specific antibody has a kd of about 10−3 sec−1 or less. In some embodiments the antibody or bi-specific antibody has a kd of between about 10−2 sec−1 and about 10−5 sec−1. In some embodiments the antibody or bi-specific antibody has a kd of between about 10−2 sec−1 and about 10−4 sec−1. In some embodiments the antibody or bi-specific antibody has a kd of between about 10−3 sec−1 and about 10−5 sec−1.
In some embodiments an antibody or bi-specific antibody as disclosed herein has a kd when dissociating from human Tim-3, as determined by surface plasmon resonance at 25° C., of between about 2.05×10−2 sec−1 and about 4.25×10−4 sec−1. In some embodiments the antibody or bi-specific antibody has a kd when dissociating from human Tim-3 of about 2.05×10−2 sec−1, about 1.40×10−2 sec−1, about 1.26×10−2 sec−1, about 3.93×10−3 sec−1, about 3.74×10−3 sec−1, about 2.49×10−3 sec−1, about 2.43×10−3 sec−1, about 1.82×10−3 sec−1, about 1.66×10−3 sec−1, about 1.59×10−3 sec−1, about 1.17×10−3 sec−1, about 5.44×10−4 sec−1, about 4.58×10−4 sec−1, or about 4.25×10−4 sec−1.
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for cynomolgus Tim-3, as determined by surface plasmon resonance at 25° C., and as indicated by KD, is between about 13.2 nM and about 0.5 nM. In some embodiments, the affinity of the antibody or bi-specific antibody for human Tim-3 is about 13.2 nM, about 12.4 nM, about 9.4 nM, about 9.3 nM, about 7.4 nM, about 6.9 nM, about 5.6 nM, about 5.5 nM, about 5.4 nM, about 5.3 nM, about 4.7 nM, about 4.6 nM, about 4.5 nM, about 4.3 nM, about 4.1 nM, about 3.0 nM, about 2.8 nM, about 2.7 nM, about 2.5 nM, about 2.3 nM, about 2.2 nM, about 2.1 nM, about 1.9 nM, about 1.7 nM, about 1.0 nM, about 0.8 nM, or about 0.5 nM.
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for PD-1, as indicated by KD, is less than about 10−5 M, less than about 10−6 M, less than about 10−7M, less than about 10−8M, less than about 10−9M, less than about 10−10 M, less than about 10−11 M, or less than about 10−12 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−11 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−10 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−9 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−7 M and 10−8M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−8M and 10−11M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−8 M and 10−10 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−9M and 10−11 M. In some embodiments, the affinity of the antibody or bi-specific antibody is between about 10−10 M and 10−11 M.
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for human PD-1 is between about 3.85×10−8 M and 2.52×10−10 M. In some embodiment, the affinity of the antibody or bi-specific antibody for human PD-1 is about 2.55×10−8 M, about 1.52×10−8 M, about 9.52×10−9 M, about 1.09×10−8 M, about 4.50×10−9 M, about 1.90×10−9 M, about 4.76×10−9 M, about 4.5×10−9 M, about 1.04×10−8 M, about 9.90×10−9 M, about 9.13×10−10 M, about 2.52×10−10 M, about 2.58×10−9 M, about 3.85×10−8 M, about 3.66×10−9 M, about 3.15×10−9 M, about 5.14×10−9 M, about 2.47×10−9 M, about 2.79×10−9 M, about 1.20×10−9 M, or about 1.28×10−8 M
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for human PD-1 expressed on the surface of a cell is between about 3.2 and about 0.2 nM. In some embodiment, the affinity of the antibody or bi-specific antibody for human PD-1 expressed on the surface of a cell is about 0.2 nM, about 0.4 nM, about 0.9 nM, about 1 nM, about 0.3 nM, about 0.7 nM, about 0.2 nM, about 0.8 nM, about 3.2 nM, about 2.9 nM, about 1.39 nM, or about 1.34 nM.
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for murine PD-1 is between about 6.09×10−8 M and 9.08×10−9 M. In some embodiment, the affinity of the antibody or bi-specific antibody for murine PD-1 is about 6.09×10−8 M, about 6.22×10−8 M, or about 9.08×10−9 M.
In some embodiments, the affinity of an antibody or bi-specific antibody as disclosed herein for cynomolgus PD-1 is between about 2.43×10−8 M and 1.95×10−10 M. In some embodiment, the affinity of the antibody or bi-specific antibody for cynomolgus PD-1 is about 2.43×10−8 M, about 1.55×10−8 M, about 2.22×10−8 M, about 2.56×10−9 M, about 2.54×10−9 M, about 5.61×10−10 M, or about 1.95×10−10 M
In some embodiments an antibody or bi-specific antibody as disclosed herein has a ka of at least about 104 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of at least about 105 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of at least about 106 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of between about 104 M−1×sec−1 and about 105 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka of between about 105 M−1×sec−1 and about 106 M−1×sec−1.
In some embodiments an antibody or bi-specific antibody as disclosed herein has a ka when associating with human PD-1 of between about 4.74×104 M−1×sec−1 and about 1.23×106 M−1×sec−1. In some embodiments the antibody or bi-specific antibody has a ka when associating with human PD-1 of about 4.88×105 M−1×sec−1, about 1.23×106 M−1×sec−1, about 7.37×105 M−1×sec−1, about 6.87×105 M−1×sec−1, about 5.63×105 M−1×sec−1, about 5.16×105 M−1×sec−1, about 2.48×105 M−1×sec−1, about 7.98×105 M−1×sec−1, about 1.82×105 M−1×sec−1, about 4.74×104 M−1×sec−1, about 1.85×105 M−1×sec−1, about 2.00×105 M−1×sec−1, about 8.12×104 M−1×sec−1, about 1.21×106 M−1×sec−1, about 1.16×106 M−1×sec−1, about 5.13×105 M−1×sec−1, or about 1.86×105 M−1×sec−1.
In some embodiments an antibody or bi-specific antibody as disclosed herein has a kd of about 10−5 sec−1 or less. In some embodiments the antibody or bi-specific antibody has a kd of about 10−4 sec−1 or less. In some embodiments the antibody or bi-specific antibody has a kd of about 10−3 sec−1 or less. In some embodiments the antibody or bi-specific antibody has a kd of between about 10−2 sec−1 and about 10−5 sec−1. In some embodiments the antibody or bi-specific antibody has a kd of between about 10−2 sec−1 and about 10−4 sec−1. In some embodiments the antibody or bi-specific antibody has a kd of between about 10−3 sec−1 and about 10−5 sec−1.
In some embodiments an antibody or bi-specific antibody as disclosed herein has a kd when dissociating from human PD-1 of between about 1.87×10−2 sec−1 and about 4.17×10−4 sec−1. In some embodiments the antibody or bi-specific antibody has a kd when dissociating from human PD-1 of about 1.24×10−2 sec−1, about 1.87×10−2 sec−1, about 7.01×10−3 sec−1, about 7.74×10−3 sec−1, about 2.54×10−3 sec−1, about 9.80×10−4 sec−1, about 1.18×10−3 sec−1, about 3.59×10−3 sec−1, about 4.68×10−4 sec−1, about 1.82×10−3 sec−1, about 6.79×10−4 sec−1, about 6.28×10−4 sec−1, about 4.17×10−4 sec−1, about 2.99×10−3 sec−1, about 3.24×10−3 sec−1, about 6.17×10−4 sec−1, or about 2.39×10−3 sec−1.
In some aspects, the KD, ka, and kd are determined at 25° C. In some embodiments, the KD, ka, and kd are determined by surface plasmon resonance. In some embodiments, the KD, ka, and kd are determined according to the methods described in the Examples provided herein.
In some embodiments, an antibody or bi-specific antibody as disclosed herein inhibits binding of one or more of PD-L1 and PD-L2 to PD-1.
In some embodiments, the antibody or bi-specific antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1 to about 7 nM. In some aspects, the antibody or bi-specific antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1.99, about 2.53, about 5.86, or about 5.96 nM.
In some embodiments, the antibody or bi-specific antibody inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.01 to about 1 nM. In some aspects, the antibody or bi-specific antibody inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.01, about 0.18, about 0.56, or about 0.58 nM.
In some aspects, the antibody or bi-specific antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 5.96 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.56 nM. In some aspects, the antibody or bi-specific antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 5.86 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.58 nM. In some aspects, the antibody or bi-specific antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 1.99 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.01 nM. In some aspects, the antibody or bi-specific antibody inhibits binding of PD-L1 to PD-1 with an IC50 of about 2.53 nM, and inhibits binding of PD-L2 to PD-1 with an IC50 of about 0.18 nM.
In some embodiments, an antibody or bi-specific antibody as disclosed herein binds the same epitope as the scFv antibody provided in SEQ ID NO: 287. In some embodiments, the antibody or bi-specific antibody binds to a different epitope from the scFv antibody provided in SEQ ID NO: 287. In some embodiments, the antibody or bi-specific antibody binds the same epitope as antibody encompassing any of SEQ ID NOs: 144-180. In some embodiments, the antibody or bi-specific antibody binds the same epitope as an antibody comprising any of the VH-VL pairs, above. In some embodiments, the antibody or bi-specific antibody binds to part of the epitope bound by the scFv antibody provided in SEQ ID NO: 287. In some embodiments, the antibody or bi-specific antibody competes for epitope binding with the scFv antibody provided in SEQ ID NO: 287. In some embodiments, the antibody or bi-specific antibody does not compete for epitope binding with scFv antibody provided in SEQ ID NO: 287. In some embodiments, the antibody or bi-specific antibody competes for epitope binding with an antibody encompassing any of SEQ ID NOs: 144-180. In some embodiments, the antibody or bi-specific antibody competes for epitope binding with an antibody comprising any of the VH-VL pairs, above.
In some embodiments, an antibody or bi-specific antibody as disclosed herein binds the same epitope as the scFv antibody provided in SEQ ID NO: 288. In some embodiments, the antibody or bi-specific antibody binds to a different epitope from the scFv antibody provided in SEQ ID NO: 288. In some embodiments, the antibody or bi-specific antibody binds the same epitope as antibody encompassing any of SEQ ID NOs: 181-220. In some embodiments, the antibody or bi-specific antibody binds the same epitope as an antibody comprising any of the VH-VL pairs, above. In some embodiments, the antibody or bi-specific antibody binds to part of the epitope bound by the scFv antibody provided in SEQ ID NO: 288. In some embodiments, the antibody or bi-specific antibody competes for epitope binding with the scFv antibody provided in SEQ ID NO: 288. In some embodiments, the antibody or bi-specific antibody does not compete for epitope binding with scFv antibody provided in SEQ ID NO: 288. In some embodiments, the antibody or bi-specific antibody competes for epitope binding with an antibody encompassing any of SEQ ID NOs: 181-220. In some embodiments, the antibody or bi-specific antibody competes for epitope binding with an antibody comprising any of the VH-VL pairs, above.
In certain embodiments, an antibody or bi-specific antibody as disclosed herein may be altered to increase, decrease or eliminate the extent to which it is glycosylated. Glycosylation of polypeptides is typically either “N-linked” or “O-linked.”
“N-linked” glycosylation refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site.
“O-linked” glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
Addition or deletion of N-linked glycosylation sites to the antibody or bi-specific antibody may be accomplished by altering the amino acid sequence such that one or more of the above-described tripeptide sequences is created or removed. Addition or deletion of O-linked glycosylation sites may be accomplished by addition, deletion, or substitution of one or more serine or threonine residues in or to (as the case may be) the sequence of an antibody.
In certain embodiments, amino acid modifications may be introduced into the Fc region of an antibody or bi-specific antibody provided herein to generate an Fc region variant. In certain embodiments, the Fc region variant possesses some, but not all, effector functions. Such antibodies may be useful, for example, in applications in which the half-life of the antibody or bi-specific antibody in vivo is important, yet certain effector functions are unnecessary or deleterious. Examples of effector functions include complement-dependent cytotoxicity (CDC) and antibody-directed complement-mediated cytotoxicity (ADCC). Numerous substitutions or substitutions or deletions with altered effector function are known in the art.
An alteration in in CDC and/or ADCC activity can be confirmed using in vitro and/or in vivo assays. For example, Fc receptor (FcR) binding assays can be conducted to measure FcγR binding. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Ann. Rev. Immunol., 1991, 9:457-492, incorporated by reference in its entirety.
Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are provided in U.S. Pat. Nos. 5,500,362 and 5,821,337; Hellstrom et al., Proc. Natl. Acad. Sci. U.S.A., 1986, 83:7059-7063; Hellstrom et al., Proc. Natl. Acad. Sci. U.S.A., 1985, 82:1499-1502; and Bruggemann et al., J. Exp. Med., 1987, 166:1351-1361; each of which is incorporated by reference in its entirety. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, using an animal model such as that disclosed in Clynes et al. Proc. Natl. Acad. Sci. U.S.A., 1998, 95:652-656, incorporated by reference in its entirety.
C1q binding assays may also be carried out to confirm that the antibody or bi-specific antibody is unable to bind C1q and hence lacks CDC activity. Examples of C1q binding assays include those described in WO 2006/029879 and WO 2005/100402, each of which is incorporated by reference in its entirety.
Complement activation assays include those described, for example, in Gazzano-Santoro et al., J. Immunol. Methods, 1996, 202:163-171; Cragg et al., Blood, 2003, 101:1045-1052; and Cragg and Glennie, Blood, 2004, 103:2738-2743; each of which is incorporated by reference in its entirety.
FcRn binding and in vivo clearance (half-life determination) can also be measured, for example, using the methods described in Petkova et al., Intl. Immunol., 2006, 18:1759-1769, incorporated by reference in its entirety.
11.1. Antigen Preparation
The Tim-3 antigen to be used for isolation of the antibodies and bi-specific antigen binding constructs disclosed herein may be intact Tim-3 or a fragment of Tim-3. The intact Tim-3, or fragment of Tim-3, may be in the form of an isolated protein or protein expressed by a cell. Other forms of Tim-3 useful for generating antibodies will be apparent to those skilled in the art.
The PD-1 antigen to be used for production of antibodies and bi-specific antigen binding constructs disclosed herein may be intact PD-1 or a fragment of PD-1. The intact PD-1, or fragment of PD-1, may be in the form of an isolated protein or expressed by a cell. Other forms of PD-1 useful for generating antibodies will be apparent to those skilled in the art.
11.2. Monoclonal Antibodies
Monoclonal antibodies may be obtained, for example, using the hybridoma method first described by Kohler et al., Nature, 1975, 256:495-497 (incorporated by reference in its entirety), and/or by recombinant DNA methods (see e.g., U.S. Pat. No. 4,816,567, incorporated by reference in its entirety). Monoclonal antibodies may also be obtained, for example, using phage or yeast-based libraries. See e.g., U.S. Pat. Nos. 8,258,082 and 8,691,730, each of which is incorporated by reference in its entirety.
In the hybridoma method, a mouse or other appropriate host animal is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell. See Goding J. W., Monoclonal Antibodies: Principles and Practice 3rd ed. (1986) Academic Press, San Diego, Calif., incorporated by reference in its entirety.
The hybridoma cells are seeded and grown in a suitable culture medium that contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
Useful myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive media conditions, such as the presence or absence of HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and MC-11 mouse tumors (available from the Salk Institute Cell Distribution Center, San Diego, Calif.), and SP-2 or X63-Ag8-653 cells (available from the American Type Culture Collection, Rockville, Md.). Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. See e.g., Kozbor, J. Immunol., 1984, 133:3001, incorporated by reference in its entirety.
After the identification of hybridoma cells that produce antibodies of the desired specificity, affinity, and/or biological activity, selected clones may be subcloned by limiting dilution procedures and grown by standard methods. See Goding, supra. Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.
DNA encoding the monoclonal antibodies may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). Thus, the hybridoma cells can serve as a useful source of DNA encoding antibodies with the desired properties. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as bacteria (e.g., E. coli), yeast (e.g., Saccharomyces or Pichia sp.), COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody, to produce the monoclonal antibodies.
11.3. Humanized Antibodies
Humanized antibodies may be generated by replacing most, or all, of the structural portions of a non-human monoclonal antibody with corresponding human antibody sequences. Consequently, a hybrid molecule is generated in which only the antigen-specific variable, or CDR, is composed of non-human sequence. Methods to obtain humanized antibodies include those described in, for example, Winter and Milstein, Nature, 1991, 349:293-299; Rader et al., Proc. Nat. Acad. Sci. U.S.A., 1998, 95:8910-8915; Steinberger et al., J. Biol. Chem., 2000, 275:36073-36078; Queen et al., Proc. Natl. Acad. Sci. U.S.A., 1989, 86:10029-10033; and U.S. Pat. Nos. 5,585,089, 5,693,761, 5,693,762, and 6,180,370; each of which is incorporated by reference in its entirety.
11.4. Human Antibodies
Human antibodies can be generated by a variety of techniques known in the art, for example by using transgenic animals (e.g., humanized mice). See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. U.S.A., 1993, 90:2551; Jakobovits et al., Nature, 1993, 362:255-258; Bruggermann et al., Year in Immuno., 1993, 7:33; and U.S. Pat. Nos. 5,591,669, 5,589,369 and 5,545,807; each of which is incorporated by reference in its entirety. Human antibodies can also be derived from phage-display libraries (see e.g., Hoogenboom et al., J. Mol. Biol., 1991, 227:381-388; Marks et al., J. Mol. Biol., 1991, 222:581-597; and U.S. Pat. Nos. 5,565,332 and 5,573,905; each of which is incorporated by reference in its entirety). Human antibodies may also be generated by in vitro activated B cells (see e.g., U.S. Pat. Nos. 5,567,610 and 5,229,275, each of which is incorporated by reference in its entirety). Human antibodies may also be derived from yeast-based libraries (see e.g., U.S. Pat. No. 8,691,730, incorporated by reference in its entirety). Human antibodies can also be generated and screened by ribosome display (see, e.g., WO 2014/176327 and WO 2014/176439, each of which is incorporated herein by reference in its entirety).
The invention also provides isolated nucleic acids encoding an antibody or bispecific antigen binding construct disclosed herein, vectors and host cells comprising the nucleic acids, and recombinant techniques for the production of the antibodies.
For recombinant production of the antibody, the nucleic acid(s) encoding it may be isolated and inserted into a replicable vector for further cloning (i.e., amplification of the DNA) or expression. In some aspects, the nucleic acid may be produced by homologous recombination, for example as described in U.S. Pat. No. 5,204,244, incorporated by reference in its entirety.
Many different vectors are known in the art. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, for example as described in U.S. Pat. No. 5,534,615, incorporated by reference in its entirety.
Illustrative examples of suitable host cells are provided below. These host cells are not meant to be limiting.
Suitable host cells include any prokaryotic (e.g., bacterial), lower eukaryotic (e.g., yeast), or higher eukaryotic (e.g., mammalian) cells. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia (E. coli), Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella (S. typhimurium), Serratia (S. marcescans), Shigella, Bacilli (B. subtilis and B. licheniformis), Pseudomonas (P. aeruginosa), and Streptomyces. One useful E. coli cloning host is E. coli 294, although other strains such as E. coli B, E. coli X1776, and E. coli W3110 are suitable.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are also suitable cloning or expression hosts for anti-Tim-3 antibody-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is a commonly used lower eukaryotic host microorganism. However, a number of other genera, species, and strains are available and useful, such as Schizosaccharomyces pombe, Kluyveromyces (K. lactis, K. fragilis, K. bulgaricus K. wickeramii, K. waltii, K. drosophilarum, K. thermotolerans, and K. marxianus), Yarrowia, Pichia pastoris, Candida (C. albicans), Trichoderma reesia, Neurospora crassa, Schwanniomyces (S. occidentalis), and filamentous fungi such as, for example Penicillium, Tolypocladium, and Aspergillus (A. nidulans and A. niger).
Suitable host cells can also include insect cells, such as, for example, Drosophila systems S2, SF9, and SF21 cells and High Five™ cells (ThermoFisher Scientific). Drosophila cells can be grown in a suitable medium, such as, for example, Schneider's Drosophila medium or other commercially available media,
Useful mammalian host cells include COS-7 cells, HEK293 cells; baby hamster kidney (BHK) cells; Chinese hamster ovary (CHO); mouse sertoli cells; African green monkey kidney cells (VERO-76), and the like.
The host cells used to produce the anti-Tim-3 antibody of this invention may be cultured in a variety of media. Commercially available media such as, for example, Ham's F10, Minimal Essential Medium (MEM), RPMI-1640, and Dulbecco's Modified Eagle's Medium (DMEM) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz., 1979, 58:44; Barnes et al., Anal. Biochem., 1980, 102:255; and U.S. Pat. Nos. 4,767,704, 4,657,866, 4,927,762, 4,560,655, and 5,122,469, or WO 90/03430 and WO 87/00195 may be used. Each of the foregoing references is incorporated by reference in its entirety.
Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics, trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
When using recombinant techniques, the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. For example, Carter et al. (Bio/Technology, 1992, 10:163-167) describes a procedure for isolating antibodies which are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation.
In some embodiments, the antibody is produced in a cell-free system. In some aspects, the cell-free system is an in vitro transcription and translation system as described in Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety. In some aspects, the cell-free system utilizes a cell-free extract from a eukaryotic cell or from a prokaryotic cell. In some aspects, the prokaryotic cell is E. coli. Cell-free expression of the antibody may be useful, for example, where the antibody accumulates in a cell as an insoluble aggregate, or where yields from periplasmic expression are low.
Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon® or Millipore® Pellcon® ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a particularly useful purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human γ1, γ2, or γ4 heavy chains (Lindmark et al., J. Immunol. Meth., 1983, 62:1-13, incorporated by reference in its entirety). Protein G is useful for all mouse isotypes and for human γ3 (Guss et al., EMBO 1, 1986, 5:1567-1575, incorporated by reference in its entirety).
The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a CH3 domain, the BakerBond ABX® resin is useful for purification.
Other techniques for protein purification, such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin Sepharose®, chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available, and can be applied by one of skill in the art. In embodiments where the antibody is a bi-specific antibody or antigen binding construct, separation techniques suitable for such molecules are described, for example, in Xu et al. 2015. mAbs 7:231-242, which is incorporated herein by reference in its entirety.
Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5 to about 4.5, generally performed at low salt concentrations (e.g., from about 0 to about 0.25 M salt).
Any of the antibodies or bi-specific antigen binding constructs provided herein can be provided in any appropriate pharmaceutical composition and be administered by any suitable route of administration. Suitable routes of administration include, but are not limited to, the inhalation, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, pulmonary, and subcutaneous routes.
The pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and one of ordinary skill in the art is capable of selecting suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients provided below are intended to be illustrative, and not limiting. Additional pharmaceutical excipients include, for example, those described in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), incorporated by reference in its entirety.
In some embodiments, the pharmaceutical composition comprises an anti-foaming agent. Any suitable anti-foaming agent may be used. In some aspects, the anti-foaming agent is selected from an alcohol, an ether, an oil, a wax, a silicone, a surfactant, and combinations thereof. In some aspects, the anti-foaming agent is selected from a mineral oil, a vegetable oil, ethylene bis stearamide, a paraffin wax, an ester wax, a fatty alcohol wax, a long chain fatty alcohol, a fatty acid soap, a fatty acid ester, a silicon glycol, a fluorosilicone, a polyethylene glycol-polypropylene glycol copolymer, polydimethylsiloxane-silicon dioxide, ether, octyl alcohol, capryl alcohol, sorbitan trioleate, ethyl alcohol, 2-ethyl-hexanol, dimethicone, oleyl alcohol, simethicone, and combinations thereof.
In some embodiments, the pharmaceutical composition comprises a cosolvent. Illustrative examples of cosolvents include ethanol, poly(ethylene) glycol, butylene glycol, dimethylacetamide, glycerin, and propylene glycol.
In some embodiments, the pharmaceutical composition comprises a buffer. Illustrative examples of buffers include acetate, borate, carbonate, lactate, malate, phosphate, citrate, hydroxide, diethanolamine, monoethanolamine, glycine, methionine, guar gum, and monosodium glutamate.
In some embodiments, the pharmaceutical composition comprises a carrier or filler. Illustrative examples of carriers or fillers include lactose, maltodextrin, mannitol, sorbitol, chitosan, stearic acid, xanthan gum, and guar gum.
In some embodiments, the pharmaceutical composition comprises a surfactant. Illustrative examples of surfactants include d-alpha tocopherol, benzalkonium chloride, benzethonium chloride, cetrimide, cetylpyridinium chloride, docusate sodium, glyceryl behenate, glyceryl monooleate, lauric acid, macrogol 15 hydroxystearate, myristyl alcohol, phospholipids, polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxylglycerides, sodium lauryl sulfate, sorbitan esters, and vitamin E polyethylene(glycol) succinate.
In some embodiments, the pharmaceutical composition comprises an anti-caking agent. Illustrative examples of anti-caking agents include calcium phosphate (tribasic), hydroxymethyl cellulose, hydroxypropyl cellulose, and magnesium oxide.
Other excipients that may be used with the pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution enhancers, emulsifying agents, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizing agents, solvents, stabilizing agents, and sugars. Specific examples of each of these agents are described, for example, in the Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009), The Pharmaceutical Press, incorporated by reference in its entirety.
In some embodiments, the pharmaceutical composition comprises a solvent. In some aspects, the solvent is saline solution, such as a sterile isotonic saline solution or dextrose solution. In some aspects, the solvent is water for injection.
In some embodiments, the pharmaceutical compositions are in a particulate form, such as a microparticle or a nanoparticle. Microparticles and nanoparticles may be formed from any suitable material, such as a polymer or a lipid. In some aspects, the microparticles or nanoparticles are micelles, liposomes, or polymersomes.
Further provided herein are anhydrous pharmaceutical compositions and dosage forms comprising an antibody, since water can facilitate the degradation of some antibodies.
Anhydrous pharmaceutical compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine can be anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
An anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
In certain embodiments, provided are parenteral dosage forms. Parenteral dosage forms can be administered to subjects by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses subjects' natural defenses against contaminants, parenteral dosage forms are typically, sterile or capable of being sterilized prior to administration to a subject. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
Suitable vehicles that can be used to provide parenteral dosage forms are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
Excipients that increase the solubility of one or more of the antibodies disclosed herein can also be incorporated into the parenteral dosage forms.
13.1. Dosage and Unit Dosage Forms
In human therapeutics, the doctor will determine the posology which he considers most appropriate according to a preventive or curative treatment and according to the age, weight, condition and other factors specific to the subject to be treated.
In certain embodiments, a composition provided herein is a pharmaceutical composition or a single unit dosage form. Pharmaceutical compositions and single unit dosage forms provided herein comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic antibodies.
The amount of the antibody or composition which will be effective in the prevention or treatment of a disorder or one or more symptoms thereof will vary with the nature and severity of the disease or condition, and the route by which the antibody is administered. The frequency and dosage will also vary according to factors specific for each subject depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the subject. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
In certain embodiments, exemplary doses of a composition include milligram or microgram amounts of the antibody per kilogram of subject or sample weight (e.g., about 10 micrograms per kilogram to about 50 milligrams per kilogram, about 100 micrograms per kilogram to about 25 milligrams per kilogram, or about 100 microgram per kilogram to about 10 milligrams per kilogram). In certain embodiment, the dosage of the antibody provided herein, based on weight of the antibody, administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is about 0.1 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 10 mg/kg, or about 15 mg/kg or more of a subject's body weight. In another embodiment, the dosage of the composition or a composition provided herein administered to prevent, treat, manage, or ameliorate a disorder, or one or more symptoms thereof in a subject is about 0.1 mg to about 200 mg, about 0.1 mg to about 100 mg, about 0.1 mg to about 50 mg, about 0.1 mg to about 25 mg, about 0.1 mg to about 20 mg, about 0.1 mg to about 15 mg, about 0.1 mg to about 10 mg, about 0.1 mg to about 7.5 mg, about 0.1 mg to about 5 mg, about 0.1 to about 2.5 mg, about 0.25 mg to about 20 mg, about 0.25 to about 15 mg, about 0.25 to about 12 mg, about 0.25 to about 10 mg, about 0.25 mg to about 7.5 mg, about 0.25 mg to about 5 mg, about 0.25 mg to about 2.5 mg, about 0.5 mg to about 20 mg, about 0.5 to about 15 mg, about 0.5 to about 12 mg, about 0.5 to about 10 mg, about 0.5 mg to about 7.5 mg, about 0.5 mg to about 5 mg, about 0.5 mg to about 2.5 mg, about 1 mg to about 20 mg, about 1 mg to about 15 mg, about 1 mg to about 12 mg, about 1 mg to about 10 mg, about 1 mg to about 7.5 mg, about 1 mg to about 5 mg, or about 1 mg to about 2.5 mg.
The dose can be administered according to a suitable schedule, for example, once, two times, three times, or for times weekly. It may be necessary to use dosages of the antibody outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with subject response.
Different therapeutically effective amounts may be applicable for different diseases and conditions, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat or ameliorate such disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with the antibodies provided herein are also encompassed by the herein described dosage amounts and dose frequency schedules. Further, when a subject is administered multiple dosages of a composition provided herein, not all of the dosages need be the same. For example, the dosage administered to the subject may be increased to improve the prophylactic or therapeutic effect of the composition or it may be decreased to reduce one or more side effects that a particular subject is experiencing.
In certain embodiments, treatment or prevention can be initiated with one or more loading doses of an antibody or composition provided herein followed by one or more maintenance doses.
In certain embodiments, a dose of an antibody or composition provided herein can be administered to achieve a steady-state concentration of the antibody in blood or serum of the subject. The steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight and age.
In certain embodiments, administration of the same composition may be repeated and the administrations may be separated by at least aboutl day, about 2 days, about 3 days, about 5 days, about 10 days, about 15 days, about 30 days, about 45 days, about 2 months, about 75 days, about 3 months, or about 6 months. In other embodiments, administration of the same prophylactic or therapeutic agent may be repeated and the administration may be separated by at least about 1 day, about 2 days, about 3 days, about 5 days, about 10 days, about 15 days, about 30 days, about 45 days, about 2 months, about 75 days, about 3 months, or about 6 months.
For therapeutic applications, the antibodies of the invention are administered to a mammal, generally a human, in a pharmaceutically acceptable dosage form such as those known in the art and those discussed above. For example, the antibodies of the invention may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, or intratumoral routes. The antibodies also are suitably administered by peritumoral, intralesional, or perilesional routes, to exert local as well as systemic therapeutic effects. The intraperitoneal route may be particularly useful, for example, in the treatment of ovarian tumors.
The antibodies provided herein may be useful for the treatment of any disease or condition involving Tim-3 and/or PD-1. In some embodiments, the disease or condition is a disease or condition that can be diagnosed by overexpression of Tim-3 and/or PD-1. In some embodiments, the disease or condition is a disease or condition that can benefit from treatment with an anti-Tim-3 antibody and/or anti-PD-1 antibody. In some embodiments, the disease or condition is a cancer. In some embodiments, the disease or condition is an autoimmune disease. In some embodiments, the disease or condition is an infection.
Any suitable cancer may be treated with the antibodies provided herein. Illustrative suitable cancers include, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, brain tumor, bile duct cancer, bladder cancer, bone cancer, breast cancer, bronchial tumor, carcinoma of unknown primary origin, cardiac tumor, cervical cancer, chordoma, colon cancer, colorectal cancer, craniopharyngioma, ductal carcinoma, embryonal tumor, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, fibrous histiocytoma, Ewing sarcoma, eye cancer, germ cell tumor, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, glioma, head and neck cancer, hepatocellular cancer, histiocytosis, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumor, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, lip and oral cavity cancer, liver cancer, lobular carcinoma in situ, lung cancer, macroglobulinemia, malignant fibrous histiocytoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, midline tract carcinoma involving NUT gene, mouth cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, nasal cavity and par nasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytomas, pituitary tumor, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell cancer, renal pelvis and ureter cancer, retinoblastoma, rhabdoid tumor, salivary gland cancer, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, spinal cord tumor, stomach cancer, T-cell lymphoma, teratoid tumor, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, and Wilms tumor.
In particular embodiments, the cancer is a cancer of epithelial origin. In some aspects, the cancer is a carcinoma. In some aspects, the cancer is selected from an adenocarcinoma, a squamous cell carcinoma, an adenosquamos carcinoma, an anaplastic carcinoma, a large cell carcinoma, small cell carcinoma, and carcinoma of unknown primary origin.
In some embodiments, the antibodies provided herein are used in diagnostic applications.
In some embodiments, an antibody or bi-specific antibody as disclosed herein may be useful in assays for Tim-3 protein. In some aspects the antibody or bi-specific antibody can be used to detect the expression of Tim-3 in various cells and tissues. These assays may be useful, for example, in making a diagnosis and/or prognosis for a disease, such as a cancer.
In some embodiments, an antibody or bi-specific antibody as disclosed herein may be useful in assays for PD-1 protein. In some aspects the antibody or bi-specific antibody can be used to detect the expression of PD-1 in various cells and tissues. These assays may be useful, for example, in making a diagnosis and/or prognosis for a disease, such as a cancer.
In some diagnostic and prognostic applications, the antibody or bi-specific antibody may be labeled with a detectable moiety. Suitable detectable moieties include, but are not limited to radioisotopes, fluorescent labels, and enzyme-substrate labels. In another embodiment, the antibody or bi-specific antibody need not be labeled, and the presence of the antibody or bi-specific antibody can be detected using a labeled antibody which specifically binds to the anti-Tim-3 antibody.
The antibodies and bi-specific antigen binding constructs disclosed herein may be used as affinity purification agents. In this process, the antibodies or bi-specific antibodies may be immobilized on a solid phase such a resin or filter paper, using methods well known in the art. The immobilized antibody or bi-specific antibody is contacted with a sample containing an antigen protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the antigen protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0 or glycine buffer, pH 3 to 4, that will release the antigen protein from the antibody. In some embodiments, the antigen protein is Tim-3. In some embodiments, the antigen protein is PD-1.
In some embodiments, an antibody or bi-specific antigen binding construct provided herein is provided in the form of a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing a procedure. In some embodiments, the procedure is a diagnostic assay. In other embodiments, the procedure is a therapeutic procedure.
In some embodiments, the kit further comprises a solvent for the reconstitution of the antibody or bispecific antibody. In some embodiments, the antibody or bispecific antibody is provided in the form of a pharmaceutical composition.
Balb/C mice were immunized with the extracellular domain of human Tim-3 fused with human Fc (R&D Systems) using standard immunization methods. The spleens and/or lymph nodes of the mice were harvested and fused with P3X cells to generate the hybridomas (Aragen Biosciences, Morgan Hill, Calif.), similar to published reports. See Chronopoulou et al., 2014, Methods Mol Biol. 1131: 47-70 (2014); Kim et al., 2014, Methods Mol Biol. 1131: 33-45; each incorporated by reference in its entirety. Total RNA was extracted from hybridoma cells using QIAGEN RNeasy Mini Kit (Cat No. 74104) and converted to cDNA using a Clontech SMARTer RACE cDNA Amplification Kit (Cat. No. 634923; Lake Pharma, Belmont, Calif.). Positive clones were identified by gel electrophoresis, cloned using an Invitrogen TOPO kit, and sequenced using standard Sanger methods. Mouse single-chain antibodies were constructed by using total gene synthesis using optimized E. Coli codons and cloned into a standard cell-free expression vector. See Yin et al., supra.
Mouse hybridoma clone 22E11 showed binding of human Tim-3 expressed on CHO cells and binding of cynomolgus Tim-3 expressed on CHO cells. The ka for the m22E11 Ab was 2.23×105 M−1×sec−1; the kd was 3.34×10−4 sec−1, and the KD was 1.50×10−9 M.
Mouse hybridoma clone 2D5 showed binding of human Tim-3 expressed on CHO cells, but no binding of cynomolgus Tim-3 expressed on CHO cells. The ka for the 2D5 Ab was 3.86×105 M−1×sec−1; the kd was 1.66×10−4 sec−1, and the KD was 4.31×10−10 M.
The CDRs for clone m22E11 were grafted onto human antibody frameworks VH1-69, VH3-23, VH4-30-4, VH5-51, VH3-33 (h22E11-5 HC), Vk1-39, Vk2-28, Vk3-11, Vk4-1 and Vk3-20 (h22E11-5) LC by standard methodology to yield humanized antibodies of every HC and LC combination. See Kuramochi et al., 2014, Methods in Molecular Biology 1060: 123-137. In the results below, “h22E11” indicates a humanized variant of m22E11. The heavy chains are indicated by framework designation (e.g., “VH1-69”) and the light chains are indicated by framework designation (e.g., “Vk1-39”).
Antibody Fab libraries were constructed using a standard overlap extension PCR protocol with mutagenic primers targeting complementary determining regions (CDRs). See Heckman and Pease, Nat. Protoc., 2007, 2:924-932; Stafford et al., 2014, Protein Eng. Des. Sel. 27:97-109, both incorporated by reference in their entireties.
Initial antibody leads from ribosome display (e.g. SRP1497 antibodies) were derived from a naïve human library which was constructed by overlapping PCR using trastuzumab HC as the base template. CDRs H1 and H2 were randomized with the same design as described by Lee et al., 2004, J. Mol. Biol. 2004, 340:1073-1093 using oligonucleotides purchased from Integrated DNA Technologies. In this design, CDRs H1 and H2 closely match the observed amino acid distributions of natural human antibodies. CDR H3 was diversified using oligonucleotides incorporating trimer phosphoramidite mixtures (TRIMs) for amino acid randomization. The TRIM oligos were synthesized as described by Yagodkin A et al., Nucleosides Nucleotides Nucleic Acids 2007, 26:473-97. Specifically, six separate oligonucleotides containing TRIMs were used to make 6 separate H3 loop-lengths (13-18; as defined by Zemlin et al.) to match the most common loop lengths observed in the human repertoire. Together these loop lengths comprise approximately 54.5% of the naturally-occurring loop length variation in human IgGs as reported by Zemlin et al., J. Mol. Biol. 2003, 334:733-749. The frequency distribution of each amino acid was designed to closely match the observed distribution of amino acids in CDR H3 of human IgGs as reported by Zemlin et al. Altogether, the library closely matches natural human antibody variation which is known in the field to improve antibody stability and folding of antibodies as described by Zhai et al., J Mol Biol. 2011, 412:55-71. The HC library was paired with a constant, unmodified trastuzumab LC throughout the selection process as described by Stafford et al., Protein Eng Des Sel 2014, 27:97-109.
Affinity maturated antibody leads (e.g. SRP1649 antibodies) were derived from a focused library, biased towards the lead (1497-A05) which was constructed by overlapping PCR using “soft-randomized” oligonucleotides purchased from Eurofins MWG Operon. Soft-randomization is a process in which a biased distribution of nucleotides is used for each soft-randomized codon such that the parent amino acid sequence is coded more frequently than other amino acids ˜30% of the time. Other amino acids are coded at each position but at a lower percentage. At each soft-randomized position, 70% of the parent nucleotide is mixed with 10% of the other three nucleotides. For the library, CDRs H1, H2, and H3 were soft-randomized simultaneously and selected by standard ribosome display protocols. As with the selection of initial leads, the affinity matured antibodies were paired with a constant, unmodified trastuzumab LC throughout the selection process as described by Stafford et al., Protein Eng Des Sel 2014, 27:97-109. For the affinity maturation, the selection was run against human and cyno TIM3 to yield human and cyno cross-reactive antibodies.
Selections for novel antibodies were performed using standard ribosome display protocols. See Dreier and PlUckthun, Methods Mol. Biol., 2003, 687:283-306, Clifton, N.J., incorporated by reference in its entirety. Fab ribosome display selections were performed according to published protocols. See Stafford et al., 2014, Protein Eng. Des. Sel. 27:97-109, incorporated by reference in its entirety. After multiple rounds of selection, the DNA from RT-PCR output was cloned into an optimized vector for cell-free expression using standard molecular biology techniques. See Yin et al., mAbs, 2012, 4:217-225, incorporated by reference in its entirety. All constructs were HIS- and FLAG-tagged to streamline purification and testing during screening.
Libraries of antibody variants generated by selection workflow were transformed into E. coli and grown on agar plates with antibiotic (kanamycin). Individual colonies were grown in liquid broth (TB+kanamycin), and used as a template for DNA amplification via rolling circle amplification (RCA). The Fab-HC variants, together with about 2.5 μg/mL of a trastuzumab LC, were then expressed in cell-free protein synthesis reactions as described in Zawada et al., Biotechnol. Bioeng., 2011, 108:1570-1578, incorporated by reference in its entirety.
Briefly, cell-free extracts were treated with 50 μM iodoacetamide for 30 min at room temperature (20° C.) and added to a premix containing cell-free components (see Groff et al., mAbs, 2014, 6:671-678, incorporated by reference in its entirety) and 10% (v/v) RCA DNA template (approximately 10 μg/mL DNA) for HC variants, in addition to 2.5 ug/mL Trastuzumab LC which is present for antibody assembly but does not contribute to the binding to the target antigen. Sixty microliters of cell-free reactions were incubated at 30° C. for 12 hr on a shaker at 650 rpm in 96-well plates. Four hundred to one-thousand-five-hundred colonies were screened, depending on the predicted diversity of different selection campaigns.
Following synthesis, each reaction was diluted 1:50 into PBST (PBS at pH 7.4 with 0.2% Tween-20+0.2% BSA) and expressed variants were tested for functional activity via ELISA-based binding to recombinant human Tim-3 extracellular domain (ECD) (Acro Biosystems, TM3-H5229, Accession # Q8TDQ0; R&D Systems, 2365-TM, Accession # Q8TDQ0). Standard ELISA-based methods were employed. Specifically, 384-well plates were coated with 2 μg/mL recombinant Tim-3 diluted in bicarbonate buffer, and then blocked with bovine serum albumin (BSA). Antibody variants of interest were allowed to bind to the Tim-3-coated plates, and detected with secondary antibodies (e.g., HRP-conjugated anti-human Fc or anti-FLAG) and then detected with chemiluminescent substrate (Pierce ELISA SuperSignal™ Substrate). Chemiluminescence was quantified on a Molecular Devices SpectraMax® M5 plate reader. Top hits were selected based on ELISA signal or signal/noise ratio and their nucleotides were sequenced. Based on functional activity and sequence analysis, a subset of variants was selected for further scale-up and characterization. The resulting antibodies are reported in Table 22, below, beginning with the designation SRP1497.
The top leads from ELISA-based screening were cultured and plasmid minipreps were performed using a QiAprep® 96 Turbo miniprep kit (Qiagen) according to the manufacturer's instructions. 10 μg/mL miniprepped DNA was added to 4 mL cell-free reactions and incubated overnight for 12 hr at 30° C., at 650 rpm. In the case of IgG variants with a common Trastuzumab LC, 7.5 ug/mL of the HC variant DNA and 2.5 ug/mL of the common Trastuzumab LC were added to the reaction.
Expressed variants from clarified cell-free reactions were purified via immobilized metal ion affinity chromatography (IMAC) purification using a semi-automated high throughput batch purification method. Briefly, purifications were performed in a 96-well plate format where 50 μL/well of IMAC resin (Ni Sepharose High Performance, GE Healthcare) was equilibrated in IMAC binding buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10 mM imidazole), incubated with 1 mL cell-free reaction for 15 minutes followed by two washes in IMAC binding buffer. His-tagged antibody variants were then eluted using 200 μL IMAC elution buffer (50 mM Tris pH 8.0, 300 mM NaCl, 500 mM imidazole) and buffer exchanged into PBS using a 96-well Zeba plate (7 kD MWCO, Thermo Fisher). Purified antibodies were quantified via high throughput capillary electrophoresis using the LabChip GXII (Perkin Elmer) against a Herceptin standard curve, according to the manufacturer's instructions.
Monoclonal Anti-FLAG M2 IgG (Sigma-Aldrich # F9291) was immobilized onto a CM5 chip (GE Life Sciences) using amine coupling chemistry (from Amine Coupling Kit, GE Life Sciences). The immobilization steps were carried out at a flow rate of 25 μL/min in 1×HBS-EP+buffer (GE Life Sciences; 10× Stock diluted before use). The sensor surfaces were activated for 7 min with a mixture of NHS (0.05 M) and EDC (0.2 M). The Anti-Flag M2 IgG was injected over all 4 flow cells at a concentration of 25 μg/mL in 10 mM sodium acetate, pH 4.5, for 7 min. Ethanolamine (1 M, pH 8.5) was injected for 7 min to block any remaining activated groups. An average of 12,000 response units (RU) of capture antibody was immobilized on each flow cell.
Off-rate and kinetic binding experiments were performed at 25° C. using 1× HBS-EP+buffer. Test and control antibodies were injected over the Anti-FLAG surface at concentrations of 5-10 μg/mL for 12 seconds at a flow rate of 10 μL/min on flow cells 2, 3 and 4, followed by a buffer wash for 30 seconds at the same flow rate. Kinetic characterization of antibody samples was carried out with a single concentration of antigen (for off-rate ranking) or a dilution series of antigen (for kinetic characterization) and 1 injection of 0 nM antigen. After capturing ligand (antibody) on the anti-FLAG surface, the analyte (human TIM-3-Fc or TIM-3-HIS) was bound at 50, 25, 12.5, 6.25 and 0 nM for 180 seconds, followed by a 600 second dissociation phase at a flow rate of 50 μl/min. Between each ligand capture and analyte binding cycle, regeneration was carried out using 2 injections of 10 mM glycine pH 2.0 for 30 seconds at 30 μL/min, followed by a 30 second buffer wash step.
The data were fit with the Biacore T200 Evaluation software, using a 1:1 Langmuir binding model. KD (affinity, nM) was determined as a ratio of the kinetic rate constants calculated from the fits of the association and dissociation phases.
Anti-Tim-3 variants were tested for their ability to block a Tim-3/Galectin9 interaction. Galectin-9 (R&D Systems) was adsorbed on Nunc 384-well white Maxisorp plates at 2 μg/mL in sodium bicarbonate buffer (pH 8.9) and incubated at 30° C. for 1 hour or overnight at 4° C. The plate was washed 3 times with PBS pH 7.4 with 0.05% Tween20 and blocked with 2% bovine serum albumin (BSA) in PBS pH 7.4+0.1% Tween20 for 1 hour at 30° C. The blocking solution was aspirated, and a dilution series of antibody was mixed with 10 nM biotinylated Tim-3-Fc (R&D Systems) in 0.2% BSA in PBS pH 7.4+0.1% Tween20 (diluent buffer) and incubated at 30° C. for 1 hour. The plate was washed, and streptavidin-HRP (Pierce) in diluent buffer was added to all wells. After 1 hour incubation at 30° C., the plate was washed, followed by detection with SuperSignal Pico Chemiluminescent Substrate (Thermo Pierce). Luminescence was detected on a SpectraMax® M5 plate reader (Molecular Devices).
Anti-Tim-3 variants were tested for their ability to bind human or cynomolgous Tim-3. Recombinant Tim-3 protein (R&D Systems, huTim-3-Fc, 2365-TM, Accession # Q8TDQ0; cyTim-3-Fc, 7914-TM, Accession # EHH54703) was adsorbed on Nunc 384-well white Maxisorp plates at 2 μg/mL in sodium bicarbonate buffer (pH 8.9) and incubated at 30° C. for 1 hour or overnight at 4° C. The plate was washed 3 times with PBS pH 7.4 with 0.05% Tween20 and blocked with 2% bovine serum albumin (BSA) in PBS pH 7.4+0.1% Tween20 for 1 hour at 30° C. The blocking solution was aspirated, and a dilution series of anti-Tim-3 antibody in 0.2% BSA in PBS pH 7.4+0.1% Tween20 (diluent buffer) was pipetted to the ELISA plate and incubated at 30° C. for 1 hour. The plate was washed, and anti-Flag-HRP (Sigma-Aldrich, A8592) in diluent buffer was added to all wells. After 1 hour incubation at 30° C., the plate was washed, followed by detection with SuperSignal Pico Chemiluminescent Substrate (Thermo Pierce). Luminescence was detected on a SpectraMax® M5 plate reader (Molecular Devices).
CHO-k cells were transfected to stably express Tim-3 on the cell surface. CHO parental and stably transfected CHO-Tim-3 cells (human or cynomolgus Tim-3) were cultured in RPMI w/10% fetal calf serum (FCS), Penicillin/Streptomycin (or Pen/Strep) and glutamine (or Gln). On day of assay, cells were washed with DPBS, detached with Accutase™ (BD Biosciences; San Jose, Calif.), and resuspended in RPMI media.
A mixture of fluoresecent-labeled parental CHO cells and unlabeled CHO-Tim-3 cells were prepared as follows. Parental CHO cells in RPMI media were incubated with 1 uM CellTrace™ Oregon Green488® (Life Technologies) at 37° C. for 15 to 30 minutes. Cells were then washed 3× with RPMI media. Labeled parental CHO and unlabeled CHO-Tim-3 cells were combined at 1:1 ratio, washed 1× in ice-cold FACS buffer (DPBS buffer supplemented with 0.5% bovine serum albumin) and seeded at 100 μl per well containing a total of 200,000 cells in 96 well polypropylene plates. Cells were spun down at 1.5K rpm and resuspended with test antibodies diluted in FACS buffer and incubated on ice for 60 mins. Cells were washed twice with FACS buffer and incubated on ice for 30 mins with R-phycoerythrin AffiniPure F(ab′)2 fragment, goat anti-Human IgG, Fcγ fragment specific secondary detection antibody (Jackson ImmunoResearch Laboratories, West Grove, Pa.) diluted at 1:200 with FACS buffer. Cells were washed twice with FACS buffer, fixed in 4% paraformaldehyde in PBS (Santa Cruz Biotechnology; Dallas, Tex.) for 20 mins on ice in the dark, washed twice with FACS buffer and analyzed using the BD LSR II Flow Cytometer (BD Biosciences; San Jose, Calif.). Data were analyzed using FlowJo (FlowJo, LLC; Ashland, Oreg.) to determine mean fluorescence intensities. Binding constants were calculated using the statistical software, GraphPad Prism (GraphPad Software; La Jolla, Calif.) using the nonlinear regression equation, one site—specific binding with Hill slope. Secondary antibody alone was used as a control, in addition to measuring non-specific antibody binding to CHO parental cells.
CD14+ monocytes and CD3+ T cells were obtained from peripheral blood mononuclear (PBMC) isolated from CMV+ human donors (AllCells, Alameda, Calif.) using MACS Cell Separation kits (Miltenyi Biotec). CD14+ monocytes were differentiated into immature dendritic cells (DC) by culturing cells at 106 cells/ml for 7 days in presence of GM-CSF and IL-4 (Peprotech) in X-Vivo 15 media (Lonza) containing 2% human AB serum (Sigma-Aldrich), penicillin-streptomycin (Corning Mediatech) and GlutaMAX (Life Technologies). Following differentiation, DCs were matured by culturing in X-Vivo 15+2% human AB serum media at 106 cells/ml for 2 days in the presence of GM-C SF, IL-4, TNF-a, IL-1b, IL-6 (Peprotech) and prostaglandin E2 (Sigma-Aldrich). To set-up the CMV recall assay, mature DCs were collected, washed and 10,000 DCs and 100,000 pan CD3+ T cells were plated per well in a 96-well U-bottom plate in a total volume of 100 μl media containing peptide pools for the CMV IE-1 and CMV pp65 protein (Miltenyi Biotec). IgG antibodies (50 ul) were added starting at a final concentration of 133 nM with 5-fold serial dilutions. Cells were co-cultured with peptides and antibodies for 5-6 days. Conditioned media was collected and tested for human IFN-g levels by ELISA (BD Biosciences).
CD14+ monocytes and CD4+ T cells were obtained from PBMC isolated from human donors using MACS Cell Separation kits. CD14+ monocytes were differentiated into immature DC by culturing cells at 106 cells/ml cell density for 7 days in presence of GM-CSF and IL-4 in RPMI media containing 10% fetal bovine serum, penicillin-streptomycin and GlutaMAX. Following differentiation, DCs were matured by culturing in RPMI+10% FBS media at 106 cells/ml cell density for 2 days in the presence of GM-CSF, IL-4, TNF-a, IL-1b, IL-6 and prostaglandin E2. To set-up the DC/CD4+ T cell MLR, mature DCs were collected, washed and 10,000 DCs and 100,000 CD4+ T cells were plated per well in a 96-well U-bottom plate in a total volume of 100 μl media. IgG antibodies (50 ul, final volume of 150 μl per well) were added starting at a final concentration of 133 nM with 5-fold serial dilutions. Cells were co-cultured with peptides and antibodies for 5-6 days. Conditioned media was collected and tested for human IFN-g levels by ELISA.
CD4+ T cells were obtained from PBMC isolated from human donors using MACS Cell Separation kit. CD4+ T cells (2e6 cells/ml) were activated with CD3/CD28 Human T-Activator Dynabeads (Life Technologies) in RPMI+10% FBS media containing 100 U/ml human IL-2 (Peprotech) for 2-3 days. Activated CD4+ T cells expressing Tim-3 were used test anti-Tim-3 antibodies for FACS cell binding.
Tables 23-24 show results obtained using the illustrative antibodies described herein.
Table 23 shows results from humanized variants of mouse hybridoma clone m22E11 with various human frameworks.
Table 24 shows results obtained from antibodies isolated from a naïve Fab TRIM ribosome display library, constructed on a Trastuzumab HC framework.
The “EC50” value is the concentration of the antibody at which half-maximum signal is achieved in an ELISA assay where Tim-3 protein is adsorbed onto a plate and then bound by the respective antibody provided herein. The anti-Tim-3 antibody is detected with horseradish peroxidase (HRP)-conjugated anti-human Fc antibody.
Table 25 shows results obtained from antibodies isolated from a second affinity matured library constructed by performing soft randomization on the SRP1497-A05 antibody.
A single-chain antibody is made in either the VHVL or VLVH orientation with a linker sequence between the VH and VL domains. Typically, scFv linkers are composed of (GGGGS)n repeats where n=3, 4, 5, or 6 for linkers of 15, 20, 25, or 30 residues respectively. For cell-free expression, an N-terminal Met is added, but for mammalian expression a leader peptide is added. On the C-terminal end of the scFv, an Fc sequence can be added to extend in vivo half-life or the scFv can be used directly. An optional linker sequence can be incorporated between the scFv and the Fc. An exemplary scFv-Fc linker sequence is AAGSDQEPKSS (SEQ ID NO: 282). C-terminal affinity tags can optionally be added to facilitate purification and assay development. An exemplary affinity tag is a C-terminal FlagHis tag GSGDYKDDDDKGSGHHHHHH (SEQ ID NO: 277). A stop codon is typically inserted at the end of the sequence. An exemplary scFv of the present disclosure is SEQ ID NO: 287, with an N-terminal Met residue, a VH domain, a GGGGSGGGGSGGGGS (SEQ ID NO: 278) linker, a VL domain, an AAGSDQEPKSS (SEQ ID NO: 282) linker, an Fc domain, a FlagHis tag, and a stop codon.
To improve solubility and reduce aggregation propensity, aspartic acid mutations were initially introduced into the heavy chain of affinity matured anti-Tim-3 antibody 1649-A01 around and in CDR H1 (S30D, R31D) and around and in light chain CDR L2 (S50D, A51D, S52D, F53D, Y55D, S56D). This general approach of targeting H1 and L2 to reduce aggregation propensity has been described previously (Dudgeon et al. 2012. PNAS 109(27):10879-10884, incorporated herein by reference in its entirety). Additional aspartic acid mutations were also designed around CDR H2 (G50D, V53D, Y56D, E58D) to determine if these mutations also reduce aggregation propensity by a similar mechanism. Trastuzumab (also known as Herceptin or 4D5) is known to be a highly stable antibody with desirable biophysical properties, including folding and low aggregation propensity (Jung and Plückthun. 1997. Protein Eng 10(8):959-966, incorporated herein by reference in its entirety). Thus, the 1649-A01 heavy chain sequence was also aligned to the 4D5 sequence using MAFFT (Katoh et al. 2013. Mol Biol Evol 30:772-780, incorporated herein by reference in its entirety) to identify additional mutations (S30K, Y32T, G50R, V53T, R54N, E58R, D65G) that could improve stability and/or reduce aggregation propensity. Following screening of the mutations as described below, combination mutants were designed to further reduce aggregation propensity (S30D/R31D, S30D/Y56D, S30D/R31D/Y56D). Only combination mutants without NxT/S glycosylation motifs were chosen to prevent glycosylation during expression in CHO.
To improve solubility and reduce aggregation propensity, an aspartic acid mutation was also made to PD-1 antibody 1353-G10 in CDR H1 (P30D). See, e.g., WO 2016/060033, incorporated herein by reference in its entirety. The mutation was introduced using the general approach described above and in the literature (Dudgeon et al. 2012. PNAS 109(27):10879-10884). IgBLAST (Ye et al. 2013. Nucleic Acids Res 41 (Web Server issue):W34-W40, incorporated herein by reference in its entirety) was used to analyze the 1353-G10 heavy chain. The analysis showed that R28T and H31S mutations would render the sequence closer to the native VH1-18 human germline sequence, which could reduce immunogenicity in humans and improve biophysical behavior, e.g., reduction of aggregationpropensity, transition melting temperature, etc. Lastly, to improve the stability of the light chain of 1353-G10, the CDRs were grafted onto a kappa framework Vk1-39 in a similar manner as described previously (Lehmann et al. 2015. mAbs 7(6):1058-1071, incorporated herein by reference in its entirety). The stabilizing mutations and kappa-grafted light chain were also made in the context of an scFv framework, both alone and in combination with each other. The sequences of these scFv are presented as SEQ ID NO: 339 (stabilizing mutations and kappa grafted light chain), SEQ ID NO: 340 (stabilizing mutations), and SEQ ID NO: 341 (kappa grafted light chain), respectively.
Affinity and kinetic binding analysis was carried out on bi-specific antibody candidates as described in Example 3. The analytes used for analyte binding (for kinetic characterization of the antibodies) were human Tim-3-Fc or cynomolgus Tim-3-Fc, R&D Systems, Minneapolis, Minn.). Additional characterization of bi-specific antibody candidates are described in Example 13 to Example 18.
A protein thermal shift assay was carried out by mixing the protein to be assayed with an environmentally sensitive dye (SYPRO® Orange, Life Technologies Cat. # S-6650) in a phosphate buffered solution (PBS), and monitoring the fluorescence of the mixture in real time as it underwent controlled thermal denaturation. Protein solutions between 0.2-2 mg/mL were mixed at a 1:1 volumetric ratio with a 1:500 PBS-diluted solution of SYPRO® Orange (SYPRO® Orange stock dye is 5000× in DMSO). Aliquots of 10 μL of the protein-dye mixture were dispensed in quadruplicate in a 384-well microplate (Bio-Rad Cat # MSP-3852), and the plate was sealed with an optically clear sealing film (Bio-Rad Cat # MSB-1001) and placed in a 384-well plate real-time thermocycler (Bio-Rad CFX384 Real Time System). The protein-dye mixture was heated from 25° C. to 95° C., at increments of 0.1° C. per cycle (˜1.5° C. per minute), allowing 3 seconds of equilibration at each temperature before taking a fluorescence measurement. At the end of the experiment, the first and second transition melting temperatures (Tm1 and Tm2, respectively) were determined using the Bio-Rad CFX manager software.
Affinity-matured anti-Tim-3 1649-A01 antibody and its derivatives were tested for their aggregation propensity with a turbidity assay. Antibody variants were formulated in PBS with 0.3 M sodium chloride and ranged from 0.5-1 mg/mL in concentration. Samples were subsequently aliquoted to a clear microtiter plate and incubated at 55° C. for 8 hours, during which absorbance at 280 nm and 600 nm were measured at periodic time intervals using a Spectramax plate reader. Antibody samples were given a qualitative score from “−” to “++++”, where “−” reflected little to no change in A600 absorbance and “++++” reflected a significant increase in A600 absorbance indicative of aggregation. Antibody variants with reduced aggregation propensity (i.e., little to no absorbance at A600) were selected for further characterization and development.
The ability of an anti-PD-1 antibody or an anti-PD-1 bi-specific antibody construct to block PD-1 binding to PD-L1 was measured as by PD-1 competition assay. CHO cells expressing human PD-L1 were seeded at 100,000 cells per 96-well in FACS buffer (1× PBS, 0.5% BSA, 0.1% sodium azide). All steps were performed on ice. Antibody titrations were prepared in FACS buffer and added to cells, followed by addition of 4 ug/ml of biotinylated recombinant human PD-1 (AcroBiosystems). Cells were incubated on ice for 1 hour and washed twice. Biotinylated PD-1 binding on CHO-human PD-L1 cells was detected with streptavidin-PE (1:100 dilution, Ebioscience) for 30 minutes, and cells were subsequently washed twice. Cells were fixed with 2% paraformaldehyde in PBS for 30 minutes. Fixed cells were washed with FACS buffer before flow cytometry analysis. FlowJo X was used to generate median MFI values for each sample and Prism 6 software was used to create one site, specific binding with Hill slope curves (Log transform) to determine IC50 values.
To validate that the generated bi-specific antibodies could bind to both protein targets simultaneously, bridging assays were developed. A homogeneous bead-based assay based on Perkin Elmer's AlphaLISA® platform (Perkin Elmer, Waltham, Mass.) was utilized. Briefly, recombinant human Tim-3-Fc protein and human PD1 protein were conjugated to AlphaLISA® acceptor and donor beads, respectively, per the manufacturer's instructions in a reductive amination reaction utilizing sodium borohydride. When Tim-3-acceptor beads and PD1-donor beads are brought into close proximity by binding to a PD-1×Tim-3 bi-specific antibody, excitation of the donor bead (680 nm) triggers an emission from the acceptor bead (615 nm). Thus, PD-1×Tim-3 bi-specific bridging was measured over a dilution series of each antibody and the result was reported as an EC50 and maximal signal (B max) of each curve.
A cell-based bridging assay was developed using the PathHunter® platform (DiscoverX, Fremont, Calif.) to detect simultaneous binding of PD-1 and Tim-3 on the cell surface. Briefly, a split beta-galactosidase reporter enzyme was utilized such that enzyme activity could only be detected when the enzyme acceptor (EA) and ProLink (PK) fragments are allowed to assemble. The EA-fragment was C-terminally fused to PD-1 (residues 1-199) and the PK fragment was C-terminally fused to Tim-3 (residues 1-223). Both fusion constructs were coexpressed in U20S cells, and stable cell pools were generated. To assess PD-1×Tim-3 bi-specific bridging, 10,000 cells per well were added to 96-well plates. The bi-specific antibodies were serially diluted (3-fold) starting at 10 ug/mL and incubated with the cells for 16 hours at 37° C. Binding was subsequently detected by measuring beta-galactosidase activity using the Beta-Glo® Assay System (Promega Cat. # TM239) and the plates were read on an Envision luminometer (integration time of 0.5 sec/well). Prism 6 software was used to create agonist vs. response curves with variable slope to determine EC50 values.
Peripheral blood mononuclear cells (PBMC) were initially isolated from CMV-positive human donors (Stanford Blood Center) by differential gradient centrifugation using NycoPrep™ 1.077 (Axis-Shield). PBMC were cryopreserved with Recovery™ Cell Culture Freezing Medium (Life Technologies) in liquid nitrogen. For the assay, PBMC (0.2×106 cells/well) were cultured in serum-free media containing 2% human AB serum and CMV peptide pools for the CMV IE-1 and CMV pp65 proteins (Miltenyi Biotec) in a total volume of 100 ul per well. Anti-PD-1/Tim-3 bi-specific antibody candidates (50 ul/well) were added as 3x stock with 5-fold serial dilution titration. Cells were cultured for 5-6 days. Conditioned media was collected and tested for human IFN-γ, IL-6 and TNF-α levels by ELISA (BD Biosciences).
Representative data for a CMV-peptide responsive human donor is shown in
Table 26 shows the results obtained using the illustrative bi-specific antibodies described herein. The bi-specific antibody of protein sample A contains the Fab of PD-1 antibody 1353-G10 and the scFv of Tim-3 humanized antibody h22E11. The bi-specific antibody of protein sample B contains the scFv of PD-1 antibody 1353-G10 and the Fab of Tim-3 humanized antibody h22E11. The bi-specific antibody of protein sample C contains the scFv of PD-1 antibody 1353-G10 and the Fab of Tim-3 humanized antibody 1649-A01. The bi-specific antibody of protein sample D contains the Fab of PD-1 antibody 1353-G10 and stump, where the stump refers to the Fc domain (hinge+CH1+CH2 regions). The results indicate that the bi-specific antibodies of samples A to C exhibited specific binding to human and cynomolgus PD-1 and to human and cynomolgus Tim-3 expressed on the cell surface of CHO cells. In addition, the bi-specific antibodies illustrated (1) the ability to effectively compete for and block the interaction between PD-1 and PDL-1 (see, e.g., the PDL-1 competition IC50 values); (2) simultaneous binding to PD-1 and TIM-3 antigens (see, e.g., AlphaLISA bridging results); and (3) better capability for bringing a higher proportion of PD-1 and TIM-3 conjugated beads into close proximity relative to the antibody construct without the TIM-3 binding arm (see, e.g., B max values of the AlphaLISA bridging assay, Samples A-C versus Sample D).
Table 27 shows additional results obtained from illustrative bi-specific antibodies described herein. The bi-specific antibodies exemplified in the table comprise an scFvFc PD-1 antibody 1353-G10 with mutations T350V/T366L/K392L/T394W (“zwB”) in the CH3 domain and Tim-3 antibody 1649-A01 with mutations T350V/L351Y/F405A/Y407V (“zwA”) in the CH3 domain, or its derivatives (Von Kreudenstein et al. 2013. mAbs 5(5):646-654; Von Kreudenstein et al. 2014. Methods 65:77-94; and U.S. 2013/0195849, each of which is incorporated herein by reference in its entirety). Several point mutations to an aspartate residue were introduced in various combinations throughout the anti-TIM-3 antibody (heavy chain: 530D, R31D, Y56D; light chain: S56D). All bi-specific antibodies showed similar ability to block recombinant human PD-1 binding to CHO cells expressing human PD-L1. In addition, all bi-specific antibodies illustrated the ability to bind simultaneously to human PD-1 and human TIM-3 that are expressed on the same cells. Overall, the mutations did not have an impact on binding affinity to recombinant CHO cell lines overexpressing PD-1 or TIM-3, nor was there a significant difference in kinetic affinity to TIM-3 antigen measured by SPR. As there were observed improvements in aggregation propensity by introduction of the mutations (Example 14), but no significant differences in the thermostability of the anti-TIM-3 Fab arm of the bispecific antibody (Tm2), this suggested that some of these point mutations may be beneficial for antibody stability without impacting functional activity.
Tables 28 and 29 provide assay results and kinetics of antigen binding to PD-1 and Tim-3 using the illustrative bi-specific antibodies. The PD-1 antibody 1353-G10 was produced either as an IgG or as a bi-specific antibody with Tim-3 antibody 1649-A01. In the bi-specific antibody format, the PD-1 antibody was provided as an scFv, the Tim-3 antibody was provided as a Fab fragment, and a mutation was introduced at V262E of the heavy chain to improve biophysical properties of the bi-specific format. In addition, the PD-1 antibody was provided as wild-type 1353-G10 IgG (SEQ ID NO: 181; Samples E, I), as a triple mutant derivative (SEQ ID NO: 197; Samples F, J), as a kappa graft derivative (SEQ ID NO: 244; Samples G, K), or as both a triple mutant and kappa graft derivative (SEQ ID NO: 197, SEQ ID NO: 244; Samples H, L). In the context of the bi-specific antibody, the 1353-G10 scFv triple mutant derivative had the impact of improved thermostability at the expense of slightly reducing affinity. The kappa-grafted 1353-G10 further improved thermostability without significantly impacting PD-1 affinity. In combination, the triple mutation and the kappa graft further enhanced thermostability, which was more pronounced in the context of the bispecific antibody when 1353-G10 was in a scFv conformation as opposed to the IgG conformation.
Table 30 provides sequences referred to herein.
Cynomolgus Tim-3
The disclosure set forth above may encompass multiple distinct inventions with independent utility. Although each of these inventions has been disclosed in its preferred form(s), the specific embodiments thereof as disclosed and illustrated herein are not to be considered in a limiting sense, because numerous variations are possible. The subject matter of the inventions includes all novel and nonobvious combinations and subcombinations of the various elements, features, functions, and/or properties disclosed herein. The following claims particularly point out certain combinations and subcombinations regarded as novel and nonobvious. Inventions embodied in other combinations and subcombinations of features, functions, elements, and/or properties may be claimed in this application, in applications claiming priority from this application, or in related applications. Such claims, whether directed to a different invention or to the same invention, and whether broader, narrower, equal, or different in scope in comparison to the original claims, also are regarded as included within the subject matter of the inventions of the present disclosure.
This application is a national stage of international application no. PCT/US2018/019248, filed Feb. 22, 2018, which claims the benefit of U.S. provisional application No. 62/462,272, filed Feb. 22, 2017, the contents of each of which are hereby incorporated by reference in their entireties.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US18/19248 | 2/22/2018 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62468272 | Mar 2017 | US |
